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ABSTRACT 
The formation of the vascular network requires a tightly controlled regulation of pro-
angiogenic and stabilising signals, including VEGF and the endothelial junctions 
respectively. Perturbation of this balance can result in dysregulated blood vessel 
morphogenesis and drive pathologies, including cancer. The Rho GTPases are major 
signaling regulators of the cytoskeleton and control functions such as cell migration and 
adhesion. 
We have identified that ARHGAP18 controls RhoC activity and functions as an 
endogenous negative regulator of angiogenesis by limiting pro-angiogeneic signaling and 
promoting vascular stability. Loss of ARHGAP18 promotes EC hypersprouting during 
zebrafish and murine retinal vessel development and enhances tumour vascularization and 
growth. Endogenous ARHGAP18 acts specifically via RhoC and relocalizes to the 
angiogenic and destabilized EC junctions in a ROCK dependent manner, where it is 
important in reaffirming stable EC junctions and suppressing tip cell behavior, at least 
partially through regulation of tip cell genes, Dll4, Flk-1 and Flt-4. The molecular 
mechanism governing the activation and translocation of ARHGAP18 to the cell 
periphery is at its infancy but phosphorylation and association with cortactin are involved.  
Aberrant Ras signaling is associated with cancer and vascular pathologies, such as 
angiosarcomas. Chronic HRas activation induces a transformed-like phenotype, with 
fibroblastic cell phenotype, increased cell migration and sprouting, dysregulated 
endothelial junctions and a partial alteration of endothelial-to-mesenchymal markers. This 
is associated with but not dependent on downregulation of ARHGAP18 expression.  
	   xviii 
These findings highlight ARHGAP18 as a specific RhoGAP to fine-tune vascular 
morphogenesis, acting as a negative regulator to limit tip cell formation and promote 
junctional integrity to stabilize the angiogenic architecture.  
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1.1.  THE VASCULAR SYSTEM 
The vascular system is a complex network of vessels that functions to transport 
oxygenated blood, nutrients and circulating cells between tissues and organs. It is also a 
critical regulator of inflammation, regulating the efflux of blood borne factors and by 
providing the mechanisms for trafficking of circulating immune cells into the tissues. 
Dysregulation contributes to pathologies including cancer and ischemia (Adams and 
Alitalo, 2007; Potente et al., 2011) (Fig 1.1). Further, the function of the vasculature is 
impacted upon by the process of ageing (Kovacic et al., 2011). 
The vascular system is organized into a hierarchical structure of large and small vessels 
that facilitate the circulation of blood between the heart, lungs and tissues (Fig 1.2). Blood 
circulation progresses from the heart through arteries to smaller arterioles then finally to 
capillary beds. Capillaries form extensive networks through tissues and organs to 
facilitate the exchange of gases and nutrients. The blood is returned though venules and 
veins to the heart and then to the lungs to be replenished with oxygen. Despite this 
complex organization, virtually all blood vessels arise by the sprouting from pre-existing 
blood vessels, a process termed angiogenesis (Herbert and Stainier, 2011). This process is 
driven by coordinated changes in the behavior of cells that line blood vessels, the 
endothelial cells (ECs).  
1.1.1.  DEVELOPMENT OF THE VASCULAR SYSTEM 
1.1.1.1. Vasculogenesis 
Vasculogenesis, the de novo formation of blood vessels, occurs during the embryonic 
development of the circulatory system (Fig 1.2) (Goldie et al., 2008; Herbert and Stainier, 
2011; Patan, 2004). Endothelial progenitors (angioblasts) differentiate from mesodermal 
cells and may acquire arterial or venous fates to generate the first embryonic blood 
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vessels: the dorsal aorta and the cardinal vein, respectively (Coultas et al., 2005; Herbert 
and Stainier, 2011). Angioblasts also aggregate to form blood islands, which fuse and 
remodel to generate the primary capillary plexus (Adams and Alitalo, 2007; Carmeliet 
and Jain, 2011; Herbert and Stainier, 2011). Vasculogenesis also initiates heart 
development (Luttun and Carmeliet, 2003; Patan, 2004) and following the establishment 
of the blood circulation, the primary plexi are remodeled into the hierarchical structure of 
arteries, arterioles, capillaries, veins and venules (Adams and Alitalo, 2007).  
1.1.1.2. Angiogenesis 
Following vasculogenesis, the expansion of the vascular network predominantly occurs 
via angiogenesis. Continuous angiogenic remodeling and extensive expansion of the 
arterial, venous and capillary blood vessels lead to the formation of the complex and 
functional vascular network (Herbert and Stainier, 2011). After birth and the 
establishment of the vascular network, most blood vessels remain quiescent and 
angiogenesis only occurs during ovulation and pregnancy (Carmeliet, 2005; Robinson et 
al., 2009). However the ECs that line the blood vessels retain the ability to respond to 
physiological stimuli in order to divide and form new vascular sprouts (Carmeliet, 2005; 
Tonnesen et al., 2000). The cellular and molecular mechanisms regulating angiogenesis 
are reviewed in the sections below. 
1.1.1.3. Lymphangiogenesis 
The early embryonic veins also give rise to the lymphatic vessels to form the lymphatic 
system. Lymphangiogenesis is a specialized form of angiogenesis and refers to the growth 
and expansion of lymphatic vessels. The lymphatic system is a unidirectional network that 
runs parallel to the vascular system and regulates tissue fluid homeostasis, immune 
function and fat metabolism (Adams and Alitalo, 2007; Alitalo et al., 2005; Norrmen et 
al., 2011; Tammela and Alitalo, 2010). The blind-ended capillaries collect fluid, 
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macromolecules and cells from the interstitial space and drain through larger collecting 
lymphatic vessels into the venous circulation (Adams and Alitalo, 2007; Alitalo et al., 
2005; Norrmen et al., 2011; Tammela and Alitalo, 2010). Lymphatic dysfunction may 
lead to lymphedema, a condition characterized by tissue oedema, immune deficiency and 
accumulation of subcutaneous fat (Alitalo et al., 2005; Norrmen et al., 2011). Despite the 
similarities between vascular angiogenesis and lymphangiogenesis, the mechanisms 
regulating these are strikingly different (Adams and Alitalo, 2007). An in depth 
description of these mechanisms in lymphangiogenesis is beyond the scope of this thesis. 
1.2.  CELLULAR MECHANISMS OF ANGIOGENESIS 
The process of angiogenesis is initiated following the sensing of pro-angiogenic growth 
factors (GFs) and involves fundamental changes in the behavior of ECs and mural cells 
such as pericytes. The key events include ECs sprouting, adhesion and fusion, perfusion, 
stabilization, and maturation to form the new vessel (Fig 1.3). These new vessels are 
further remodeled into specific tissue and vessel types in order to fulfill the physiological 
functions.  
1.2.1.  STRUCTURE OF BLOOD VESSELS 
In stable vessels, ECs typically form a monolayer of quiescent cells that line the luminal 
surface of blood vessels (Herbert and Stainier, 2011). To optimize blood flow, these 
vessels adjust the shape of endothelial cells and range from the highly aligned elongated 
cells in the arteries to the cobblestone-like shape in the quiescent capillary ECs (Carmeliet 
and Jain, 2011; Mazzone et al., 2009; Potente et al., 2011). The long lived ECs are 
attached to the laminin and collagen-rich basement membrane and are ensheathed by 
mural cells, including vascular smooth muscle cells (arteries and veins) and pericytes 
(capillaries), on the outer wall (Fig 1.3 A) (Adams and Alitalo, 2007; Carmeliet and Jain, 
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2011; Eble and Niland, 2009; Herbert and Stainier, 2011). These mural cells stabilise the 
vessel by suppressing EC proliferation and promoting EC survival (Carmeliet and Jain, 
2011). The ECs are tightly interconnected by junctional molecules, which regulate the 
passage of fluids, cells and macromolecules into the tissues (Dejana et al., 2009). 
Although quiescent, these ECs dynamically respond to signals from the nearby 
microenvironment. For example, during inflammation, the ECs are activated and the cell-
cell junctions altered to allow infiltration of immune cells and mediators (Dejana et al., 
2009).  
1.2.2.  ANGIOGENIC SPROUTING 
The inactive phenotype of the quiescent ‘phalanx’ ECs is maintained until the ECs sense 
an angiogenic signal, such as VEGF (Potente et al., 2011). These angiogenic signals are 
released in the microenvironment by other cells, such as inflammatory or tumour cells 
during pathological angiogenesis or neuronal cells during development (Herbert and 
Stainier, 2011; Potente et al., 2011). These factors initiate and act to guide the process of 
angiogenesis (Fig 1.3 B) (Carmeliet and Jain, 2011; Herbert and Stainier, 2011; Potente et 
al., 2011). The pericytes are first detached from the vessel wall in response to 
Angiopoietin-2, a pro-angiogenic growth factor released by ECs (Augustin et al., 2009; 
Huang et al., 2010). ECs then loosen their cell-cell contacts, and liberate themselves from 
the basement membrane by proteolytic degradation by matrix metalloproteinases (MMPs) 
(Carmeliet and Jain, 2011; Herbert and Stainier, 2011; Potente et al., 2011). This is 
mediated by MT1-MMP, which is enriched in the sprouting endothelial cell (Potente et 
al., 2011; Sounni et al., 2002). The nascent vessel dilates and plasma proteins extravasate 
to form a provisional extracellular matrix (ECM) scaffold on which the ECs migrate 
(Carmeliet and Jain, 2011). The MMPs also liberate angiogenic growth factors from the 
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matrix and remodel the ECM into an angiogenic environment (Carmeliet and Jain, 2011; 
Potente et al., 2011).  
Of the ECs that respond to angiogenic stimuli, only a small proportion become selected to 
lead the formation of the new sprout. The leading endothelial cell, the ‘tip cells’ (TCs), 
are highly motile and extend numerous dynamic filopodia that sense the attractive and 
repulsive guidance signals within the immediate microenvironment (De Smet et al., 2009; 
Gerhardt et al., 2003). These TCs are trailed by the ‘stalk’ cells (SCs), which are less 
motile but responsible for elongating and supporting the extension of the sprouting vessel, 
maintaining connectivity with the parent vessel and for the formation of the vascular 
lumen (Gerhardt et al., 2003; Herbert and Stainier, 2011; Phng and Gerhardt, 2009). The 
expansion of the vascular network requires the coordination of both the TC and SC 
responses. Importantly though, the TC and SC fates are transient phenotypes and a 
dynamic reshuffling of TCs and SCs occurs within the emerging sprout to promote 
vascular patterning and expansion (Bentley et al., 2014; Jakobsson et al., 2010). This 
regulation of TC and SC selection is mediated by VEGF-Notch signaling and is described 
in detail in section 1.4.1. 
1.2.3.  VESSEL FUSION AND PERFUSION  
EC sprouting occurs in a highly directional manner to guidance cues until TCs contact 
other vessels, undergo anastomosis and fuse with the connecting vessels (Fig 1.3 C, Fig 
1.4 A) (Adams and Alitalo, 2007; Herbert and Stainier, 2011). Upon contact with other 
TCs or capillaries, TC behavior is repressed, with loss of their motile phenotype (Adams 
and Alitalo, 2007; Herbert and Stainier, 2011; Potente et al., 2011). Macrophages support 
vessel anastomosis by accumulating at the bridge sites and facilitating TC interaction with 
neighbouring ECs (Fantin et al., 2010). Once contact is established between ECs, strong 
EC-EC junctions containing the endothelial-specific cadherin, VE-cadherin, consolidate 
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the connection (Potente et al., 2011). The importance of the EC junctions is described in 
detail in section 1.4.2. 
The establishment of a functional perfused blood vessel requires the formation of a 
vascular lumen, which may occur within growing endothelial sprouts or following vessel 
fusion (Adams and Alitalo, 2007). The process of lumen formation is complex and not 
well understood but thought to occur by different mechanisms, including cell hollowing 
and cord hollowing (Potente et al., 2011). In cell hollowing, ECs form a lumen by the 
fusion of intracellular pinocytic vacuoles and subsequently intercellular fusion of 
vacuoles from neighbouring cells (Fig 1.4 B) (Gamble et al., 1999; Iruela-Arispe and 
Davis, 2009; Kamei et al., 2006; Meyer et al., 1997). In cord hollowing, ECs adjust their 
shape and rearrange their junctions to open up a lumen (Potente et al., 2011) (Fig 1.4 C). 
Prior to lumen formation, nascent vessels consist of multicellular rods of ECs 
interconnected by uniform EC-EC junctions (Herbert and Stainier, 2011). The first phase 
involves lateral redistribution of junctional proteins from the apical EC surface to the 
vessel periphery (Xu et al., 2011; Zovein et al., 2010). Thereafter negatively charged 
glycoproteins are recruited to the apical membranes, which confer a repulsive signal to 
open up a lumen, and is followed by cytoskeletal retraction to expand the lumen (Strilic et 
al., 2009; Wang et al., 2010). However, the molecular events that initiate and manifest in 
lumen formation are yet to be completely elucidated (Herbert and Stainier, 2011; Iruela-
Arispe and Davis, 2009; Potente et al., 2011). 
1.2.4.  VESSEL STABILIZATION, MATURATION AND REMODELLING 
The newly formed immature vessels must be stabilized in order to be incorporated into 
the functional vascular network (Potente et al., 2011). This process of stabilization 
includes the recruitment of supporting pericytes, deposition of ECM into the basement 
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membrane, the strengthening of EC junctions and suppression of endothelial proliferation 
and sprouting (Fig 1.3 D, Fig 1.5 A) (Adams and Alitalo, 2007; Potente et al., 2011).  
Pericytes function to stabilize vessels by suppressing EC sprouting and proliferation and 
promoting EC survival (Gaengel et al., 2009; Hellstrom et al., 2001). Pericytes ensheath 
and establish direct contacts with ECs from capillaries and are recruited to immature 
sprouts in the growing blood vessel (Adams and Alitalo, 2007). There are a few signaling 
mechanisms of different origins that are known to regulate pericyte recruitment (Jain, 
2003). Platelet derived growth factor B (PDGFB) is produced by endothelial cells, in 
particular the TCs, in response to VEGF, and signals to the PDGF receptor (PDGFR)-β 
expressed on pericytes to control their proliferation and migration (Abramsson et al., 
2003; Hellstrom et al., 2001; Lindblom et al., 2003). Genetic knockout of PDGFB or 
PDGFR-β results in the lack of pericyte-EC attachment and mice display abnormal 
vascular morphogenesis, endothelial hyperplasia and embryonic lethality due to vascular 
oedema (Hellstrom et al., 2001; Lindahl et al., 1997). Further, angiopoietin-1 is produced 
by pericytes and activates the endothelial receptor TIE2 to promote pericyte adhesion and 
reduce vascular leak by signaling to tighten endothelial junctions (Augustin et al., 2009; 
Gamble et al., 2000; Uemura et al., 2002). Another GF, transforming growth factor β 
(TGF-β) triggers the differentiation, proliferation, migration and maturation of mural cells 
from progenitor cells (Chambers et al., 2003; Pardali et al., 2010). TGF- β also promotes 
vascular stabilization by stimulating ECM production (Jain, 2003). This is mediated by 
inducing the expressing of plasminogen activator inhibitor 1 in endothelial cells to 
prevent the degradation of the provisional ECM scaffold around the nascent vessel (Jain, 
2003).  Finally, sphingosine-1-phosphate (S1P) is a circulating ligand that binds to the 
S1PR1 receptor expressed on endothelial cells (Gaengel et al., 2012; Liu et al., 2000). 
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S1PR1 signaling regulates the trafficking of N-cadherin to the surface of ECs, which 
establishes and strengthens EC-pericyte interactions (Liu et al., 2000; Paik et al., 2004). 
In addition to circulating mediators, it has also been speculated that the onset of blood 
flow following lumen formation helps to stabilize new vessel connections (Fig 1.5 B) 
(Adams and Alitalo, 2007; Potente et al., 2011). Blood flow remodels the EC shape and 
contacts in the nascent vessel. Induction of the shear stress-responsive transcription factor, 
Krüppel-like factor 2 (KLF2) acts to modulate MAPK and PI3K to induce vessel 
remodelling (Nicoli et al., 2010). Moreover, oxygen delivery to the perfused vessel 
inactivates oxygen sensors to suppress hypoxia-driven VEGF expression, thereby shifting 
the ECs towards a quiescent phenotype (Adams and Alitalo, 2007; Potente et al., 2011). 
Vascular regression is the pruning of vessel connections and may occur in vessels that 
have failed to become perfused (Fig 1.5 C) (Potente et al., 2011). Vascular regression is 
thought to occur by a reverse migrating mechanism by which endothelial cells retract 
from the vessel connection (Chen et al. 2012; Franco et al. 2015) resulting in the 
formation of empty basement membrane sleeves (Inai et al. 2004; Potente et al., 2011; 
Phng et al., 2007). Another mechanism regulating vascular regression involves the 
activation of apoptotic pathways (Dimmeler and Zeiher, 2000), triggered by the absence 
of pro-survival signals including pericyte-EC interactions, EC-EC contacts, integrin-
matrix interactions (Jain, 2003) and VEGF activation of the PI3K/Akt survival pathway 
(Carmeliet et al., 1996; Hlushchuk et al., 2011). 
1.2.5.  EC SPECIALIZATION  
ECs display remarkable heterogeneity in structure and function within the vascular 
system. This occurs not only at the macrovasculature level with respect to arteries, veins 
and lymphatic vessels, but also among the microvascular capillary beds of different 
organs (Aird, 2007). The differentiation of ECs into arteries or veins occurs during the 
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early embryo remodeling of the primary capillary plexi and continues throughout 
development (Adams and Alitalo, 2007; Torres-Vazquez et al., 2003). This process is 
termed arteriovenous differentiation and reflects the response to distinct haemodynamic 
environments within the vascular network (Fig 1.6) (Adams and Alitalo, 2007). Arteries 
form a high pressure and pulsatile flow system to transport blood to the capillaries 
whereas the veins are a low-pressure system (Torres-Vazquez et al., 2003). Structurally, 
arteries resist the high pressure shear stress by being surrounded in layers of vSMCs and a 
specialized matrix of elastin fibres (Adams and Alitalo, 2007). Meanwhile veins are 
thinner, enveloped by fewer vSMCs and possess flap-like structures to prevent the 
backflow of blood (Torres-Vazquez et al., 2003). The regulation of arterial and venous 
differentiation is controlled by several ligand-receptor signaling pathways including 
Notch, ephrin and neurophilins (Torres-Vazquez et al., 2003). Blood flow dynamics also 
regulate arteriovenous differentiation; changing arterial to venous flow in the embryonic 
chick yolk sac suppresses the arterial phenotype (Kwei et al., 2004; le Noble et al., 2004). 
Furthermore, engraftment of veins into arterial vasculature results in the development of 
an arterial wall structure (Jain, 2003) and suggests that ECs possess a plasticity to adapt to 
the local environmental cues. ECs from arterial and venous vessels show functional 
differences in the regulation of endothelial permeability, leukocyte recruitment and in 
haemostasis (Aird, 2007). 
EC heterogeneity and adaption to microenvironmental cues is further demonstrated by the 
functional differences capillary beds from different organs (Fig 1.7 A) (Adams and 
Alitalo, 2007). For example, ECs in the central nervous system form the blood brain 
barrier that tightly restricts the passage between the tissue and the circulating blood and is 
in stark contrast to the highly permeable fenestrae-containing ECs in the endocrine glands 
(Rocha and Adams, 2009). The mechanisms regulating tissue specificity are poorly 
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understood, but are believed to be due to specific molecular signatures in the 
microvascular ECs in response to the tissue microenvironment (Nolan et al., 2013). The 
ECs also play fundamental roles in regulating organogenesis. The ECs respond to the 
tissue specific microenvironment and secrete factors such as PDGF-B and Notch to 
regulate the development of organs including the kidney and liver (Ramasamy et al., 
2015). In addition, the tissue specific ECs have critical roles in organ regeneration. These 
ECs support the homeostasis and regeneration of progenitor cells following tissue injury 
by secreting trophic GFs (angiocrine factors) (Nolan et al., 2013). Following partial liver 
hepatectomy, pro-angiogenic growth factors such as VEGF trigger liver sinusoidal EC 
proliferation and expression of Wnt2, hepatocyte growth factor (Ding et al., 2010) and 
CXCR7 (Ding et al., 2014) which drive liver regeneration. However, the liver sinusoidal 
ECs when transplantation into injured lungs are unable to promote lung regeneration (Fig 
1.7 B) (Ding et al., 2011). Thus, ECs have unique signatures within each organ and are 
programmed to satisfy the functions of each particular organ (Ramasamy et al., 2015). 
1.2.5.1. Endothelial-to-mesenchymal transition 
In addition to displaying tissue and vessel heterogeneity, ECs possess the ability to 
differentiate into mesenchymal cells in a process known as Endothelial-to-Mesenchymal 
Transition (EndMT). EndMT is a specialized and related form of Epithelial-to-
Mesenchymal Transition (EMT) that occurs in ECs rather than epithelial cells (Kovacic et 
al., 2012). This results in the progressive loss of endothelial and the gain of mesenchymal 
characteristics, including changes in cell polarity, adhesion and migration and is 
accompanied by a change in the expression of endothelial (e.g. VE-cadherin, PECAM-1) 
and mesenchymal (e.g. α-SMA, FSP-1) markers (Fig 1.8) (Medici and Kalluri, 2012). 
Many of the signaling pathways regulating EMT are also regulators of EndMT. EndMT 
can be initiated following the activation of a variety of signaling pathways, most notably 
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TGF-β 1 or 2, but also others including Notch, Wnt and PDGF (Kovacic et al., 2012; 
Medici and Kalluri, 2012). These act to activate the Snail family of transcription factors 
which act to coordinate the change from endothelial to mesenchymal marker expression 
(Medici and Kalluri, 2012). EndMT is crucial in the development of the embryonic heart, 
where the ECs contribute to the mesenchymal cells that form the atrioventricular cushion, 
valve and septa (Liebner et al., 2004). Further, EndMT derived cells also have stem-like 
properties and can differentiate into osteoclasts and chondrocytes (Medici et al., 2010). 
However, EndMT also contributes to pathology in kidney fibrosis (Zeisberg et al., 2008) 
and myocardial infarction and ischemia, where it contributes to cardiac fibrosis (Zeisberg 
et al., 2007b). EndMT also accounts for approximately 40% of the cancer-associated 
fibroblasts that form the tumour stroma (Zeisberg et al., 2007a). These fibroblasts can act 
to promote tumour formation through the secretion of factors that can promote tumour 
growth and/or angiogenesis. It has also been thought that the TC, which are highly 
migratory and have no lumen, may in fact be ECs undergoing EndMT (Gerhardt et al., 
2003; Potenta et al., 2008).  
1.2.6.  OTHER FORMS OF VESSEL FORMATION 
There are several other modes of vessel formation that have been identified. As 
previously mentioned, the developing vasculature is formed from progenitors in a process 
known vasculogenesis, while the expansion of the vascular network occurs by 
angiogenesis, in the cellular mechanisms detailed above. Arteriogenesis refers to the 
growth of pre-existent collateral arterioles into large functional arteries in response to 
occluded arteries (Fig 1.9 A) (Carmeliet, 2000; Heil et al., 2006; Semenza, 2007). This 
process is mediated by increases in shear stresses in collaterals following the narrowing of 
a main artery, which results in recruitment of circulating cells that secrete factors to 
promote the enlargement of the vascular wall structures (Heil et al., 2006).  
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Another mechanism by which the vessel network can be expanded is the splitting of blood 
vessels by the insertion of tissue pillars resulting in daughter vessels, a process termed 
intussusception (Fig 1.9 B) (Djonov and Makanya, 2005). However little is known about 
the physiological role and molecular mechanisms regulating intussusception (Adams and 
Alitalo, 2007; Carmeliet and Jain, 2011). Finally albeit debatable, bone marrow-derived 
circulating endothelial progenitor cells (EPCs) are also thought to contribute regenerative 
or pathological vessel growth in the adult in a process known as post-natal vasculogenesis 
(Fig 1.9 C) (Adams and Alitalo, 2007; Rafii et al., 2002). EPCs are recruited to the sites 
of repair or pathology and incorporate into the endothelial lining of the vascular wall 
(Adams and Alitalo, 2007; Carmeliet and Jain, 2011). While the existence of EPCs 
remains controversial, there is enormous potential of harnessing EPCs in the treatment of 
diseases (Rafii et al., 2002). 
1.3.  THE VASCULAR SYSTEM IN PATHOLOGY 
Angiogenesis requires tight coordinated changes in pro-angiogenic and stabilizing signals 
to establish functional vascularization. Dysregulation of this balance can lead to abnormal 
vessel growth and function, which contribute to many pathologies, including cancer, 
ischemia and inflammatory diseases (Potente et al., 2011). Hence angiogenesis has been 
suggested to be a potential therapeutic target in these diseases. To date however, clinical 
applications of angiogenesis targets are of mixed results. 
1.3.1.  IN CANCER 
1.3.1.1. Angiogenesis as a clinical target in cancer 
Cancer is one of the leading causes of death worldwide with people having approximately 
a 1 in 2 risk of developing cancer in their lifetime and 1 in 4 chance of dying from this 
disease (World cancer report 2014, World Health Organisation statistics, www.iarc.fr). 
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The process of tumourigenesis is a multistep, diverse and complex process, but several 
critical hallmarks have been defined of which the vascular system plays a major role in 
three of these (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). Firstly, in 
order to progress to a larger size, tumours require active angiogenesis to drive tumour 
vessel expansion and infiltration into the growing tumour to supply oxygen and nutrients 
(Hanahan and Weinberg, 2000; Weis and Cheresh, 2011). Secondly, the vascular system 
is important in regulating tumour metastasis by providing a systemic conduit for primary 
tumour dissemination (Weis and Cheresh, 2011). Thirdly, immune cells, which can both 
promote and inhibit tumour growth, infiltrate the tumour through crossing the vascular 
barrier (Gajewski et al., 2013). 
The idea of targeting tumour angiogenesis dates back to 1971, where Folkman proposed 
that tumour growth is angiogenesis-dependent and that stopping the blood supply would 
cause the tumour to die (Folkman, 1971). Since the initial proposition decades ago, 
discoveries including the identification of the main angiogenic growth factor, vascular 
endothelial growth factor (VEGF) (Keck et al., 1989; Leung et al., 1989; Senger et al., 
1983) and its receptors (Millauer et al., 1993) have established angiogenesis as a viable 
therapeutic target.  
Clinically, VEGF blockers have been approved for clinical use in cancer treatment; the 
most notable being the VEGF neutralizing antibody bevacizumab (Avastin) in the 
treatment of a variety of metastatic cancers (Carmeliet and Jain, 2011; Jain et al., 2006). 
Further, several multi-targeted tyrosine kinase inhibitors (e.g. sunitinib (Sutent) which 
block signaling pathways such as those downstream of VEGF have also been used 
(Carmeliet and Jain, 2011). However, the clinical use of VEGF and signaling blockers as 
anti-angiogenic therapy is proving to be more difficult than anticipated; treatment with 
inhibitors only prolongs survival in the order of months (Carmeliet and Jain, 2011; Jain et 
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al., 2006). This has been attributed to the activation of an invasive and metastatic tumour 
switch following vessel regression by anti-VEGF treatment (Keunen et al., 2011; Weis 
and Cheresh, 2011). Furthermore, patients inevitably develop resistance to anti-VEGFA 
inhibitors (Lu et al., 2013). An emerging concept of “vascular normalization” where 
restoring endothelial function and co-targeting the tumour is more promising (Goel et al., 
2011; Weis and Cheresh, 2011). Such treatments include using convention cytotoxics 
(e.g. doxorubicin) in combination with normalization therapies including pericyte-
targeted (PDGF-D overexpression) or anti-angiogenic therapies (bevacizumab, TNP-470) 
(Goel et al., 2011).  
1.3.1.2. The tumour vasculature is abnormal 
The first stage of tumourigenesis is the acquisition of DNA damage to induce oncogene 
activation or tumour suppressor inactivation resulting in uncontrolled cell proliferation 
and hyperplasia (Hanahan and Weinberg, 2000). Tumour growth however is confined to a 
few millimeters due to nutrient deprivation and hypoxia (Weis and Cheresh, 2011). 
Tumours overcome this by triggering an ‘angiogenic switch’; secreting pro-angiogenic 
factors, such as VEGF, into the microenvironment to stimulate the sprouting of ECs into 
the tumour (Weis and Cheresh, 2011). Other factors in the tumour microenvironment, 
including the cancer associated fibroblasts, myeloid cells and the ECM also secrete 
factors to drive tumour angiogenesis (Weis and Cheresh, 2011). The tumour vasculature, 
however, is highly abnormal at all levels of structure and function: the vessels lack the 
normal hierarchical organization, are heterogenous, tortous, highly sprouting and 
branching and have uneven lumen (Fig 1.10 A) (Carmeliet and Jain, 2011; Jain, 2003; 
Potente et al., 2011; Weis and Cheresh, 2011). The tumour ECs lack cobblestone 
appearance, are poorly interconnected and form an imperfect and disorganized lining 
within the vessels (Jain, 2003; Potente et al., 2011). The basement membrane is irregular 
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and fewer loosely attached abnormal tumour-associated pericytes cover the tumour 
vessels (Jain, 2003; Potente et al., 2011). As a result, vessels are leaky and blood flow is 
heterogenous leading to the irregular distribution of nutrients and oxygen within the 
tumour (Potente et al., 2011; Weis and Cheresh, 2011). This deprivation further drives 
proangiogenic stimulation and continuous but non-productive and disorganised 
remodeling of the vasculature (Potente et al., 2011). This creates a hostile acidic and 
hypoxic microenvironment that selects for more malignant clones and promotes tumour 
cell intravasation and dissemination through the already loosely structured vessel wall 
(Potente et al., 2011; Weis and Cheresh, 2011).   
1.3.1.3. Vascular normlisation for treatment of cancers 
The vasculature is central in triggering the cascade from a hyperplastic lesion to a highly 
malignant and invasive lesion and this understanding has led to the development of anti-
angiogenic therapies, such as bevacizumab (Willett et al., 2004). The abnormal tumour 
vasculature poses many challenges in the delivery of drugs to the tumour. The high 
interstitial pressure, leaky vessels and irregular distribution of vessels impedes drug 
penetrance throughout the tumour  (Carmeliet and Jain, 2011; Potente et al., 2011). 
Further tumour hypoxia also reduces the efficacy of many chemotherapeutic agents, due 
to their reliance on the formation of oxygen radicals (Carmeliet and Jain, 2011). 
Excessive pruning of the vasculature by anti-angiogenic therapy however aggravates 
tumour invasiveness and metastasis by increasing hypoxia (Fig 1.10 B) (Ebos et al., 2009; 
Paez-Ribes et al., 2009). The pruning of immature vessels while retaining the more 
mature efficient vessels, the so called ‘vascular normalization’ concept, is believed to be 
the key to drug delivery into tumours (Fig 1.10 B) (Goel et al., 2011; Jain, 2005). VEGF 
inhibitors block tumour vessel branching and induce the regression of pericyte-devoid 
leaky vessels while maintaining the mature functional tight vessels to promote tumour 
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oxygenation (Benjamin et al., 1999; Goel et al., 2011; Jain, 2005). Therapies to promote 
pericyte coverage on tumour vessels also endorse functional vessels (Goel et al., 2011; 
Jain, 2005). This increases the efficacy of combined cytotoxic therapies and may also be 
combined with hormone withdrawal therapies to reduce VEGF production (Izumi et al., 
2002; Jain, 2005), or pericyte directed therapies to destabilize tumour vessels (Bergers et 
al., 2003; Goel et al., 2011). However recent clinical studies have demonstrated that 
vascular normalization following anti-angiogenic therapy is only transient, and thus future 
strategies will be aimed at optimizing cytotoxic therapies specifically while the window is 
open (Goel et al., 2011).  
1.3.1.4. In Ischemic disease 
Another leading cause of death is cardiovascular disease (CVD), which accounts for 
approximately one-third of deaths worldwide (Deaton et al., 2011; Khurana et al., 2005). 
While tumourigenesis is driven by an over-abundance of angiogenic signals, insufficient 
angiogenesis leading to tissue ischemia occurs in CVD, such as myocardial infarction, 
stroke and coronary artery disease (Khurana et al., 2005; Marti and Risau, 1999; Ware 
and Simons, 1997) and also in non-cardiovascular conditions, such as preeclampsia 
(Maynard et al., 2008) and limb ischemia (Tongers et al., 2008). Clinical studies of 
angiogenic cytokine therapy in patients with myocardial ischemia have been shown to 
promote neovascularization and improve myocardial perfusion (Losordo and Dimmeler, 
2004). However, some patients do not show clinical improvement and this is postulated to 
be due to a lack of blood delivery by arteriogenesis rather than by angiogenesis (Potente 
et al., 2011). Further, various studies have suggested that neovascularization contributes 
to the growth of atherosclerotic lesions and is key in plaque destabilization and rupture 
(Khurana et al., 2005; Moussa and Moses, 1999). While an attractive approach, further 
clinical studies would be needed to identify suitable targets for the treatment of CVD.  
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1.3.1.5. In inflammatory diseases 
The acute inflammatory response to infections and wounds involves the recruitment of the 
immune cells to local sites to facilitate repair or clearance of the pathogen. The changes in 
the vasculature are under strict regulation, opening to permit immune cell extravasation 
and rapidly returning the vessel to homeostasis (Dejana, 2004; Vestweber et al., 2009). 
However, in a chronic inflammatory setting, the balance between the positive and 
negative regulators is disturbed with accumulation of inflammatory cells and 
inflammatory mediators that ultimately leads to damage and destruction. Such factors 
include pro-angiogenic cytokines (eg. VEGF, FGF) that promote angiogenesis, which in 
turn contributes to the inflammatory pathology by transporting additional inflammatory 
cells and providing nutrients and oxygen to the site of inflammation (Jackson et al., 1997). 
As such, angiogenesis has been shown to be important in many chronic inflammatory 
diseases such as rheumatoid arthritis (Bainbridge et al., 2006), retinopathy (Crawford et 
al., 2009) and psoriasis (Heidenreich et al., 2009). Clinical studies with bevacizumab have 
shown improvement in patients suffering from diabetic retinopathy with marked reduction 
in neovascularization and hemorrhage (Avery et al., 2006; Spaide and Fisher, 2006). Anti-
VEGF therapies injected locally into the eye is also a treatment for age-related macular 
degeneration, inhibiting vascular leak and limiting neovascularisation (Kovach et al., 
2012). 
1.3.1.6. Vascular anomalies 
In addition to contributing to other diseases, the vascular system also has direct 
pathological conditions. Vascular anomalies are congenital conditions of abnormal 
vascular development and include vascular tumours and malformations (Richter and 
Friedman, 2012). The genetic defects underlying these conditions, however, are poorly 
understood. 
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Hemangiomas are a common tumour in infants, occurring in approximately 10% of the 
population (Richter and Friedman, 2012). This usually involves hyperplasia of endothelial 
cells and results in rapidly growing tumours during the first 6 months, although most 
regress with time and are rarely infiltrative. Hemangiomas are often managed by close 
observation, with medical or surgical interventions occurring in a small proportion of 
tumours.  
Vascular malformations are rare vascular anomalies composed of irregular vascular 
networks and are classified by the vessel type, for example venous malformations 
(Richter and Friedman, 2012). In contrast to hemangiomas, vascular malformations are 
slow growing, infiltrative and often destructive vascular lesions, and often require 
intervention. Vascular malformations do not regress and continue to expand with cycles 
of rapid growth, infiltration and soft tissue destruction. Therapeutic interventions depend 
on the type of malformation and can consist of laser therapy, surgical resection and 
sclerotherapy. 
1.4.  MOLECULAR REGULATION OF SPROUTING 
ANGIOGENESIS  
One of the key steps in angiogenesis is sprouting angiogenesis, the formation of the initial 
vascular sprout. These vascular sprouts organize into the leading TCs that guide the 
direction of sprouting and the trailing SCs that support the elongation of the sprout. Many 
recent studies have begun extrapolating the molecular mechanisms that regulate sprouting 
angiogenesis. Here we describe two of the most important mechanisms: pro-angiogenic 
VEGF signaling and the stabilizing EC junctions. 
1.4.1.  VEGF-NOTCH SIGNALING  
1.4.1.1. VEGF receptors and ligands 
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VEGFA is the principal master regulator of blood vessel sprouting during development 
and in disease. VEGFA was initially identified as vascular permeability factor (VPF), as it 
induces vascular leak (Keck et al., 1989; Senger et al., 1983) and is part of a large family 
of non-redundant angiogenic regulators including placental growth factor (PIGF), VEGF-
B, VEGF-C and VEGF-D (Ferrara et al., 2003; Hoeben et al., 2004; Olsson et al., 2006). 
All members have a VEGF homology domain with a cysteine knot-core region that is 
important in dimerisation (Hoeben et al., 2004; Olsson et al., 2006). The ligands are 
organised as homodimers in an anti-parallel orientation with each pole of the dimer 
interacting with the receptor binding sites (Muller et al., 1997; Olsson et al., 2006).	  The 
VEGF ligands bind to three receptor tyrosine kinases (RTKs), known as VEGF receptor-1 
(VEGFR1/Flt1), -2 (VEGFR2/Flk1) and -3 (VEGFR3/Flk4) as well as to co-receptors 
such as heparan suphate proteoglycans (HSPGs) and neuropilins (Olsson et al., 2006). 
These VEGFRs follow the typical mechanism of RTK activation with ligand binding 
triggering receptor dimerization, tyrosine kinase activation, autophosphorylation of the 
receptor and opening docking sites for the recruitment of signal transducers (Ferrara et al., 
2003). The receptors differ in ligand binding specificity and in function (Fig 1.11 A). 
VEGFA binds to VEGFR1 and VEGFR2 to regulate blood vessel morphogenesis, while 
VEGFC and VEGFD bind to VEGFR3 to primarily regulate lymphangiogenesis (Joukov 
et al., 1996; Olsson et al., 2006).  
While VEGFA binds to both VEGFR1 and VEGFR2, the functional effects of the two 
receptors are very distinct. Binding to the cognate receptor Tyr kinase, VEGFR2, 
activates multiple downstream pathways including Ras/RAF/MEF/ERK (MAK), 
PI3K/Akt, phospholipase Cγ and small GTPases (Hoeben et al., 2004; Olsson et al., 2006) 
(Fig 1.11 B). As a result, VEGFA signaling regulates EC proliferation, survival, 
filopodial extension, degradation of the ECM and chemotaxis (Neufeld et al., 1999; 
Chapter 1. Introduction 
	   21 
Olsson et al., 2006). VEGFA is primarily regulated by hypoxia and drives the motile and 
invasive behavior of TCs to activate the angiogenic response to tissue oxygen deficiency 
during development and disease (Gerhardt et al., 2003; Pugh and Ratcliffe, 2003). 
Consequently, flk1(VEGFR2) knockout and Vegfa+/- mice are embryonically lethal and 
display severe vascular deficiencies (Carmeliet et al., 1996; Ferrara et al., 1996; Shalaby 
et al., 1995). 
VEGFR1, on the other hand, has higher affinity for VEGFA than does VEGFR2, but 
possesses weak Tyr kinase activity and is considered to be a decoy receptor that 
counteracts angiogenic signaling (Seetharam et al., 1995)	   (Hiratsuka et al., 2005). 
Furthermore, alternative splicing of VEGFR1 generates a secreted isoform of VEGFR1 
(soluble VEGFR1 (sVEGFR1)) that acts as a sink for VEGFA in the microenvironment 
(Hiratsuka et al., 2005). As a result, flt1(VEGFR1) knockout is associated with EC 
hypersprouting, abnormal angiogenesis and embryonic lethality in mice and zebrafish 
(Fong et al., 1995; Hiratsuka et al., 2005; Krueger et al., 2011). 
Other co-receptors that lack distinct kinase signaling mechanisms are also important in 
modulating VEGFR signaling. Alternative splicing of the VEGFA transcript gives rise to 
variants that have divergent functions and bioavailabilities, with the most predominant 
being VEGFA165 (VEGFA164 in mice) and VEGFA121 (VEGFA120 in mice) that vary 
in the presence or absence of the heparan sulphate-binding and neuropilin-binding 
domains (Hoeben et al., 2004). The heparin sulphate-binding VEGFA165 is matrix 
associated and forms gradients to promote the directional migration and filopodial 
extension of ECs (Ruhrberg et al., 2002). In contrast, VEGF121 is unable to bind heparin 
sulphate, is highly diffusible and controls EC proliferation but not migration (Ruhrberg et 
al., 2002). Another variant is VEGF188, which is completely matrix bound (Hoeben et al., 
2004). Furthermore, the NRP co-receptors modulate angiogenic sprouting by complexing 
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with VEGFR and enhancing VEGF signaling when bound to VEGA, but only the 
VEGFA165 isoform and not the VEGFA121 isoform (Gerhardt et al., 2004; Kawasaki et 
al., 1999). 
Finally, while VEGFC-VEGFR3 signaling is crucial in lymphangiogenesis (Joukov et al., 
1996; Olsson et al., 2006), recent studies have shown additional roles of VEGFC in 
regulating sprouting angiogenesis (Siekmann and Lawson, 2007; Tammela et al., 2011; 
Tammela et al., 2008). VEGFR3 is highly expressed in TCs and forms VEGFR2-
VEGFR3 heterodimers that binds VEGFC to positively influence angiogenic sprouting 
(Tammela et al., 2011). The function of VEGFR3 signaling is dependent on VEGFR2 
expression during angiogenesis but not during lymphangiogenesis (Zarkada et al., 2015).  
Hence, the correct spatiotemporal expression of VEGFR3 is considered to be an important 
determinant of TC function (Herbert and Stainier, 2011). 
1.4.1.2. VEGF-Notch signaling controls Tip and Stalk cell selection 
Sprouting angiogenesis requires the organization of angiogenic sprouts into the leading 
TCs and trailing SCs and is coordinated by VEGF-Notch signaling (Fig 1.12). ECs 
express multiple Notch receptors (Notch1 being the most important) and transmembrane 
Notch ligands (including Delta-like ligand 4 (DLL4), and Jagged 1) (Phng and Gerhardt, 
2009). Cells expressing the Notch ligands transactivate Notch signals in the adjacent 
neighbouring cells. Ligand binding induces cleavage of the Notch receptor and release of 
the Notch intracellular domain (NICD), which functions in association with other 
transcription factors as a transcriptional regulator that controls cell fate specification 
(Phng and Gerhardt, 2009).  
The default endothelial response to VEGFA is the TC phenotype. The ECs expressing the 
highest level of VEGFA signaling become selected as the TCs and transactivate Notch 
signals to laterally inhibit TC and promote SC fates (Herbert and Stainier, 2011; Potente 
Chapter 1. Introduction 
	   23 
et al., 2011). VEGFA-VEGFR2 signaling promotes transcriptional DLL4 expression in 
TCs (Hellstrom et al., 2007; Lobov et al., 2007; Siekmann and Lawson, 2007). DLL4 is 
expressed on the surface of the TCs and binds to the Notch1 receptor on the adjacent 
cells. DLL4-Notch signaling suppresses TC fate and VEGFA responsiveness by 
downregulating VEGFR2, VEGFR3 and NRP1 in addition to upregulating VEGFR1 
(Hellstrom et al., 2007; Jakobsson et al., 2010; Lobov et al., 2007; Siekmann and Lawson, 
2007; Suchting et al., 2007). Consequently, reduced DLL4-Notch signaling is 
accompanied by excessive TC formation, uncontrolled hypersprouting and disordered 
vessel branching  (Hellstrom et al., 2007; Lobov et al., 2007; Suchting et al., 2007).  
Whereas DLL4 negatively regulates sprouting angiogenesis, another Notch ligand, Jagged 
1, promotes TC formation and angiogenesis (Benedito et al., 2009). Jagged 1 is expressed 
primarily by SC, and binds to Notch1 but poorly transactivates Notch signals. 
Accordingly, SC-restricted Jagged 1 competes with DLL4 for binding to Notch1 on TCs 
to suppress Notch signaling in TCs. 
1.4.1.3. ECs dynamically rearrange positions in vascular sprouts 
To expand the vascular network, ECs undergo cycles of sprouting, branching and 
tubulogenesis, which require the dynamic balance and transitions between the tip and 
stalk cell phenotypes. VEGFR2 inhibition causes sprouting defects with blunt ended 
channels, while DLL4 or Notch1 inactivation, although resulting in more vessels, leads to 
poorly perfused dysfunctional vessels (Phng and Gerhardt, 2009; Potente et al., 2011). 
Recent studies have demonstrated that the TC and SC fates are transient and that the ECs 
are continuously shuffling within the sprout and are in constant competition for the 
leading TC position (Fig 1.13 A) (Bentley et al., 2014; Bentley et al., 2009; Jakobsson et 
al., 2010). This is mediated by the relative expression of VEGFR2 and VEGFR1 in the 
neighbouring cells, such that cells with high VEGFR2 and low VEGFR1 stand a better 
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chance to occupy the leading position (Jakobsson et al., 2010). However, every cell within 
the sprout has a distinct level of Notch signaling compared to its neighbouring cells and 
continuously re-regulates its expression of VEGFR2 and VEGFR1 and position within the 
sprout (Bentley et al., 2014). Therefore rather than a single TC directing uniform 
migration, this dynamism allows the sprout to constantly assess the microenvironment 
and direct sprouting according to the availability of the pro-angiogenic growth factors 
(Bentley et al., 2014; Jakobsson et al., 2010). This tight sensory control of TC and SC 
fates is regulated by the dynamic changes in DLL4 expression. The TEL/CtBP repressor 
complex at the DLL4 promoter is transiently disassembled upon VEGFR2 signaling to 
allow a temporary pulse of DLL4 transcription (Fig 1.12) (Roukens et al., 2010). Hence, 
the cells that have highest VEGFA signaling express DLL4 more quickly or at higher 
levels transiently become the TCs. However, without the continuous VEGF signaling and 
DLL4 expression, these cells then lose the position to other cells that are more responsive 
to VEGF.  
In line with a tightly controlled system, activation of Notch and the release of NICD not 
only regulates the expression of VEGFR but also promotes its own turnover to prevent 
sustained Notch activation (Fig 1.12) (Phng et al., 2009; Potente et al., 2011). The NICD 
complexes with the RBPj/CBF1 transcription factors and regulates the expression of 
Notch-regulated ankyrin repeat protein (NRARP), which negatively regulates Notch by 
disassembling the co-activator complex and promoting NICD degradation. Additionally, 
NRARP also promotes stalk cell proliferation and maintains the stability of the nascent 
vessel connections via signaling through the Wnt/β-catenin pathway (Corada et al., 2010; 
Phng et al., 2009). 
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1.4.2.  ENDOTHELIAL JUNCTIONS  
The endothelial cell-cell junctions are the key regulators of vascular integrity in 
maintaining intercellular adhesion and regulating the flux of blood fluids, proteins and 
cells through the blood vessels. During responses to angiogenic or inflammatory stimuli, 
the EC junctions are dynamically remodeled to facilitate vascular permeability and 
leukocyte extravasation. However, the cell-cell junctions are not only sites of attachment 
between ECs; they also function as intercellular signals to modulate the limitation of cell 
growth, cell polarity, lumen formation and interactions with mural cells (Dejana, 2004; 
Dejana et al., 2009). One major implication of these signals is in the regulation of 
angiogenic sprouting. 
1.4.2.1. Organisation and function of the EC junctions  
The cell-cell junctions are organized into two specialized adhesive junctional regions: the 
tight junctions (TJs) and the adherens junctions (AJs) (Fig 1.14). The Gap junctions are 
also present in ECs, but have limited roles in regulating EC permeability and sprouting, so 
are therefore not further described here. The AJs are involved in the initiation and 
maintenance of cell-cell contacts while TJs regulate paracellular passage of ions and 
solutes and limit the free movement of lipids and proteins through the vessel (Bazzoni and 
Dejana, 2004; Dejana et al., 2009). Both the TJs and the AJs consist of homophillic 
interactions of transmembrane proteins that line and form zipper-like structures along the 
cell borders (Dejana et al., 2009). These transmembrane proteins interact through their 
cytoplasmic tails with cytoskeletal and signaling proteins to anchor the junctions to actin 
microfilaments and transfer of intracellular signals (Dejana et al., 2009). Cytoskeletal 
association is important for stabilization of the junctions, but also for regulation of the 
dynamic changes in junction opening and closure, and in controlling cell shape and 
polarity (Dejana, 2004; Dejana et al., 2009; Hartsock and Nelson, 2008). The AJs are first 
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formed at the initiation of cell contract and followed by TJ organization (Dejana, 2004). 
Moreover, the AJs are required for TJ assembly, although interestingly are not essential 
for TJ maintenance (Capaldo and Macara, 2007; Dejana, 2004). 
The major functions of the TJs are in the regulation of vascular permeability and 
leukocyte extravasation (Matter and Balda, 2003). The TJs show considerable variability 
amongst different vascular beds. For example, the ECs that comprise the tight brain 
microvasculature are rich in TJs, while the post-capillary venules, which are the primary 
site of leukocyte extravasation, display less TJ complexity (Wallez and Huber, 2008). The 
core components of the TJs that promote cell-cell adhesion are the Claudin proteins. 
There are over 20 Claudin proteins, of which claudin-5 is endothelial specific (Wallez and 
Huber, 2008). While Claudin-5 deficiency has limited vascular defects in embryos, the 
mice suffer from post-natal defects in the blood-brain barrier leading to death after a few 
hours of birth (Nitta et al., 2003). The TJs are also comprised of other transmembrane 
proteins, including occludin and JAMs, which also contribute to intercellular adhesion 
(Dejana et al., 2009). These adhesive proteins all contribute to intracellular signaling by 
interacting with binding partners, such as the ZO proteins, which in turn can bind to TFs, 
such as ZONAB (Balda et al., 2003) and β-catenin (Rajasekaran et al., 1996). The stable 
TJs in confluent cells restrain the TFs away from the nucleus and as a result inhibit cell 
proliferation. However, to date there have been no studies examining the roles of TJs in 
sprouting angiogenesis. 
In contrast to the TJs, the AJs are ubiquitous in all types of vessels (Dejana, 2004). The 
transmembrane proteins of the AJs complex are the cadherin proteins, which are calcium-
dependent adhesion molecules (Giannotta et al., 2013). In ECs, these include VE-cadherin 
and N-cadherin. N-cadherin is also expressed in neural and mural cells and regulates EC-
pericyte interactions, and loss of N-cadherin results in early embryonic death due to 
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defects in vascular development owing to an inability to stabilize the vasculature (Luo and 
Radice, 2005; Tillet et al., 2005). VE-cadherin is an EC-specific cadherin and is the major 
regulator of EC-EC adhesion. The cytoskeletal tails of the cadherins bind catenins, in 
particular p120, β-catenin and plakoglobin, which in turn interact with α-catenin that 
regulates the cell cytoskeleton to reinforce cell adhesion (Abraham et al., 2009; Giannotta 
et al., 2013; Vestweber et al., 2009).  
Despite the essential function of VE-cadherin for EC adhesion, Cdh5-/- mice initially form 
the primitive vascular network, but then fail to develop into a mature vessel system 
(Carmeliet et al., 1999; Gory-Faure et al., 1999). Vascular sprouts still recognize each 
other and form connections but fail to stabilize and anastomose correctly (Crosby et al., 
2005). Importantly, when sprouting tip cells from WT mice connect with each other to 
anastomose, they stop forming filopodia to regulate uncontrolled sprouting and vascular 
branching. However, in cells lacking VE-cadherin, they continue to form filopodia, but do 
not sense the cell to cell contact, and instead continue searching for other connections 
(Giannotta et al., 2013; Lenard et al., 2013). This is further supported in inducible Cdh5-/- 
mice, whereby loss of VE-cadherin leads to uncontrolled sprouting and branching in the 
retina (Gaengel et al., 2012). This indicates that while VE-cadherin is not essential for 
initial EC interaction, it is required for stabilising EC-EC adhesion to allow the fusion of 
vascular sprouts and in the transfer of negative signals to switch the cells to a quiescent 
state. 
1.4.2.2. VE-cadherin regulates VEGF signaling 
In addition to promoting EC-EC adhesion, VE-cadherin and the AJs also act as 
intracellular signaling mediators, underlining the concept that stable EC junctions act to 
inhibit growth signals and reinforce the quiescent state. The natural state of mature 
vessels is that of confluent, resting quiescent cells with VE-cadherin clustered at the cell-
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cell contacts and structured organization of the AJs. Under these conditions, VE-cadherin 
signaling promotes vascular stability, such as contact inhibition, limiting cell migration, 
protection from apoptosis and control of endothelial permeability (Giannotta et al., 2013). 
In particular this is mediated through the interaction and clustering of VE-cadherin with 
GFRs, most notably VEGFR2 (Dejana and Orsenigo, 2013). VE-cadherin interacts with 
VEGFR2 and inhibits its downstream MAPK-ERK mediated proliferation signal while 
maintaining anti-apoptotic PKB/Akt signaling (Dejana and Orsenigo, 2013; Lampugnani 
et al., 2002). This is mediated via interactions with β-catenin and the DEP-1 phosphatase 
to retain VEGFR2 at the cell membrane where it is quickly dephosphorylated (Fig 1.15) 
(Lampugnani et al., 2006). VEGFR2 signaling is strongly influenced by internalization, 
including maintenance of signaling from the endosomal compartments to degradation and 
recycling of the receptors (Giannotta et al., 2013; Nakayama et al., 2013). VEGFA 
binding to VEGFR2 triggers Src activation, which in turn activates Rac signaling leading 
to the phosphorylation of Ser665 and other tyr residues on VE-cadherin (Gavard and 
Gutkind, 2006). These serve to recruit β-arrestin and activate the internalization 
machinery, thereby promoting VE-cadherin endocytosis into clathrin-coated vesicles 
(Gavard and Gutkind, 2006; Gavard et al., 2008) (Fig 1.15). This disassembly of the AJs 
increases vascular permeability and destabilizes cell-cell contacts, which are crucial steps 
in the initiation of angiogenic sprouting. Additionally, this also allows β-catenin and other 
VE-cadherin binding partners to translocate to the nucleus to regulate transcription, where 
they can act to control cell proliferation (Dejana et al., 2009).  
Another mechanism of regulation is the association of VE-cadherin with the vascular 
endothelial receptor-type protein tyrosine phosphatase (VE-PTP), an endothelial specific 
phosphatase (Hayashi et al., 2013). VE-PTP dephosphorylates substrates at the EC 
junctions, including VE-cadherin, plakoglobin, and VEGFR2 (Hayashi et al., 2013). 
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During sprouting angiogenesis, VE-PTP regulates VEGFR2 activation in SCs to 
dephosphorylate VEGFR2 and VE-cadherin to stabilize EC junctions, establish cell 
polarity and lumen formation (Hayashi et al., 2013). Furthermore, it has been recently 
established that the EC junctions are differentially regulated during sprouting 
angiogenesis (Bentley et al., 2014). As described above, vascular sprouts exhibit a mosaic 
of TC and SC phenotypes that are constantly shuffling and transitioning and this is 
regulated by DLL4-Notch signaling (Fig 1.13). It has been further demonstrated that these 
Notch/VEGFR interactions regulates differential VE-cadherin dynamics such that Notch 
signaling stabilizes EC junctions and limits EC mobility within the stalk (Fig 1.13 B) 
(Bentley et al., 2014). On the contrary, the TCs that are high in VEGFR signaling and 
DLL4 expression exhibit active junctions with serrated localization of VE-cadherin at the 
junctions and increased mobility. Thus, sprouting angiogenesis is a dynamic process with 
constant regulation of VEGFR-Dll4-Notch signaling and differential VE-cadherin during 
cell rearrangement and the establishment of effective vascular patterning. 
1.4.3.  OTHER REGULATORS 
In addition to the aforementioned regulators, there are an abundance of other important 
regulators that are involved in angiogenic sprouting. These include other GF/GFR 
signaling pathways such as FGF2, PDGF, Wnt/β-catenin, the stabilising 
Angiopoietin/Tie2, VEGFA and the VEGF co-receptor Nrp1/2, Ephrin, and guidance 
signals such as Netrins, ROBO, Sema/Plexin D1. The roles of these pathways in sprouting 
angiogenesis are covered in other reviews (Adams and Alitalo, 2007; Herbert and 
Stainier, 2011; Potente et al., 2011). However, these are beyond the scope of this thesis, 
where the regulation by VEGFA and the EC junctions are of most concern.  
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1.5.  RHO GTPASES IN ANGIOGENESIS 
The Rho GTPases are the major signaling molecules that regulate the actomyosin 
cytoskeleton. Through this, the Rho proteins control many cellular functions including 
cell migration and adhesion, two critical processes in sprouting angiogenesis. However, 
the exact roles that Rho GTPases play in angiogenesis are not completely understood. 
Here we discuss some of the mechanisms of the Rho GTPases in regulating the 
cytoskeleton during cell migration and adhesion. 
1.5.1.  RHO FAMILY AND GENERAL FUNCTIONS 
The Rho GTPases are small GTPases, members of the Ras superfamily and comprise over 
20 intracellular signaling molecules that regulate the actinomyosin cytoskeleton 
(Heasman and Ridley, 2008). The best characterized of these Rho GTPases are RhoA, 
Rac1 and Cdc42, which are important in regulating actin stress fibres, lamellipodia and 
filopodia, respectively. These Rho proteins are further classified into eight subfamilies 
that share substantial homology within each (Fig 1.16) (Heasman and Ridley, 2008). This 
homology could account for functional redundancy between some of the closely related 
Rho proteins – upregulation of other Rho GTPases are seen in some Rho knockout 
models (Heasman and Ridley, 2008). Most Rho proteins act as molecular switches that 
cycle between active GTP bound and inactive GDP bound forms (Fig 1.17 A). This 
regulation of Rho activity is mediated by interaction with three sets of proteins, guanine 
nucleotide exchange factors (GEFs), GTPase activating proteins (GAPs) and guanine 
nucleotide dissociation inhibitors (GDIs). The Rho GTPases interact with downstream 
effector proteins only when GTP bound and regulate various aspects of the actin 
cytoskeleton (Fig 1.17 B). 
The Rho proteins are direct downstream targets of GF signaling such as VEGF. VEGFA 
stimulation leads to a dramatic and rapid activation of RhoA, Rac1 and Cdc42 and 
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localisation to the membrane (Bryan and D'Amore, 2007). This rapid activation then 
returns to baseline suggesting that these have critical functions in the early stages of 
angiogenesis, namely in regulating cell migration, adhesion and cell shape changes, but 
that there are also important negative regulators that restrict this activation. 
1.5.2.  IN CELL MIGRATION 
During directed cell migration, there is a coordinated interplay between the three major 
Rho GTPases generating a protrusive force at the leading edge and simultaneous 
retractive force at the rear of the cell (Fig 1.18) (Bryan and D'Amore, 2007). This 
involves the activation of Cdc42 at the leading edge to promote the formation of fine, 
actin-rich filopodia, which function to sense the microenvironment and guide the 
direction of cell migration. This is followed by Rac-1 dependent actin polymersation at 
the cell periphery to form the lamellipodia to promote forward movement of the cell. Both 
Cdc42 signaling through WASP and Rac signaling via the WAVE complex converge on 
ARP2/3, which regulates actin polymersation to form new actin filaments (Ridley, 2001). 
This is then followed by Rho and Rac-dependent formation of new focal complex 
structures localized in the lamellipodia that mediates attachment of the extending 
lamellipodia to the ECM. Cell body contraction then occurs, and is dependent on Rho 
mediated actomyosin contractility (Ridley, 2001). This is mediated by Rho signaling via 
ROCK (also known as Rho-kinase) to phosphorylate MLC, thus enabling the myosin 
crossbridge to bind the actin filament and initiate contraction (Ridley, 2001).  
1.5.3.  IN ADHESION AND PERMEABILITY  
Another important role of the Rho GTPases is in the regulation of cell-cell adhesion and 
vascular permeability. Under resting conditions, VE-cadherin regulates AJ stability and 
Rho GTPase activation through interactions with the catenins (Lampugnani et al., 2002) 
(Fig 1.19 A). VE-cadherin clustering increases the concentration of Tiam1 and Vav2, Rac 
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GEFs, and p21 activated kinase (PAK), a Rac effector, thus promoting lamellipodia 
formation that favours barrier maintenance (Lampugnani et al., 2002). Further, while it is 
generally assumed that RhoA mediated stress fibres and contraction impairs barrier 
integrity, it has been shown that in resting conditions a basal level of ROCK is essential 
for continuous EC junction remodeling and maintenance (Szulcek et al., 2013). In 
response to barrier destabilizing mediators such as thrombin and VEGF, the Rho GTPases 
act to regulate transient and sustained increases in vascular permeability. Upon thrombin 
stimulation, rapid RhoA signaling to ROCK and MLC phosphorylation leads to 
contractility, which in turn weakens the connected junctional complex (Giannotta et al., 
2013; van Nieuw Amerongen et al., 2003). In contrast, VEGFA mediated Rho GTPase 
activation has a more direct effect on the disruption of the AJs (Fig 1.19 B). VEGFA 
stimulation activates Src, which stimulates Vav2 to activate Rac1 and PAK. This in turn 
phosphorylates VE-cadherin S665 leading to its endocytosis, and thus an increase in cell 
permeability (Gavard and Gutkind, 2006). While RhoA signaling can promote 
contractility and weaken cell-cell contacts through ROCK, it can also stabilize the AJs 
through downstream activation of mDia (Sahai and Marshall, 2002). mDia promotes actin 
polymerization, localization of the cadherins to the cell periphery, and microtubule 
organisation to effectively stablise the AJs (Sahai and Marshall, 2002). Moreover, 
Angiopoietin-1 acts to stabilise the AJs through its activation of RhoA and mDia, which 
counteracts the effects of VEGFA by sequestering Src (Gavard et al., 2008). This has 
been attributed to the Rho GEF, Syx, which is recruited following Ang1 to activate Rho 
and mDia, and dissociated from the junctions following VEGFA stimulation (Ngok et al., 
2012).  
Also of interest is RhoC, which is part of the RhoA subfamily and shares 92% identity 
with RhoA. RhoC is not required for embryogenesis, which is likely due to compensation 
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by the other Rho subfamiliy members (Hakem et al., 2005). However, RhoC is 
functionally distinct from RhoA. RhoC displays higher affinity for ROCK than RhoA, 
and when overexpressed drives activation of ROCK and actomyosin contraction to disrupt 
the AJs (Sahai and Marshall, 2002). On the other hand, RhoA-mDia signaling drives AJ 
stabilization (Sahai and Marshall, 2002). This RhoC-ROCK signaling also regulates VE-
cadherin mediated suppression of cell sprouting, whereby overexpression of RhoC 
reverses the increase in cord formation following VE-cadherin blockade (Abraham et al., 
2009). RhoC is also critical in tumour cell biology, where it is overexpressed in many 
cancers and mediates disruption of the AJs to promote invasion and metastasis (Hakem et 
al., 2005; Iiizumi et al., 2008; Islam et al., 2014; Ruth et al., 2006; Simpson et al., 2004; 
van Golen et al., 2000a; van Golen et al., 2000b). However, little is known about the role 
of RhoC in endothelial cells and angiogenesis. 
1.5.4.  RHOJ, AN ENDOTHELIAL SPECIFC RHO GTPASE  
RhoJ, an EC specific Rho GTPase is of recent interest. A few studies have reported RhoJ 
as a regulator of EC motility and tube morphogenesis via its effects on controlling 
actimyosin contractility and focal adhesions (Kaur et al., 2011). Further, RhoJ deficient 
mice display delayed radial growth of the retinal vasculature with increased vascular 
regression (Fukushima et al., 2011). Due to its endothelial specificity, RhoJ is seen as an 
effective and selective target for tumour vasculature disruption (Kim et al., 2014). Dual 
blockade of RhoJ and VEGFA signaling effectively suppresses tumour progression and 
metastasis (Kim et al., 2014). 
1.5.5.  REGULATION OF RHO GTPASE ACTIVITY 
As mentioned briefly above, the activity of the RhoGTPases is regulated by interaction 
with the GEF, GAP and GDI proteins (Fig 1.17 A). GEFs promote the release of bound 
GDP and subsequent binding of the more abundant GTP while GAPs on the other hand 
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catalyse the intrinsic hydrolysis of GTP and therefore act to inhibit the GTPase activity 
(Vega and Ridley, 2008). GDI proteins bind to the C-terminal end of RhoGTPases and 
prevent membrane association and sequester them in the cytoplasm, thereby inhibiting 
access to downstream targets. There are over 70 GEFs, 80 GAPs, and 3 GDI proteins of 
which there is substantial redundancy and also some proteins that regulate multiple 
GTPases (Heasman and Ridley, 2008). Aberrant Rho GTPase signaling is one of the 
major causes of disease including cancer and vascular diseases (Vega and Ridley, 2008). 
However, unlike the Ras superfamily counterparts, the RhoGTPases are rarely mutated in 
cancers. Instead, aberrant activation of Rho signaling involves constitutively active splice 
variants of RhoGTPases, altered localization mediated by GDIs, and altered expression 
and function of the regulatory GEFs and GAPs (Vega and Ridley, 2008). Many GAPs and 
GEFs have been identified as oncogenes, including the Rac GEFs Vav2 and Tiam1 
mentioned above (Cook et al., 2013), and DLC-1, a RhoA GAP and tumour suppressor 
that is frequently mutated and lost in liver, breast and many other cancers (Ng et al., 2000; 
Xue et al., 2008; Yuan et al., 2003).  
Taken together, this highlights the importance of Rho signaling in regulating critical 
processes of angiogenesis, namely cell migration and junctional integrity. Aberrant Rho 
signaling through perturbations in the regulatory Rho GEF and Rho GAP proteins is 
associated with diseases, hence Rho GTPase signaling is recognized as an attractive 
therapeutic target (van der Meel et al., 2011; Vega and Ridley, 2008). 
1.6.  ARHGAP18 
The vascular biology laboratory previously identified a role of ARHGAP18 in the 
regulation of EC biology. ARHGAP18 was first isolated from a macrophage library and 
termed MacGAP (NM_33515). Subsequent studies from our laboratory identified 
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ARHGAP18 in a screen for angiogenic genes, and showed a novel role in senescence 
(hence the alias SENEX). ARHGAP18 has also been implicated in epithelial migration 
and morphogenesis.  
1.6.1.  BIOINFORMATICS ANALYSES 
1.6.1.1. Protein domains and isoforms 
The human ARHGAP18 gene is located on chromosome 6q22.33 and encodes for a 3.5 
kb transcript (Accession ID NM_033515.2). The translated protein is 663 amino acids 
with a predicted molecular weight of ~75 kDa and an isoelectric point of 6.4 (Accession 
ID NP_277050.2). The actual ARHGAP18 protein exists as two isoforms, an ~78 kDa 
and a smaller ~75 kDa, which is proposed to be due to translation from the downstream 
start codon at amino acid 55 (Coleman et al., 2010; Maeda et al., 2011). It is unclear if 
there are any functional differences between these two isoforms. 
ARHGAP18 belongs in the family of RhoGAP proteins due to the presence of the 
RhoGAP domain. As described above, the RhoGAP proteins catalyse the GTPase activity 
of the RhoGTPases thus causing their inactivation. The RhoGAP domain in ARHGAP18 
is located between amino acids 324-523 (Fig 1.20 A). Apart from the RhoGAP domain, 
there are no other known classic domains.  
By phylogenetic analysis of ARHGAP18 sequences, ARHGAP18 is highly conserved in 
many species (Fig 1.20 B, Table 1.1). Amongst the mammals, including mice, 
ARHGAP18 shows over 84% identity and 90% similiarity. ARHGAP18 is less conserved 
in the non-mammals including chicken (Gallus gallus), zebrafish (Danio rerio) and frogs 
(Xenopus laevis). However, the GAP domain of ARHGAP18 in these species is 
considerably more conserved compared to the rest of the protein. This indicates that the 
function of ARHGAP18 through its RhoGAP domain is likely to be similar in the 
different species. 
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Comparison of ARHGAP18 to the sequences of 17 of the closest other RhoGAP proteins 
reveals that it shows highest similarity to ARHGAP28 and ARHGAP40 (Fig 1.21) 
approximately 30% identity and 40% similarity between these two proteins. Further, the 
GAP domain of ARHGAP18 shares close to 50% identity and over 70% similarity 
respectively. This may indicate that ARHGAP18 is more functionally similar and shows 
redundancy to ARHGAP28 and ARHGAP40. There is currently one publication that has 
identified ARHGAP28 to be a predominantly bone-restricted RhoA GAP protein (Yeung 
et al., 2014). When overexpressed in epithelial cells, ARHGAP28 was found to inhibit 
stress fibre formation and induce membrane ruffles. However, ARHGAP28-/- mice have 
limited phenotypes, which is thought to be due to the compensatory upregulation of 
ARHGAP6, but not ARHGAP18, in these mice. There are currently no studies on the 
function of ARHGAP40. 
1.6.1.2. Expression analysis 
Using BioGPS (Wu et al., 2009) (biogps.org), murine ARHGAP18 is found to be 
ubiquitously expressed in different cells and tissues, albeit at different levels (Fig 1.22). 
Most notably, there is high-level expression of ARHGAP18 in mast cells and 
macrophages, which may suggest potential roles of ARHGAP18 in degranulation. In the 
mouse tissues, there are various levels of expression with the most notable in the 
hormonal tissues (e.g. mammary gland, ovaries) and the gastrointestinal tissues except for 
the liver. Intriguingly, there is very little expression of ARHGAP18 in the tissues of the 
nervous system. We and others (Maeda et al., 2011) have previously shown that 
ARHGAP18 is also expressed abundantly in many cell lines of different organ origins. 
However, ARHGAP18 is most highly expressed in ECs (Coleman et al., 2010; Maeda et 
al., 2011), which has been found to be 22-fold higher relative to other tissues (van Buul et 
al., 2014). 
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Analysis of cancer databases (COSMIC (cancer.sanger.ac.uk/cosmic), cBioPortal 
(cbioportal.org)) reveals that ARHGAP18 is aberrantly regulated in many types of cancer. 
ARHGAP18 is mutated in up to 2% of cancer cases with various mutations throughout 
the protein, including the GAP domain. ARHGAP18 shows little changes in copy number 
variation, however it has been found to be overexpressed in over 5% of cancers including 
those of the cervix, liver, central nervous system, stomach, large intestine and esophageal 
tissues. 
1.6.2.  PREVIOUS PUBLICATIONS 
1.6.2.1. In tube formation in vitro 
The Vascular Biology laboratory originally identified ARHGAP18 (alias SENEX) 
through a PCR array screen of genes regulated during in vitro capillary tube formation 
(Coleman et al., 2010; Hahn et al., 2005). Using this model, the ECs undergo a 
synchronized process of angiogenesis with coordinated changes in EC proliferation, 
migration, stabilization, lumen formation and maturation (Hahn et al., 2005). It was found 
that ARHGAP18 is dynamically regulated with an initial downregulation during the early 
migratory phase then upregulated at the later stabilization phase (Coleman et al., 2010; 
Hahn et al., 2005). Furthermore, knockdown of ARHGAP18 did not affect cell migration 
and alignment but prevented the formation of stable tubes resulting in EC death. On the 
other hand, ARHGAP18 overexpression did not affect tube formation. These observations 
suggested that ARHGAP18 might have potential roles in regulating EC migration or 
stabilization. ARHGAP18 was chosen for further analysis based on its high level of 
expression in EC and its biphasic regulation of expression during capillary tube 
formation. In addition, at the time of its characterisation in angiogenesis, the function of 
ARHGAP18 in any cell had not been identified. 
1.6.2.2. In anti-inflammatory EC senescence 
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While ARHGAP18 overexpression does not affect tube formation, it induces EC 
senescence (Coleman et al., 2010). The induction of senescence is a response to oncogene 
activation or DNA damage and is a critical tumour suppressive mechanism (Hanahan and 
Weinberg, 2000; Perez-Mancera et al., 2014). Senescent cells cease to proliferate and are 
characterized by a large flattened morphology, polyploidy and accumulation of 
senescence-associated β-galactosidase (SA-β-gal) (Perez-Mancera et al., 2014). 
ARHGAP18 overexpression induces premature senescence that is associated with 
activation of the p16INK4a, but not the p53/p21 pathway (Coleman et al., 2010). 
Furthermore, senescent cells induced by oxidative stress, but not replicative stress had an 
accumulation of ARHGAP18. 
While senescence undoubtedly is a tumour suppressive response, it also has deleterious 
effects through the senescence-associated secretory phenotype (SASP) (Perez-Mancera et 
al., 2014). Senescent cells accumulate with age and disease and contribute to pathology 
through the secretion of the proinflammatory SASP mediators, such as TNF-α, and IL-6 
(Coppe et al., 2010; Perez-Mancera et al., 2014). Intriguingly, ARHGAP18 
overexpression mediates a profoundly anti-inflammatory senescence phenotype, with 
reduced expression of inflammatory adhesion molecules (VCAM1, E-selectin) and 
perturbed neutrophil attachment and transmigration (Coleman et al., 2010). This has been 
demonstrated to be dependent on caveolae, small specialized lipid rafts on the cell 
membrane, that act as critical signaling molecules (Powter et al., 2015). During 
endothelial senescence induced by oxidative stress, hypoxia, or shear stress, there is an 
equal mixture of pro- and anti-inflammatory senescent cells (Coleman et al., 2013). This 
ARHGAP18-associated anti-inflammatory population is speculated to have unique 
protective roles in limiting uncontrolled proliferation and the local inflammatory response 
(Coleman et al., 2013). Thus, the work by (Coleman et al., 2010) showed a novel cellular 
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phenotype (anti-inflammatory senescent EC) induced by a newly described gene 
(ARHGAP18). 
1.6.2.3. As a RhoA GAP in epithelial cell rounding and migration 
Following our initial publication (Coleman et al., 2010), Maeda et al. (2011) then 
demonstrated that ARHGAP18 is a regulator of cell shape, spreading and motility through 
its RhoA GAP function. Knockdown of ARHGAP18 in HeLa and MDA-MB-231 
epithelial cells induces a contractile phenotype with prominent stress fibres and focal 
adhesions. On the contrary, overexpression of full-length ARHGAP18, but not GAP 
deficient or a GAP mutant, could reverse the effects on stress fibres and focal adhesions. 
The contractile phenotype was further demonstrated to be dependent on RhoA and 
downstream ROCK activation. This has critical functions in regulating cell spreading and 
migration, with the knockdown contractile cells displaying reduced cell spreading and 
migration. 
1.6.2.4. Regulation of tissue tension 
A recent study by Porazinski et al. (2015) demonstrated a role of ARHGAP18 in 
regulating tissue tension. During vertebrate development, correct tissue and organ shape 
and alignment are essential for function. This process of tissue tension is primarily 
regulated by actomyosin contraction. It was identified that medaka fish embryos with a 
mutation in the YAP protein results in pronounced body and tissue flattening and collapse 
(Porazinski et al., 2015). ARHGAP18 was revealed as a downregulated gene in the 
screening of YAP mutants and knockdown of ARHGAP18 phenocopied the YAP 
mutants. Further, expression of a membrane-targeted ARHGAP18 was able to rescue the 
body flattening phenotype indicating that ARHGAP18 acts downstream of YAP in the 
regulation of the cortical actomyosin network.  
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1.6.2.5. In Drosophila as Conundrum  
The ARHGAP18 orthologue, Conundrum (Conu), has been identified as a regulator of 
Rho1 during epithelial morphogenesis in Drosophila (Neisch et al., 2013). Rho1 (the 
RhoA homologue in Drosophila) regulates epithelial integrity and morphogenesis by 
controlling F-actin assembly and actomyosin contractility. Conu regulates Rho1 and Rac1 
activity through its localization at the cell cortex and interaction with Moesin to control 
epithelial morphology and proliferation. However, phylogenetic analyses of ARHGAP18 
related amino acid sequences revealed that Conu actually displays higher similarity to 
ARHGAP28 and ARHGAP40 than to ARHGAP18 (Porazinski et al., 2015).  
1.6.2.6. In breast cancer 
This PhD was initially aimed at investigating ARHGAP18 in breast cancer and breast 
epithelial cell senescence. However this was indefinitely suspended due to technical 
feasibilities after 1.5 years into the project. The detailed results of this project are not 
discussed in this thesis.  
We identified that ARHGAP18 is overexpressed in breast cancer, with increasing 
expression correlating with cancer progression (unpublished data). ARHGAP18 is highly 
expressed in the mammary epithelium, and is regulated during lactation (unpublished 
data, BioGPS). Furthermore, analysis of cancer databases reveals that ARHGAP18, while 
rarely mutated (<1% of cases), is amplified in breast cancer patients, with one particular 
study identifying gene amplification in over 30% of cases (Eirew et al., 2015). In murine 
mammary tumourigenesis, the ARHGAP18 locus has been demonstrated to be a novel 
integration site for mouse mammary tumour virus (Kim et al., 2011). ARHGAP18 is 
overexpressed in murine mammary tumours, and its overexpression increases mammary 
epithelial cell proliferation, cell cycle and 3D acinar morphogenesis (Kim et al., 2011).  
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1.7.  PROJECT AIMS  
Angiogenesis requires a highly coordinated set of molecular and cellular changes in EC 
behavior to drive the process including sprouting, elongation, stabilization and 
remodeling. Sprouting requires a highly regulated balance of sprout inducing signals, such 
as VEGF, and stabilizing signals, such as maturation of EC junctions, to effectively 
pattern the vascular network. Both of these factors converge on the RhoGTPases, core 
signaling molecules that regulate the actin cytoskeleton and control fundamental cell 
processes.  
We had previously identified ARHGAP18 as a key regulator of EC biology in its 
regulation of anti-inflammatory senescence. At the commencement of this study, there 
had been little understanding into the function of ARHGAP18 in cell biology. Taking into 
consideration the current literature on the function and regulation of expression of 
ARHGAP18 during tube formation and 3D morphogenesis, we hypothesise that 
ARHGAP18 acts via its RhoGAP function as a key regulator of angiogenesis (Fig 
1.23). 
To address this possibility, we have investigated ARHGAP18 in relation to:  
1. Its role in Ras induced EC sprouting and EndMT. The initial project was aimed at 
investigating Ras-induced oncogene induced EC senescence and the role of 
ARHGAP18. However, the results refocused the overall aim to investigate the role 
of ARHGAP18 in regulating EC sprouting angiogenesis. 
2. EC sprouting angiogenesis and TC/SC regulation. 
3. Its mechanism of ARHGAP18 in regulating EC sprouting angiogenesis. 
4. Its post-translation modifications that regulate its function.  
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Fig 1.1. Angiogenesis in health and disease 
Angiogenesis plays a major role in health and disease. Angiogenesis is crucial in embryonic 
development and in organ development. Balanced angiogenesis is required to maintain vascular 
homeostasis. Under or over regulated angigoenesis are major contributors to pathology including 
heart disease, cancer, chronic in!ammation and vascular malformations. 
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Fig 1.2. Development and assembly of the vasculature. 
During early embryo development, endothelial progenitors (angioblasts) diﬀerentiate from 
mesodermal cells. When formed, angioblasts may acquire arterial (red) or venous (blue) fates and 
form the #rst blood vessels, the dorsal aorta and the cardinal vein. Angioblasts also aggregate to 
form blood islands, which fuse and remodel to generate the primary capillary plexus.  
Following vasculogenic assembly, angiogenic remodeling assembles the hierarchical network of 
arteries, arterioles, capillaries, venules and veins. Oxygenated nutrient rich blood travels from the 
heart through the arteries and arterioles to the capillaries which facilitate the exchange of gases and 
nutrients. Deoxygenated blood returns through the veins to the heart and then to the lungs to be 
replenished with oxygen.  
The lymphatic system runs parallel to the vascular system and functions in the clearance of !uids, 
and immune cells. The formation of the lymphatic system is initiated from the lymphangiogenic 
sprouting of lymphatic ECs originating from the early embryonic veins. Blind ended lymphatic 
capillaries feed into the larger collecting vessels and ducts and #nally into the venous circulation. 
 
Adapted from Herbert and Stainier (2011). 
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Fig 1.3. Cellular mechanisms of vessel formation. 
A. Endothelial cells (ECs) line the luminal surface of quiescent blood vessels. The ECs are tightly 
interconnected by junctional molecules and are ensheathed by pericytes which help maintain the 
inactive state of the endothelium. 
B. During sprouting, high levels of pro-angiogenic growth factors select tip cells (TCs) for sprouting.  
Sprouting requires the modulation of junctional contacts, pericyte detachment and basement 
membrane degradation. The TCs migrate towards gradients of pro-angiogenic factors along a 
provisional extracellular matrix (ECM) scaﬀold. 
C. TCs continue migrating until reaching other vessels, whereby TC behaviour is repressed and the 
cells undergo anastomosis, which is assisted by myeloid cells. Stalk cells (SCs) trail the leading TC 
and support the extension of the sprout. SCs are responsible for depositing basement membrane, 
dividing to elongate the vessel and initiating lumen formation. 
D. Nascent vessels are perfused and stabilised by pericyte recruitment. The pericyte-endothelium 
interactions, strengthening of the EC-EC contacts and ECM deposition re-establish the quiescent 
vessel. 
 
Adapted from Herbert and Stainier (2011). 
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Fig 1.4. Vessel fusion and perfusion. 
A.  Tip cell fusion. Tip cells sprout until sensing other tip cells and initiate VE-cadherin mediated cell 
adhesion. Branch anastomosis is also facilitated by macrophages.  
B-C. Models of lumen formation. The formation of the lumen in sprouting vessels can occur by cell 
hollowing (B) or cord hollowing (C). In cell hollowing, ECs form a lumen by fusing intracellular 
and intercellular pinocytic vacuoles. In cord hollowing, ECs rearrange the EC junctions, and 
recruit negatively charged glycoproteins that repel to open up a lumen that is reinforced by 
cytoskeletal retraction. 
 
Adapted from Potente et al. (2011). 
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Fig 1.5. Vessel stabilisation and remodelling 
A.  Vessel stabilisation relies on the recruitment of pericytes and deposition of basement 
membrane. TCs and SCs secrete a variety of factors to recruit pericytes including PDGFB and 
mediate EC-pericyte interactions via N-cadherin. Pericytes ensheath and stabilise vessels by 
suppressing EC sprouting and proliferation and promote cell survival. 
B.  Blood !ow remodels the EC shape and contacts in the nascent vessel. The delivery of oxygen to 
the perfused vessel inactivates oxygen sensors to suppress hypoxia driven VEGF responses to 
promote endothelial quiescence. 
C.  Vascular regression. Remodelling of the vessels occurs in vessels that fail to perfuse. Occlusions 
trigger EC regression via apoptosis or via a reverse migration mechanism and form empty 
basement membrane sleeves. 
 
Adapted from Potente et al. (2011). 
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Fig 1.6. Arteriovenous diﬀerentiation 
A.  ECs have heterogeneity in structure and function by diﬀerentiating into arterial or venous 
phenotypes. Arterial ECs have a aligned spindle-like morphology in the direction of blood !ow, 
and are surrounded by layers of elastin #bres. Venous ECs are thinner, are enveloped by fewer 
layers of vSMCs and possess !ap-like structures to prevent back!ow. This diﬀerentiation is 
regulated by hemodynamic factors. Arterial and venous ECs have distinct gene expression 
pro#les such as the expression of Ephrin-B2 and EphB4 respectively. 
 
Adapted from Adams and Alitalo (2007). 
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Organ Function 
B 
A 
Fig 1.7. Endothelial heterogeneity and the regulation of organ regeneration 
A.  ECs from diﬀerent organs display extensive heterogeneity in structure and function. ECs in the 
brain form the tight blood brain barrier that restrict !ow while ECs in the endocrine glands are 
fenestrated allowing for secretion. The mechanisms that regulate tissue-speci#c EC structure and 
function are poorly understood but are postulated to be due to speci#c molecular signatures of 
microvascular ECs in response to the tissue microenvironment. From Hoﬀman and Calabrese 
(2014). 
B.  Tissue-speci#c ECs regulate organ-speci#c regeneration via speci#c angiocrine factors. Following 
lung or hepatic injury, ECs respond to the microenvironmental cues and secrete angiocrine 
factors to facilitate organ regeneration. However, ECs from the liver are unable to regenerate 
injured livers. Adapted from Ramasamy et al. 2015. 
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Endothelial cells (ECs) 
§  Apical/basal polarity 
§  Strong cell-cell adhesion 
§  Non-migratory 
§  Express endothelmarkers 
Mesenchymal cells: 
§  Front and end polarity 
§  Loss of cell-cell adhesion 
§  Highly invasive and migratory 
§  Express mesenchymal markers 
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Fig 1.8. Endothelial-to-mesenchymal transition 
A.  Endothelial-to-mesenchymal transition (EndMT) can be initiated by the activation of multiple 
signaling pathways. During EndMT, ECs lose endothelial characteristics in polarity, adhesion and 
migration and the expression of EC makers, and gain mesenchymal characteristics and markers. 
EndMT is important in regulating embryonic heart development and has stem cell-like 
properties. Endothelial derived #broblasts also have important roles in regulating #brosis of the 
lung, kidney and heart, and are a signi#cant proportion of the cancer-associated #broblast 
population. 
Modi#ed from LeBleu and Kalluri (2011). 
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Fig 1.9. Other forms of vessel formation 
A.  Arteriogenesis. Following vessel blockage, there is an increase in shear stress in the existing 
collateral arteries. This results in enlargement of the collateral arteries to compensate for the 
function of the original vessel. Adapted from Simons and Ware (2003). 
B.  Vessel intussusception. The splitting of vessels through the insertion of tissue pillars. Little is 
known about the function or regulation of intussusception. From Adams and Alitalo (2007). 
C.  Post-natal vasculogenesis. Circulating endothelial progenitors can be recruited and incorporated 
into the endothelial wall and can contribute to angiogenic sprouting. From Adams and Alitalo 
(2007). 
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§  Increased tumour oxygenation 
§  Increased delivery and responsiveness to 
chemotherapeutics 
Vascular normalisation 
(pericyte targeted,  
anti-angiogenic) 
Anti-VEGF 
e.g Bevacizumab 
+ Tumour directed 
cytotoxics 
A 
B 
Fig 1.10. The tumour vasculature and vascular normalisation 
A.  The tumour vessels have a highly disorganised vasculature structure. The ECs lining the tumour 
vessels are poorly interconnected and are surrounded by few pericytes. The vessels are leaky and 
promote a hostile hypoxic and acidic environment that faciliates further anigogenesis, tumour 
cell dissemination, and inhibits drug delivery and the eﬃcacy of chemotherapeutic agents. 
B.  Vascular normalisation for treatment of cancers. Anti-angiogenic therapy alone drives excessive 
vessel regression, leading to increased hypoxia and in!ammation that drives an invasive tumour 
switch. Vascular normalisation, where vessel function is restored in the tumour, and the co-
targeting of the tumour is an emerging concept. Restoring barrier function and tumour 
oxygenation would allow increased eﬃcacy of chemotherapeutics and limit the invasive switch 
of tumours. 
Modi#ed from Carmeliet and Jain (2011). 
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Fig 1.11. VEGF receptors and signaling 
A.  The VEGF family includes VEGFA, VEGFB, VEGFC and VEGFD that bind to diﬀerent VEGFRs to 
regulate diﬀerent aspects of angiogenesis. VEGFA is the major ligand that binds to VEGFR2 and 
coreceptors such as NRP1/2, to regulate angiogenesis. VEGFA also binds to the decoy receptor 
VEGFR1 and its soluble isoform sVEGFR1. VEGFC and VEGFD are major regulators of 
lymphangiogenesis by signaling via VEGFR3. VEGFC also regulates angiogenesis via VEGFR2/
VEGFR3 heterodimer signaling. Modi#ed from Herbert and Stainier (2011). 
B.  VEGFA-VEGFR2 signaling pathways. Binding of VEGFA to VEGFR2 triggers typical receptor tyrosine 
kinase activation and recruits signal transducers to activate downstream pathways such as PI3K/
Akt, p38MAPK, FAK, MAPK/ERK and PKC. These act to regulate processes such as cell survival, 
migration, proliferation, and cytoskeletal rearrangements which are all important in 
angiogenesis. 
 
B 
A 
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VEGF
Tip
VEGFR2
Stalk
DLL4
Notch
VEGFR
Tip cells (TCs): 
§  Highest expression of VEGFR2 
§  Highly motile 
§  Numerous #lopodia sense microenvironment and 
guide angiogenesis 
§  Induces DLL4 expression to laterally inhibit TC 
phenotype in neighbouring cells 
Stalk cells (SCs): 
§  Activated by Notch signaling from TC-induced DLL4 
§  Suppress VEGFR signaling 
§  Less motile 
§  Support cells to stabilise the sprouting vessel 
§  Initiate lumen formation 
Fig 1.12. VEGF-Notch signaling regulates TC-SC diﬀerentiation 
A.  The vascular sprouts are organised into the leading TCs and the trailing SCs. The TCs guide 
angiogenesis by sensing the microenvironmental cues while the stalk cells support the vessel 
structure and initiate lumen formation. TCs have high levels of VEGFR signaling that induces DLL4 
expression to laterally suppress the TC phenotype in the SCs. 
B.  VEGF signaling triggers the TC phenotype and transcriptionally activates DLL4 expression. DLL4 is 
expressed on the cell surface to activate NOTCH1 on the SCs. This liberates NICD, which acts as a 
transcription factor to upregulate Flt1/VEGFR1 and downregulate VEGFR3 to suppress the TC 
phenotype. SCs also express Jagged 1 which competes with DLL4 to prevent Notch signaling in 
the TCs. NICD also regulates its own degradation via NRARP to prevent excessive Notch signaling. 
Adapted from Herbert and Stainer (2011). 
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Fig 1.13. Sprouting angiogenesis involves dynamic rearrangements of TCs and SCs. 
A.  Static and dynamic models of angiogenic sprouting. Under static models, there is a single tip cell 
with the supporting stalk. Computer modeling has indicated that angiogenic sprouts contain a 
mosaic of TC and SCs that vary in the expression of VEGFRs, DLL4 and Notch and in shuﬄing 
capacity. This regulates the dynamic rearrangements of the cells within the sprout. The TC and SC 
fates are also transient through continuously regulation of the VEGFRs, DLL4 and Notch levels. 
This permits constant sensing of the microenvironment to allow for the development of new TCs 
and long range movement and vessel sprouting. Adapted from Bentley et al (2014). 
B.  Dynamic rearrangement of TCs and SCs involves diﬀerential regulation of cell junctions. Cells 
expressing high VEGF activity and high DLL4 have weaker active serrated EC junctions. As a result 
these cells have high shuﬄing capacity and a higher preference for the TC position. 
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Fig 1.14. Organisation of the EC junctions 
A.  The endothelial junctions are organised into the tight junctions (TJs) and the adherens junctions 
(AJs). Both junctions consist of transmembrane proteins, the claudins, JAMs, occludins (TJs) and 
the cadherins (AJs) that function to regulate cell-cell adhesion. The TJs and the AJs are anchored 
to the actin cytoskeleton through interaction with intermediate signaling molecules. 
Functionally, the TJs regulate the paracellular passage of !uids and cells, while the AJs are the 
main regulators of cell-cell contact.  
 
From Lemichez et al (2010). 
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Fig 1.15. Regulation of VE-cadherin-VEGFR2 signaling 
A.  In resting cells, the stable AJs interact with DEP-1 phosphatase to retain VEGFR2 at the cell 
membrane and inhibit its phosphorylation. Following VEGF stimulation, VEGFR2 signals via Src 
and Rac to phosphorylate VE-cadherin. VEGFR2 activation promotes angiogenic signaling is also 
internalised. Phoshorylation of VE-cadherin weakens the cell junctions and recruits β-arrestin 
which triggers VE-cadherin endocytosis into clathrin-coated vesicles and thus causing junction 
disruption and vascular leak. 
 
Adapted from Gavard et al. (2006). 
P 
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Fig 1.16. The Rho GTPase family 
A.  Phylogenetic tree of Rho GTPases. The tree demonstrates the relationship between the diﬀerent 
subfamilies and the individual Rho GTPases. The percentage indicates the amino-acid sequence 
identity between the subfamily members. The classical Rho GTPases cycle between the GTP and 
GDP bound states, whereas the atypical Rho GTPases are all GTP-bound. 
 
From Heasman and Ridley (2008). 
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Fig 1.17. Regulation of Rho GTPase activation and function 
A.  The Rho GTPase cycle. RhoGTPases cycle through active GTP-bound and inactive GDP-bound 
forms. This is catalysed by interaction with GEF and GAP proteins, respectively. The active GTP-
bound form is recruited to the cell membrane and interacts with downstream eﬀectors. The GDIs 
inhibit Rho movement to the membrane by sequestering them in the cytosol. From Akitores 
(2011). 
B.  Downstream eﬀector pathways of Rho, Rac and Cdc42. The RhoGTPases interact with a variety of 
diﬀerent eﬀectors to regulate the actomyosin cytoskeleton. In general, RhoA regulates cell 
contraction, Rac1 actin polymerisation at the lamellipodia, and Cdc42 regulates actin 
polymerisation in the #lopodia.  
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1. Extension of #lopodia 
2. Lamellipodia protrusion &  
attachment to focal complexes 
Fig 1.18. Rho GTPase activation in cell migration. 
A.  Cell migration requires coordination activation of the Rho GTPases. Firstly, Cdc42 guides the cell 
and extends actin-rich #lopodia at the leading edge towards the direction of migration. Rac1 
then promotes lamellipodia protrusion and in combination with RhoA form focal complexes that 
attach the cell to the ECM. The rear of the cell retracts and the cell body contracts via RhoA 
activation. 
Modi#ed from Mattila and Lappalainen (2008). 
3. Retraction of trailing end 
4. Contraction of cell body 
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Fig 1.19. Rho GTPases in the regulation of EC junctions. 
A.  In resting cells, Rac1 promotes lamellipodia and stable junctions through Tiam1, PAK and Vav2 
RacGEFs. On the other hand, RhoA-ROCK regulation of stress #bres acts to impair barrier integrity. 
B.  Following VEGF stimulation, Rac1 and RhoA have opposite eﬀects. VEGF stimulation of Rac1 
phosphorylates VE-cadherin causing its endocytosis leading to junctional disruption. In the 
combined presence of the Ang-1 and VEGF, RhoA acts to inhibit the junctional disruption 
mediated by Rac1. RhoA activation activates mDia which sequesters Src and prevents 
phosphorylation and endocytosis of VE-cadherin. 
Modi#ed from Gavard et al. (2006) and Gavard et al. (2008). 
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Fig 1.20. Domains and phylogenetic analysis of ARHGAP18. 
A.  Human ARHGAP18 contains a single RhoGAP domain between amino-acids 320 and 523. No 
other domains are known. 
B.  Phylogenetic alignment of ARHGAP18 from other species. ARHGAP18 sequences from diﬀerent 
species were aligned by ClustalW. ARHGAP18 is well conserved amongst diﬀerent species with 
high conservation in the RhoGAP domain (red).  
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Identity((%) Similarity((%) Identity((%) Similarity((%) Identity((%) Similarity((%)
Homo$sapiens 100 100 100 100 100 100
Pan$troglodytes$ 98.9 99.4 99 99 98.9 99.6
Felis$catus$ 92 95.2 95.6 97.5 90.5 94.2
Canis$lupus$familaris$ 89.3 93.4 91.6 96.1 88.3 92.2
Rattus$norvegicus$ 85.1 92.3 92.1 96.1 82.1 90.7
Mus$musculus$ 84.2 90.2 91.6 96.1 81 87.7
Gallus$gallus$ 69.6 79.3 82.3 89.7 64.1 74.8
Xenopus$laevis$ 64.9 78.4 69.9 83 62.7 76.4
Danio$rerio$ 40.6 54.6 70 86.7 28.3 41.3
Full(length GAP(domain Rest(of(protein
Species
Table 1.1. Amino acid identity and similarity of ARHGAP18, and the ARHGAP18 RhoGAP 
domain, in diﬀerent species compared to the human sequence. 
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A. Full length alignment 
 
B. GAP domain alignment 
 
RHGAP18 
 
HGAP18 
 
/ DLC1 
 
/ DLC1 
 
Protein Identity (%) Similarity (%) Protein Identity (%) Similarity (%)
ARHGAP13 8.2 15 ARHGAP6 4.4 15.9
ralA-BP1 8.9 19.6 ARHGAP27 10.5 21.6
ARHGAP27 9.3 17.4 ARHGAP12 7.2 15.6
ARHGAP12 7.3 12.6 ARHGAP23 5.2 11.7
ARHGAP23 5.2 11.2 ARHGAP21 4.7 9.3
ARHGAP21 5 9.4 ARHGAP46 8.6 20
ARHGAP46 8.4 17.2 ARHGAP22 3.2 10
ARHGAP22 7.8 13.9 ARHGAP24 4.2 12.7
ARHGAP24 6.8 12.8 ARHGAP11A 4.9 14.4
ARHGAP11A 4.9 9.4 ralA-BP1 5.2 18.4
ARHGAP44 6.9 15.4 ARHGAP18 100 100
ARHGAP19 11.5 21 ARHGAP28 44.7 71.6
ARHGAP6 9.4 18.1 ARHGAP40 49.1 72.9
ARHGAP18 100 100 ARHGAP13 8.5 19.5
ARHGAP28 26.3 39.9 ARHGAP7/DLC1 6.4 13.9
ARHGAP40 29.2 46.5 ARHGAP19 5.7 15.8
ARHGAP7/DLC1 6.1 11.3 ARHGAP44 5.9 17.5
GAP DomainFull length
Protein Identity (%) Similarity (%) Protein Identity (%) Similarity (%)
ARHGAP13 8.2 15 ARHGAP6 4.4 15.9
ralA-BP1 8.9 19.6 ARHGAP27 10.5 21.6
ARHGAP27 9.3 17.4 ARHGAP12 7.2 15.6
ARHGAP12 7.3 12.6 ARHGAP23 5.2 11.7
ARHGAP23 5.2 11.2 ARHGAP21 4.7 9.3
ARHGAP21 5 9.4 ARHGAP46 8.6 20
ARHGAP46 8.4 17.2 ARHGAP22 3.2 10
ARHGAP22 7.8 13.9 ARHGAP24 4.2 12.7
ARHGAP24 6.8 12.8 ARHGAP11A 4.9 14.4
ARHGAP11A 4.9 9.4 ralA-BP1 5.2 18.4
ARHGAP44 6.9 15.4 ARHGAP18 100 100
ARHGAP19 11.5 21 ARHGAP28 44.7 71.6
ARHGAP6 9.4 18.1 ARHGAP40 49.1 72.9
ARHGAP18 100 100 ARHGAP13 8.5 19.5
ARHGAP28 26.3 39.9 ARHGAP7/DLC1 6.4 13.9
ARHGAP40 29.2 46.5 ARHGAP19 5.7 15.8
ARHGAP7/DLC1 6.1 11.3 ARHGAP44 5.9 17.5
GAP DomainFull length
Fig 1.21. ARHGAP18 related proteins. 
A-B. Phylogenetic tree of closely related proteins to ARHGAP18. The full length sequences (A) and 
RhoGAP domains (B) of similar human proteins were aligned using ClustalW. ARHGAP18 shows 
highest similarity to ARHGAP28 and ARHGAP40 when aligning the full-length sequences or RhoGAP 
domains. 
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Fig 1.22. Tissue expression of ARHGAP18. 
BioGPS (biogps.org) data of ARHGAP18 expression in murine cells and tissues, ARHGAP18 shows 
highest expression in mast cells and macrophages. In tissues, ARHGAP18 is highly expressed in 
hormonal tissues and very lowly expressed in the central nervous system. 
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Fig 1.23. Functions of ARHGAP18 
ARHGAP18 has roles in the regulation of EC tube formation and anti-in!ammatory senescence. 
Recent studies have also demonstrated that ARHGAP18 is a regulator of epithelial cell shape and 
tissue morphogenesis. The project aimed to investigate the functions of ARHGAP18 in the regulation 
of angiogenesis. 
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2.1.  MOLECULAR CLONING 
2.1.1.  MATERIALS FOR MOLECULAR CLONING 
LB Broth 10 g/L Bacto tryptone (Sigma Aldrich), 5 g/L yeast extract (Sigma 
Aldrich), 10 g/L NaCl. 
LB-Amp LB Broth containing 100 µg/ml ampicillin sodium salt (Sigma Aldrich) 
LB Agar LB broth containing 15 g/L agar (Sigma Aldrich). 
TAE buffer 40 mM Trizma-acetate (Sigma Aldrich), 1mM EDTA, pH 8.0. 
TE buffer 10 mM Tris-HCl (Sigma Aldrich), 1mM EDTA, pH 7.5. 
2.1.2.  PLASMIDS AND RETROVIRAL VECTORS 
pcDNA3.1-GFP and pcDNA3.1-GFP-ARHGAP18, consisting of the human ARHGAP18, 
were previously constructed by Paul Coleman (Centenary Institute). pcDNA3-mCherry 
was a gift from Dr. Carol Wadham (Centenary Institute). pMIG and pMIG-Ras retroviral 
vectors were a gift from Dr. Alex Swarbrick (Garvan Insitute of Medical Research). 
pQCXIN was a gift from Dr. Joshua Moses (Centenary Institute). The retroviral envelope 
plasmid, pVSV-G, was a gift from Dr. George Sharbeen (Centenary Institute). The use of 
retroviral vectors was in compliance with OGTR guidelines of the Royal Prince Alfred 
Hospital IBC. 
2.1.3.  PLASMID AND DNA FRAGMENT MANIPULATIONS 
Restriction enzymes for cloning were sourced from New England Biolabs (NEB) (MA, 
USA). Restriction enzyme digests were performed at 37°C using at least 500 ng plasmid 
or insert DNA according to manufacturers’ instructions. Fragments generated from 
restriction digests or PCR amplification were ligated into Antarctic phosphatase (NEB) 
treated vector backbones using T4 DNA ligase (NEB) at RT for 10 min or 4°C overnight. 
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2.1.4.  HIGH-FIDELITY POLYMERASE CHAIN REACTION (PCR)  
Specific DNA fragments were amplified using Phusion high-fidelity DNA polymerase 
(Finnzyme). Reactions were performed in 0.2 mL PCR tubes (Interpath, VIC, Australia) 
in a total volume of 25 µL reactions consisting of 1X Phusion master mix buffer, 0.4 U 
Phusion DNA polymerase, 1.5 mM MgCl2, 200 µM dNTP, 0.5 µM forward and reverse 
primers and DNA template. PCR amplification was performed in a BioRad thermocycler 
(BioRad, NSW, Australia) using the conditions outlined in Table 2.1 
Table 2.1. High fidelity PCR thermocycling conditions 
 Step Temperature Time 
 Initial Denaturation 98°C 60 s 
30 cycles 
Denaturation 98°C 10 s 
Annealing 60°C 20 s 
Extension 72°C 30 s/kb 
 Final Extension 72°C 5 min 
 Hold 4°C ∞ 
2.1.5.  AGAROSE GEL ELECTROPHORESIS 
Electrophoresis of DNA fragments was performed using 1% (w/v) agarose gels dissolved 
in TAE buffer and containing 0.5X GelRed DNA stain (Jomar Bioscience, SA, Australia). 
DNA samples were mixed with DNA loading dye (Fermentas, Thermo Scientific) prior to 
loading. DNA samples were co-electrophoresed with the 1kb DNA plus ladder (Life 
Technologies) to determine the sizes of the DNA fragments. Electrophoresis was 
performed in a Bio-Rad sub cell (Bio-Rad) electrophoresis tank containing TAE buffer at 
100 V for approximately 60 min. DNA bands were visualized using the ChemiDoc MP 
Gel imaging system (Bio-Rad). 
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2.1.6.  GEL PURIFICATION AND PCR PURIFICATION 
DNA fragments from agarose gels were recovered by excision of the desired DNA band 
with a scalpel. The recovery of purified DNA was performed using the QIAquick Gel 
Extraction Kit (Qiagen) according to manufacturer’s instructions. All other DNA 
purifications were performed using the QIAquick PCR Purifcation Kit (Qiagen).  
2.1.7.  ASSESSMENT OF DNA QUALITY AND CONCENTRATION 
Purified DNA was quantified using the NanoDrop 2000 spectrophotometer (NanoDrop 
Technologies, DE, USA). The absorption at 260 nm was used to determine the 
concentration of DNA, and the ratio of the absorbance at 260 nm to 280 nm (A260/280) and 
260 nm to 230 nm (A260/230) was used to determine the quality of the DNA. A sample was 
considered clean with an A260/280 ratio of ~1.8 and an A260/230 ratio ~2.0. DNA fragments 
were purified using the PCR purification kit when the quality was poor. 
2.1.8.  DNA SEQUENCING 
DNA sequencing reactions were prepared using 1 µg of DNA and 10 pmol of sequencing 
primer and performed through the service offered by the Australian Genome Research 
Facility (AGRF) (Sydney, Australia). The DNA sequencing results were viewed using 
FinchTV (Geospiza, PerkinElmer, Seattle, USA).  
2.1.9.  BACTERIAL TRANSFORMATION 
The chemically competent Escherichia coli DH5α (Life Technologies) were used for the 
propagation of plasmids and ligation products. Briefly, 5 µL of plasmid or ligation 
products was added to 50 µL of DH5α cells for 30 min on ice. The cells were then heat-
shocked at 42°C for 45 s and recovered with 500 µL SOC media at 37°C for 1 h. The 
bacteria were then spread onto LB agar plates containing 100 µg/ml ampicillin. Single 
colonies were screened, cultured and used for plasmid preparations. 
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2.1.10.  SCREENING OF POSITIVE TRANSFORMANTS 
Single colonies were screened for the presence of DNA inserts by PCR and restriction 
digest of plasmids. Colony PCR was performed using crude DNA prepared by lysing a 
single bacterial colony in 100 µL of 1% (v/v) Triton-X100 (Sigma Aldrich) in TE and 
heating at 95°C for 5 min. Colony PCR reactions were performed in 10 µL reactions 
consisting of 1X Go Taq Green master mix (Promega, NSW, Australia), 0.5 µM forward 
and reverse primer and 4 µL crude colony DNA. Thermocycling conditions used are 
listed in Table 2.2. 
Table 2.2. Thermocycling conditions for colony PCR 
 Step Temperature Time 
 Initial Denaturation 95°C 2 min 
30 cycles 
Denaturation 95°C 30 s 
Annealing 60°C 45 s 
Extension 72°C 60 s/kb 
 Final Extension 72°C 5 min 
 Hold 4°C ∞ 
Positive transformants were subcultured in 2 mL LB-Amp for small-scale plasmid 
cultures to be used for screening by restriction digest. The bacteria were grown at 37°C 
with shaking at 250 rpm overnight. Plasmid DNA was isolated using the Qiagen Plasmid 
Mini kit (Qiagen), and screened by restriction enzyme digest and confirmed by DNA 
sequencing.  
2.1.11.  BACTERIAL AND PLASMID PROPAGATION  
Large-scale plasmid preparations were performed on confirmed colonies. Starter cultures 
of positive clones were first established in 2 mL LB-Amp for 6-8 h at 37°C with shaking. 
Large scale 100 mL LB-Amp cultures were prepared in conical flasks using 100 µL of the 
starter culture and cultured for 12-16 h at 37°C with shaking. Endotoxin-free plasmid was 
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isolated using the EndoFree Plasmid Maxi Kit (Qiagen) and the plasmid resuspended in 
0.1X TE in H2O. 
2.1.12.  SPECIFIC CLONING METHODS 
2.1.12.1. pMIG-ARHGAP18 & pQCXIN-ARHGAP18 
The human ARHGAP18 fragment was excised by EcoRI digest of pcDNA3.1-GFP-
ARHGAP18 and cloned into the EcoRI site of pMIG or pQCXIN. Correct orientation of 
the ARHGAP18 fragment was determined by restriction digest and sequencing of the 
plasmid. 
2.1.12.2. pQCXIN-mCherry and pQCXIN-mCherry-ARHGAP18 
For pQCXIN-mCherry, the mCherry fragment was amplified by high-fidelity PCR using 
the forward primer 5’-GCGGATCCGCCAATGGTGAGCAAGGGCGAGGAGCC-3’ 
and reverse primer 5’-CGGAATTCTTACTTGTACAGCTCGTCCATGCC-3’ to insert a 
5’ BamHI site and 3’ EcoRI site. The fragment was digested using BamHI and EcoRI and 
inserted into BamHI and EcoRI-digested pQCXIN backbone. 
For pQCXIN-mCherry-ARHGAP18, the mCherry fragment was amplified by high-
fidelity PCR using the forward primer 5’-
GCGGATCCGCCAATGGTGAGCAAGGGCGAGGAGCC-3’ and reverse primer 5’-
CGGAATTCCCGCTTGTACAGCTCGTCCATGCC-3’ to insert a 5’ BamHI site and 3’ 
EcoRI site preceeded by a linker codon. The fragment was digested using BamHI and 
EcoRI and inserted into BamHI and EcoRI-digested pQCXIN backbone. The human 
ARHGAP18 fragment was excised from pcDNA3-GFP-ARHGAP18 by EcoRI digestion 
and inserted into the EcoRI-digested pQCXIN-mCherry-linker backbone.  
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2.2.  CELL BIOLOGY 
2.2.1.  CELL CULTURE 
2.2.1.1. Tissue culture media and solutions 
PBS 1X Dulbecco’s phosphate-buffered saline (PBS), pH 7.1, was 
prepared from a 10X PBS solution (Gibco, Life Technologies, 
CA, USA) and contained of 20 mg/L KCl, 20 mg/L KH2PO4, 
800 mg/L NaCl, and 216 mg/L Na2HPO4.   
PBS-EDTA 1X PBS containing 10 mM EDTA (Sigma Aldrich, MI, USA). 
Trypsin-EDTA 1X Trypsin-EDTA, pH 7.1 was prepared from a 10X Trypsin-
EDTA solution (Gibco, Life Technologies) in PBS and 
contained of 500 mg/L trypsin and 200 mg/L EDTA. 
DMEM Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Life 
Technologies) contained 4.5 g/L glucose, 4 mM L-glutamine, 25 
mM HEPES and was supplemented with 10% fetal calf seum 
(FCS) (AusGeneX, Brisbane, Australia). 
HUVEC base media Medium M199 (Sigma Aldrich) supplemented with 20 mM 
HEPES (Gibco, Life Technologies), 1 mM sodium pyruvate 
(Gibco, Life Technologies), 1X MEM non-essential amino acids 
(Gibco, Life Technologies), 1.125 g/L NaHCO3 (Gibco, Life 
Technologies) 100 U/mL penicillin, 100 µg/mL streptomyocin 
(Gibco, Life Technologies).  
HUVEC SF media HUVEC base media.  
HUVEC wash media HUVEC base media supplemented with 2% (v/v) FCS 
(HyClone, ThermoFisher, Scoresby, Australia). 
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HUVEC culture media HUVEC base media supplemented with 15% (v/v) FCS 
(Hyclone), 15 µg/mL endothelial cell growth supplement (BD 
Biosciences, MA, USA) and 15 µg/mL heparin (Sigma Aldrich). 
Gelatin Gelatin coating solution consisted of 17.5 mg/mL gelatin (Sigma 
Aldrich), 3.75% FCS (Hyclone), 1.56 g/L NaHCO3, in Hank’s 
buffered saline solution (Gibco, Life Technologies). 
EGM-2 Endothelial Growth Medium 2 (EGM-2) (Lonza, Sydney, 
Australia) consisted of EBM-2 Basal Medium supplemented 
with EGM-2 growth factors. 
2.2.1.2. Cell line culture 
HEK293T and GP2-293 cells were gifts from Dr. Charles Bailey (Centenary Institute). 
NIH-3T3 mouse fibroblasts were a gift from Dr. Chris Jolly (Centenary Institute). Cell 
lines were maintained at 37°C in a 5% CO2 humidified tissue culture incubator. The cell 
lines were cultured in DMEM in vented tissue-culture treated flasks (Corning, VIC, 
Australia) and were routinely passaged by trypsin digest and re-seeded at 1:5 split ratios, 
three times per week.  
2.2.1.3. HUVEC isolation and culture 
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical 
cords of donors at the Royal Prince Alfred Hospital, Sydney according to approved 
human ethics guidelines. HUVECs were isolated by collagenase digestion as previously 
described (Coleman et al., 2010). Isolation of HUVECs was performed by Lijun Wang, 
Elena Zaporoshenko and Lutfun Khan. 
HUVECs were routinely split every 4 d or when confluent. Briefly, confluent HUVECs 
were washed once with PBS-EDTA to remove trypsin-inhibiting factors, and detached by 
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trypsin-EDTA digestion. The trypsin was inactivated by addition of HUVEC wash media, 
and cells were collected by centrifugation at 500 x g for 5 min. The cell pellet was 
resuspended in HUVEC culture media and re-seeded in gelatin-coated vented tissue 
culture flasks at 1:3 split ratios. HUVECs were routinely used between passages 2-4 for 
experiments. 
2.2.2.  CELL TRANSFECTION FOR GENE OVEREXPRESSION AND 
KNOCKDOWN 
2.2.2.1. Transient transfection of cell lines with plasmids 
HEK293T and GP2-293 cell lines were transiently transfected for retroviral production 
and protein overexpression experiments by lipid transfection. Transfections were 
performed using Lipofectamine 2000 (Life Technologies) according to manufacturer’s 
instructions. Briefly, cells were seeded at ~80% confluence overnight in poly-L-lysine 
(Sigma Aldrich)-coated tissue culture dishes or plates. The tissue culture media was 
replaced 30 min prior to transfection with fresh DMEM. For 10 cm dishes, 60 µg of 
Lipofectamine 2000 was first activated in 1.5 mL OptiMEM (Life Technologies) at RT 
for 5 min. In a separate tube, 24 µg of total DNA was diluted in 1.5 mL OptiMEM. The 
DNA and Lipofectamine solutions were then mixed and incubated for 20 min for complex 
formation. The complexes were then added drop-wise to cells. Penicillin and 
streptomyocin was added 4-6 h following transfection to prevent contamination. The 
media was changed 24 h post-transection. Transfected cells were routinely used 48-72 h 
following transfection for protein experiments and retrovirus production. Experiments 
were upscaled or downscaled using the equivalent ratios of DNA and Lipofectamine. 
Successful transfection was monitored by the examining EGFP or mCherry expression on 
a Nikon Eclipse Ti inverted fluorescence microscope (Nikon, NY, USA). 
2.2.2.2. siRNA transfection of HUVECs for gene knockdown 
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HUVECs at P2, unless stated otherwise, were seeded at 2.0 x 105 cells in gelatin-coated 6-
well plate wells overnight. Prior to transfection, the cell media was removed, washed once 
with serum-free HUVEC media and replaced with 1.5 mL EGM-2 media. 
Lipofectamine:siRNA complexes were formed by mixing 2.5 µL of Lipofectamine 
RNAiMax (Life Technologies), diluted in 250 µL OptiMEM, and 5 nM of siRNA, diluted 
in 250 µL OptiMEM, for 10 min. The complexes were added drop-wise to cells and 
incubated for 4-6 h after which the media was replaced with HUVEC media. Cells were 
fixed or harvested at 3 d following knockdown, which represented the time point of 
greatest knockdown effectiveness.  For double knockdown experimentsm ECs were first 
transfected with ctrl or ARHGAP18 siRNAs for 1 d then transfected with RhoA/C or ctrl 
siRNAs on the next day and cells used 3 d following RhoA/C siRNA transfection. siRNA 
sequences used are listed in Table 2.3. 
Table 2.3. siRNA manufactuers and sequences 
Gene siRNA Manufacturer siRNA sequence/Product ID 
Control 
siCtrl-1 Life Technologies Stealth siRNA Negative Control Lo GC 
siCtrl-2 Sigma Aldrich Mission siRNA Universal Control #1 
siCtrl-pool Dharmacon ON-TARGETplus Control Pool (D-001810) 
Flu-Ctrl Life Technologies BLOCK-iT AlexaFluor Red Control 
ARHGAP18 
siGAP18-1 
Life 
Technologies 
UGGCAAAGAUUCUUGAUUCUAAUGG 
siGAP18-2 UACAAUGGCUUUGACUUUAUAACCC 
siGAP18-3 UUUACAAUAAACUUGGGAAUUGUCC 
siGAP18-4 
Sigma Aldrich 
GGCAAUACAGCUAACUGAA 
siGAP18-5 CUAUUGGAUAGAACUAGAA 
siGAP18-6 GAUGAUGCCACAUUACCUA 
siGAP18-7 GCCAUUUAGCCCUAAUUGA 
RHOA siRhoA Dharmacon SMARTpool RhoA siRNA (L-003860) 
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RHOC siRhoC SMARTpool RhoC siRNA (L-008555) 
CTTN 
siCTTN-1 
Life 
Technologies 
GGAUCGGAUGGAUAAGAAUGCGUCA 
siCTTN-2 AUGAGAUCUCAUUUGACCCUGAUGA 
siCTTN-3 GAGUCACAGAGAGAUUACUCCAAAG 
2.2.3.  ADENOVIRUS TRANSDUCTION FOR GENE OVEREXPRESSION 
Infectious adenovirus particles were prepared using the Adeasy system, as previously 
described (Coleman et al., 2010). The adenoviral particles transiently overexpress GFP 
and ARHGAP18 or empty vector (EV) off separate CMV promoters. For high level 
transduction (section 3.2.11) HUVECs were seeded overnight at 1.2 x 105 cells in gelatin-
coated 6-well plate wells overnight. The cell media was replaced with HUVEC media 
containing 2% FCS and adenovirus particles were added at a predetermined MOI for 
~70% transduction. After 2 h, the media was supplemented with HUVEC media 
containing 38% FCS and cultured overnight. The media was replaced completely at 24 h 
with HUVEC culture media and cells routinely used at 3 d following transduction. For 
low-level overexpression (section 5.2.5), HUVECs were seeded at 1.8 x 106 cells in 
gelatin-coated 10 cm dishes overnight and transduced with adenoviral particles in 
HUVEC media containing 2% FCS and 8 µg/mL polybrene (hexadimethrine bromide) 
(Sigma Aldrich) for 2 h. The media was completely changed and cells used 1 d following 
transduction. 
2.2.4.  RETROVIRUS PRODUCTION AND TRANSDUCTION 
2.2.4.1. Retrovirus production 
Pantropic retroviruses were used for transduction of HUVECs for ectopic gene 
expression. Pantropic retroviruses were produced using the GP2-293 system (Clontech). 
In this system, GP2-293 cells, which stably express the Moloney Murine Leukemia Virus 
(MMLV) gag and pol genes, were transfected with the envelope vector, pVSV-G, which 
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confers pantropism, and a retrovirus expression vector (pMIG or pQCXIN backbones) to 
encode for genes of interest. GP2-293 cells were seeded at 1 x 107 cells in 10 cm dishes 
pre-coated with 0.1% (w/v) poly-L-lysine and allowed to attach overnight. Transfection of 
GP2-293 cells were performed as mentioned in section 2.2.2.1, using 9.6 µg pVSV-G and 
14.4 µg retrovirus expression vectors, for a combined 24 µg. Following 24 h transfection, 
the cell media was replaced with 7 mL of DMEM media and incubated at 32°C overnight 
to promote virus stability. At 48 h post-transfection, the live retrovirus was collected by 
removing the culture supernatant and passing through a 0.45 µm polyvinylidene 
difluoride (PVDF) filter (MillexHV Millipore, VIC, Australia). The virus was distributed 
into 1.5 mL aliquots, snap-frozen in dry ice and stored at -80°C until use. The virus was 
also collected at 72 h post transfection after replacing the media with another 7 ml of 
media following virus harvest at 48 h. Retrovirus production was up and down-scaled as 
required. 
2.2.4.2. Retroviral titre 
To determine the retroviral titre for subsequent transduction experiments in HUVECs, 
NIH3T3 mouse fibroblasts were transduced with pantropic retroviruses. NIH3T3 cells are 
easily transduced, and are commonly used as a standard for determining viral titre by 
EGFP expression (Dolnikov et al., 2003). NIH3T3 cells were seeded at 2.0 x 105 cells in 6 
well plate wells overnight. Retroviruses were diluted in 3.16-fold serial dilutions (half 
log10) in DMEM and polybrene  (Sigma Aldrich) added to a final concentration of 4 
µg/mL. The cell media was replaced with 1.5 mL of diluted virus and the virus was 
spinoculated onto the cells by centrifugation at 1,500 rpm (520 x g) for 90 min at RT. 
Following centrifugation, the cells were returned to 37°C for 30 min, and subsequently 
media changed. The cells were collected by trypsin detachment at 48 h post-transduction, 
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fixed and analysed for GFP expression by flow cytometry (see section 2.2.5). The viral 
titre, green fluorescence units per mL, is represented by the following formula:  
Viral titre (GFU/ml) = % of transduced cells x cell no. at time of 
transduction / volume of virus (ml) 
This only holds true when the percentage of transduced cells is less than 15%, where it 
represents a single virus particle per cell (Dolnikov et al., 2003). At higher transduction 
efficiencies, there is a higher propensity for multiple viruses transducing the same cell, 
resulting in higher copy numbers. The multiplicity of infection (MOI) for HUVECs was 
defined as the number of virus particles per cell and is represented by: 
MOI = GFU / no of cells at time of transduction 
2.2.4.3. Retrovirus transduction of HUVECs 
HUVECs were seeded at 1.5 x 105 cells in gelatin-coated 6 well plate wells overnight. 
The following day, the cells were washed once in serum-free HUVEC media to remove 
residual hepain (a polyanion) and replaced with virus-containing DMEM media with the 
addition of 8 µg/mL polybrene. Transduction of HUVECs was routinely performed at 
MOIs between 1-10 and represented at least 80% transduction efficiency. The cells were 
spinoculated at 1,500 rpm (520 x g) for 90 min at RT, and returned to 37°C for 30 min 
following centrifugation, after which the media was replaced with HUVEC media. EGFP 
and mCherry was readily expressed 2 d following transduction, but maximally from 4 d 
transduction. Cells were either harvested from 2 d transduction or split and kept in culture 
for other experiments up to 8 d transduction. 
2.2.5.  FLOW CYTOMETRY FOR GFP EXPRESSION 
The measurement of GFP transfected and transduced cells was determined by flow 
cytometry. GFP-expressing cell lines and ECs were harvested by trypsin detachment and 
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fixed in 2% formaldehyde (w/v), 0.02% sodium azide (Sigma) in PBS for 30 min. The 
cells were washed in PBS and resuspended in 1% (w/v) FCS in PBS in 5 mL round 
bottom tubes (BD Biosciences). The samples were analysed on a FACS Canto II flow 
cytometer (BD Biosciences) and the data analysed using FlowJo software (version 9.4, 
Treestar) . 
2.2.6.  CELL STIMULATION AND TREATMENT 
2.2.6.1. Stimulation with growth factors and thrombin 
For stimulation with growth factors and thrombin for molecular assays and for cell 
imaging, the HUVECs were first starved in HUVEC SF media containing 2% FCS for 2 
h. VEGF-A (Sigma) was used at 10 ng/mL. Thrombin (Sigma) was used at 1 U/mL. 
2.2.6.2. Treatment with drug inhibitors 
Treatments of HUVECs with signaling inhibitors following Ras activation were 
performed in normal culture media. U0126 (30 µM), LY294002 (30 µM) and PD98059 
(100 µM) were from Sigma and were added to culture media every 2 d.  
ROCK inhibitor experiments were performed using the starvation conditions for thrombin 
treatment. HUVECs were pretreated with 2.5 µM Y-27632 (Sigma) for 30 min prior to 
thrombin stimulation. 
2.2.7.  CELL PROLIFERATION 
Transduced or transfected HUVECs were seeded at 4 x 105 cells in 25 cm2 flasks in 
HUVEC media. Cell proliferation was determined at different days by trypsin detachment 
of cells, and counting the number of cells in a hemocytometer. The media was replaced 
every 3 days during the assay until the end of the experiment.  
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2.2.8.  CELLULAR SENESCENCE BY SA-Β-GAL STAINING 
Cytochemical detection of Senescence-associated β-galactosidase (SA-β-gal) at pH 6.0 
was performed according to (Charalambous et al., 2007). Control or HRasV12-transduced 
ECs cultured in 25 cm2 flasks for 5 d were washed twice in PBS then fixed in 2% (w/v) 
formaldehyde, 0.2% gluteraldehyde in PBS for 15 min at RT. The fixed cells were 
washed once with PBS, then twice with dH2O before staining overnight at 37°C with SA-
β-gal staining solution consisting of: 5 mM potassium ferrocyanide (Sigma Aldrich), 5 
mM potassium ferricyanide (Sigma Aldrich), 2 mM MgCl2, 0.02% (v/v) NP-40 (Sigma 
Aldrich), 0.01% (w/v) sodium deoxycholate (Sigma), 40 mM sodium citrate (Sigma), 150 
mM NaCl, and 1 mg/ml X-gal (Merck), pH 6.0. Stained cells were washed with dH2O and 
imaged on the Nikon Ti Eclipse inverted microscope (Nikon). 
2.2.9.  CELL MIGRATION 
Transfected or transduced HUVECs were seeded in triplicate wells at 3 x 105 cells in 6 
well plates and cultured for 3 d. Confluent ECs were first washed once with HUVEC 
wash media then scratched with a cell scraper in a vertical and horizontal direction. The 
cells were washed twice with HUVEC wash media to remove scratched and semi-
detached cells, after which the media was replaced with HUVEC media. The scratches 
were imaged at 0, 3 and 5 h post-scratch and the scratch area determined by manual 
outline using Fiji (version 1.48 e, fiji.sc).  
2.2.10.  SPHEROID SPROUTING  
2.2.10.1. Solutions for spheroid sprouting assay 
Methylcellulose stock 1.2% (w/v) High viscosity methylcellulose (Sigma 
Aldrich) in serum-free HUVEC media. 
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Spheroid media 20% (v/v) methylcellulose stock, 80% (v/v) HUVEC 
media, 15 µg/mL endothelial cell growth supplement, 15 
µg/mL heparin 
Spheroid resuspension media 60% (v/v) methylcellulose stock, 40% (v/v) FCS. 
Collagen solution 2 mg/mL rat tail collagen (type I) (BD Biosciences), 1X 
EBSS, 20 mM NaOH. 
2.2.10.2. Spheroid sprouting assay 
The spheroid sprouting assay was performed according to (Korff and Augustin, 1998). 
Transduced or 1 d siRNA-transfected HUVECs were resuspended in spheroid media and 
600 cells seeded into U-bottom 96 well plates (Greiner Bio One, Stonehouse, UK) 
overnight. The spheroids were harvested using a Pasteur pipette and collected by 
centrifugation at 500 x g for 3 min. The supernatant was removed, resuspended gently by 
scratching on a rough surface and overlayed with 500 µL of spheroid resuspension media. 
The collagen solution was freshly prepared and 500 µL mixed with the spheroids. Of the 
1 mL, 800 µL, containing roughly 75 spheroids, were added to a pre-warmed 24-well 
suspension plate and the gel allowed to set at 37°C for 30 min. The spheroids were then 
stimulated with 200 µL of HUVEC media containing 125 ng/mL VEGFA or 125 ng/mL 
FGF-2. FGF-2-stimulated spheroids were cultured for 48 h and re-stimulated at 24 h, 
while VEGFA spheroids were cultured up to 24 h. Spheroids were imaged at the end-
point using the Nikon Ti Eclipse at 100X total magnification. The total number and length 
of sprouts was determined by manual measurement using Fiji. At least 20 spheroids were 
analysed per experiment. 
2.2.10.3.  Spheroid sprouting competition 
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A spheroid tip cell competition assay was performed using control and ARHGAP18 
siRNA transfected HUVECs to determine the relative potential of each cell type to 
occupy the sprouting front position. One day control and ARHAGP18 siRNA-transfected 
HUVECs were stained using 2.5 µm CellTracker Orange CMTMR (5,6-4-chloromethyl-
benzoyl-amino-tetramethyl-rhodamine) (Life Technologies) or CellTracker Green 
CMFDA (5-chloromethyl-fluorescein diacetate) (Life Technologies), and nuclei stained 
using 3 µg/ml Hoechst 33342 (Life Technologies) for 30 min in HUVEC media 
containing 5% FCS. The cells were then washed once with wash media, and incubated in 
culture media for 30 min to allow for excess dye secretion and chloromethyl modification. 
The cells were harvested by trypsinisation, mixed at 50:50 ratios and used to form 
spheroid sprouts, which were stimulated with 50 ng/ml VEGFA and FGF-2 to facilitate 
more pronounced and stable sprouts. The actual distributions of sictrl:siARHGAP18 cells 
were determined following mixing by imaging on the Nikon Ti Eclipse and determining 
the relative proportions of green and orange cells. The collagen gels were fixed overnight 
with 4% formaldehyde at 4°C, transferred to a glass-bottomed MatTek dish (MatTek, 
MA, USA), washed with H2O and partially air-dried to prevent xy-drift and imaged by 
confocal. The distribution of each cell population in the spheroid sprouts and at the tip 
position were determined manually. 
2.2.11.  CELL PERMEABILITY 
The measurement of endothelial permeability was performed by measuring fluorescein 
isothiocyanate (FITC)-dextran (40 kDa) leak through an endothelial monolayer. ECs 
transfected with siRNAs for 2 d were seeded at 1.0 x 105 cells in triplicate on 3 µm 24-
well polycarbonate transwell inserts (Corning) pre-coated with 50 µg/ml fibronectin (BD 
Biosciences) and allowed to attach overnight. The cells were stimulated with 0.3 U/mL 
thrombin (Sigma) or left non-stimulated together with 1 mg/mL FITC dextran (40 kDa) in 
Chapter 2. Materials and Methods 
	   84 
the upper chamber. At indicated time points, 20 µL was transferred from the lower 
chamber to a black 96-well plate (BD Biosciences) with 180 µL of serum-free HUVEC 
media. The samples were excited at 490 nm and read at 520 nm using the POLARstar 
Omega (BMG LabTech, Mornington, Australia).  
2.3.  MOLECULAR BIOLOGY 
2.3.1.  GENE EXPRESSION ANALYSIS BY QUANTITATIVE RT-PCR 
2.3.1.1. RNA isolation from cell monolayers 
Isolation of RNA from HUVECs was performed using TRIzol (Life Technologies). Cells 
seeded in 6 well plates were lysed with 500 µL TRIzol reagent at RT for 5 min, and either 
isolated immediately or stored at -80°C until RNA isolation. Fresh or thawed TRIzol 
lysates were mixed and 100 µL of chloroform (Sigma Aldrich) was added to the samples 
and shaken vigorously for 15 s. The samples were let to settle at RT for 2 min prior to 
centrifuging at 12,000 x g for 15 min at 4°C. The upper aqueous phase of the 
trizol:chloroform separation was then transferred to a new tube and 250 µL of isopropanol 
(Sigma Aldrich) added and mixed. The samples were incubated at RT for 10 min prior to 
centrifuging at 12,000 x g for 10 min at 4°C. The resultant RNA pellet was washed once 
with 1 mL of 75% (v/v) ethanol (Sigma Aldrich) and centrifuged at 7,500 x g for 5 min at 
4°C, air dryed and resuspended in 30 µL of nuclease-free H2O (Sigma Aldrich). The yield 
and quality of the RNA was determined using the Nanodrop and used immediately for 
cDNA synthesis. A pure RNA sample had an A260/280 ratio of 1.8-2.0 and an A260/230 ratio 
of approximately 2.0.  
2.3.1.2. RNA isolation from spheroid sprouts 
The RNA from 96 spheroids was isolated following overnight (18 h) VEGFA sprouting 
using TRIzol LS, a more concentrated TRIzol reagent suitable for liquid samples. 
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Following sprouting, the stimulation media was removed, and the remaining 0.8 mL of 
collagen I gel lysed with 2 ml of TRIzol LS. The samples were pipette mixed for 10 min, 
transferred to tubes, and centrifuged at 12,000 x g for 10 min at 4°C to clear insoluble 
collagen and extracellular matrix materials. The RNA-containing supernatant was 
transferred to a new tube and 266 µL of chloroform added, mixed, settled and centrifuged 
as per normal monolayer RNA isolation. The aqueous phase was transferred to a new tube 
and 10 µg of glycogen (Life Technologies) was added as a carrier to facilitate RNA 
isolation. The RNA and glycogen was precipitated by the addition of 666 µL of 
isopropanol, incubating at RT for 10 min, before centrifuging at 12,000 x g for 10 min at 
4°C. The RNA pellet was washed once with 1 mL of 75% ethanol, centrifuged at 7,500 x 
g for 5 min at 4°C, air dryed and resuspended in 20 µL of nuclease-free H2O. The RNA 
was used immediately for cDNA synthesis. 
2.3.1.3. DNase I treatment and cDNA synthesis 
Trizol extracted RNA contains trace levels of genomic DNA (gDNA). In order to prevent 
the contribution of residual gDNA to mRNA expression results, the samples were first 
treated with deoxyribonuclease I (DNase I) prior to cDNA synthesis using the high 
capacity reverse transcription kit (Life Technologies). DNase I treatment of RNA samples 
was performed using amplification grade DNase I (Sigma Aldrich). Specifically, 1 µg of 
freshly isolated total RNA was treated with 1 U of DNase I in 1X DNase reaction buffer 
at RT for 15 min in a final volume of 10 µL in 0.2 ml PCR tubes. The reaction was 
stopped by the addition of 1 µL of 50 mM EDTA and heating at 70°C for 10 min, before 
being cooled on ice. A 9 µL mix of cDNA reverse transcription reagents (Life 
Technologies) consisting of 1X RT buffer, 1X RT random primers, 4 mM dNTP, 1 U 
RNase inhibitor, and 2.5 U MultiScribe reverse transcriptase was then added for a total 
volume of 20 µL. Controls of DNase-treated RNA, but no reverse transcriptase enzyme, 
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were also prepared as a negative control for the downstream PCR. The reactions were run 
in a BioRad thermocycler according to the conditions listed in Table 2.4. 
Table 2.4. Reverse transcription conditions 
Step Temperature Time 
Hold 25°C 10 min 
RT 37°C 120 min 
Terminate 85°C 5 min 
Hold 4°C ∞ 
2.3.1.4. Quantitative reverse transcriptase PCR (qRT-PCR) 
qRT-PCR was performed on reverse transcribed cDNA samples using SYBR Green 
JumpStart Taq ReadyMix (Sigma Aldrich) to analyse relative gene expression changes. 
qRT-PCR reactions were performed in 0.1 mL strip tubes (Qiagen) and consisted of 1X 
SYBR Green Jumpstart Mix, 0.2 µM of forward and reverse primer, and cDNA at the 
equivalent of 2.5 ng of pre-RT RNA in a final volume of 10 µL. Triplicate reactions were 
setup and run in a Rotor-Gene 3000 real-time PCR machine (Corbett Research, Qiagen) 
using a 4-step PCR cycling protocol as listed in Table 2.5. 	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Table 2.5. Quantitative RT-PCR thermocycling conditions 
 Step Temp Time Acquisition 
 Initial Denaturation 95°C 10 min 
 
40 cycles 
Denaturation 95°C 15 s 
Annealing 60°C 40 s 
Extension 72°C 40 s 
Non-specific Melt 78°C 15 s FAM 
Melt 
Curve 
Hold 60°C 60 s  
Hold 72-95°C 1°C/5 s FAM 
The fourth PCR step (non-specific melt) is added to denature any non-specific products 
prior to signal acquisition. The specific amplification of a single PCR product was 
confirmed by the presence of a single peak in the melt curve and by electrophoresis of 
DNA amplicons on an agarose gel. 
2.3.1.5. qRT-PCR primer design 
qRT-PCR primers were designed using Primer3 (version 0.4.0, 
http://bioinfo.ut.ee/primer3-0.4.0/) (Rozen and Skaletsky, 2000). PCR primers were 
designed to consist of 20-28 bp oligonucleotides with a melting temperature of 60°C, 50% 
GC content, and amplicon size of 140-300 bp. The primers used are listed in Table 2.6. 	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Table 2.6. Primer sequences for qRT-PCR 
Gene Direction Sequence (5’-3’) Amplicon Size (bp) 
ARHGAP18 
F CGAGCAAGCACTCAATCAGAAAGAGAG 
273 
R GCTGTCAATGGAACGCAAAAAAGACCAG 
PECAM1 
F CCCAGCCCAGGATTTCTTAT 
163 
R ACCGCAGGATCATTTGAGTT 
CDH5 
F CAGCCCAAAGTGTGTGAGAA 
162 
R CAGCCCAAAGTGTGTGAGAA 
ACTA2 
F TGACAATGGCTCTGGGCTCTGTAA 
142 
R TTCGTCACCCACGTAGCTGTCTTT 
SNAI1 
F ACCCCACATCCTTCTCACTG 
217 
R TACAAAAACCCACGCAGACA 
FLT1 
F GGCTCTGTGGAAAGTTCAGC 
223 
R GCTCACACTGCTCATCCAAA 
FLK1 
F GTGACCAACATGGAGTCGTG 
218 
R TGCTTCACAGAAGACCATGC 
FLT4 
F GAGACAAGGACAGCGAGGAC 
186 
R TCACGAACACGTAGGAGCTG 
DLL4 
F AGGCCTGTTTTGTGACCAAG 
142 
R CTCCAGCTCACAGTCCACAC 
GAPDH 
F GAGTCAACGGATTTGGTCGT 
238 
R TTGATTTTGGAGGGATCTCG 
ACTB 
F CCCTCCATCGTCCACCGCAAATGCTTC 
203 
R CGACTGCTGTCACCTTCACCGTTCCAG 
2.3.1.6. Mathematical model for relative gene expression quantification 
The cycle threshold (CT), the cycle number at which the sample reached the threshold 
fluorescence value, was determined following qRT-PCR using the Rotor-Gene software 
(Corbett, Qiagen). This threshold fluorescence value represented the fluorescence 
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significantly above the background and that lied in the linear phase of the amplification. 
The relative gene expression changes were calculated using the 2-ΔΔCT method (Pfaffl, 
2001), where: 
Relative Gene Expression = 2-ΔΔCT  and 
ΔΔCT = (CTGOI – CTHK)Sample – (CTGOI – CTHK)Control 
GOI represents the gene of interest and HK represents the housekeeping gene. 
β-actin was used as the housekeeping gene. β-actin expression was verified to not change 
in the treatment conditions used. This expression model assumes the perfect amplification 
of the genes of interest and the housekeeping gene, and is valid only when the efficiencies 
of the genes of interest and housekeeping gene are similar. The efficiencies of the 
amplicons were determined by serial dilution of template and were, on average, around 
1.8. While the genes did not have perfect amplification the net effect on actual fold 
changes are insignificant, and more importantly, the trend of up- or down-regulation are 
maintained, hence this method was valid to use for calculating expression changes. 
2.3.2.  PROTEIN EXPRESSION ANALYSIS BY IMMUNOBLOTTING 
2.3.2.1. Immunoblotting solutions 
Lysis buffer 50 mM Tris HCl, 150 mM NaCl, 2 mM EGTA, 1% NP40, pH 
7.6. 
IP lysis buffer 10 mM NaH2PO4, 150 mM NaCl, 1 mM EDTA, 0.5% (w/v) 
CHAPs, pH 7.2. 
MOPS running buffer 50 mM MOPS, 50mM Tris Base, 0.1% (w/v) SDS, 1 mM 
EDTA, pH 7.7. 
MES running buffer  50 mM MES, 50 mM Tris Base, 0.1% (w/v) SDS, 1 mM EDTA, 
pH 7.3. 
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Transfer buffer 25 mM Bicine, 25 mM Bis-Tris, 1 mM EDTA, 20% (v/v) 
Methanol, 1 mL NuPAGE anti-oxidant pH 7.2. 
Blocking buffer 5% (w/v) BSA or skim milk, 0.1% (v/v) Tween-20 in PBS. 
Wash buffer 0.1% (v/v) Tween-20 in PBS. 
2.3.2.2. Cell lysis 
Monolayer cells for protein harvesting were first washed twice with cold PBS. The PBS 
was aspirated and 80 µL (6 well plate well) or 500 µL (10 cm dish) of lysis buffer or IP 
lysis buffer containing 1X protease inhibitor cocktail (Sigma Aldrich) and 1X PhosSTOP 
phosphatase inhibitor cocktail (Roche) added to the cells. The cells were incubated on ice 
for 10 min and then scraped with a cell scraper. The cell lysate was transferred to a 1.5 
mL tube and centrifuged at 13,000 rpm for 10 min at 4°C. The supernatant was 
transferred to a new 1.5 ml tube and stored at -80°C until gel electrophoresis. 
2.3.2.3. Protein preparation and SDS-PAGE 
The protein concentration of whole cell lysates was determined using the Detergent 
Compatible Protein Assay (Bio-Rad) according to manufacturer’s instructions. The 
sample was read at 690 nm against a serially diluted BSA standard curve in the microplate 
reader (BioRad). Whole cell lysates were prepared at 1.0 mg/mL in 1X NuPAGE LDS 
sample buffer (Life Technologies) and 1X NuPAGE sample reducing agent (Life 
Technologies) and heated at 70°C for 10 min. Ten µg of protein samples were 
electrophoresed in NuPAGE Novex 4-12% Bis-Tris gels in MOPS or MES (for low 
molecular weight proteins) buffers containing 0.5 mL of NuPAGE antioxidant (Life 
Technologies) at 150 V until the dye front reached the end of the gel. The Precision Plus 
Protein Kaleidoscope standard was electrophoresed in conjunction with protein samples 
as a protein size marker.  
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2.3.2.4. Protein transfer 
Electrophoresed proteins were transferred onto PVDF membranes (Millipore) by wet 
transfer using the XCell II blot module (Life Technologies). The PVDF membrane was 
activated in 100% methanol for 30 s, and equilibrated in transfer buffer for 2-3 min. Filter 
paper (Whatman, Dassel, Germany) and sponges (Life Technolgies) were pre-soaked in 
transfer buffer. The gels were removed from the cassettes following electrophoresis, 
washed in transfer buffer and assembled into a stack and transferred at 30 V for 75 min. 
2.3.2.5. Blocking, antibody incubation and detection 
Following protein transfer, the membranes were removed from the assembly and blocked 
in blocking buffer for 1 h at RT with rocking. The membranes were washed once with 
washing buffer before incubation in primary antibody (prepared in wash buffer or BSA 
blocking buffer) overnight at 4°C with rotation. Primary antibodies and dilutions used are 
listed in Table 2.7. After overnight incubation, the membranes were washed 5 times for 5 
min with washing buffer. The membranes were subsequently incubated in horseradish 
peroxidase (HRP)-conjugated secondary antibodies for 1 h at RT, after which they were 
washed 5 times for 5 min. The HRP was detected using Enhanced Chemiluminescence 
(ECL) substrate (Thermo Fisher) or ECL Plus substrate (Thermo Fisher) with 1 min or 5 
min pre-incubation, respectively, on the ChemiDoc MP gel imaging system (Bio-Rad). 	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Table 2.7. Antibodies used for immunoblotting 
Antigen Species and Clonality Manufacturer 
Concentration/ 
Dilution 
ARHGAP18 Mouse mAb (2A3) In house 0.5 µg/mL 
ARHGAP18 Rabbit pAb In house 1:400 
Pan-Ras Rabbit pAb Cell Signaling 1:1000 
PECAM-1 Rabbit pAb Abcam 1:500 
α-SMA Rabbit pAb Abcam 1:500 
VE-Cadherin Goat pAb Santa Cruz 1:500 
Snail Rabbit mAb (C15D3) Cell Signaling 1:1000 
p-Erk1/2 (T202/Y204) Mouse mAb (E10) Cell Signaling 1:1000 
p-Akt (S473) Rabbit mAb (D9E) Cell Signaling 1:1000 
Akt Mouse mAb (40D4) Cell Signaling 1:1000 
pMLC (S19) Rabbit pAb Cell Signaling 1:1000 
pAkt Substrate 
(RXXS*T*) 
Rabbit mAb 
(110B73E) Cell Signaling 1:1000 
RhoA Rabbit mAb (67B9) Cell Signaling 1:1000 
RhoC Rabbit mAb (D40E4) Cell Signaling 1:1000 
Rac1 Mouse mAb Cytoskeleton 1:1000 
Cdc42 Mouse mAb Cytoskeleton 1:1000 
RhoJ Mouse mAb (1E4) Abnova 1:1000 
Ezrin/Radixin/Moesin Rabbit pAb Cell Signaling 1:1000 
Moesin Rabbit pAb Cell Signaling 1:1000 
Cortactin Rabbit pAb Cell Signaling 1:1000 
DsRed Rabbit pAb Clontech 1:1000 
GAPDH Mouse mAb (6C5) Abcam 1:2000 
Nucleolin Rabbit pAb Abcam 1:1000 
Tubulin Mouse mAb (B-5-1-2) Sigma Aldrich 1:1000 
β-Actin Rabbit pAb Sigma Aldrich 1:2000 
Rabbit IgG-HRP 
conjugated Goat pAb Cell Signaling 1:4000 
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Antigen Species and Clonality Manufacturer 
Concentration/ 
Dilution 
Mouse IgG-HRP 
conjugated Goat pAb Cell Signaling 1:4000 
Goat IgG-HRP 
conjugated Donkey pAb Santa Cruz 1:4000 
 
2.3.3.  IMMUNOPRECIPITATION 
IP lysis buffer 0.5% (w/v) CHAPs, 10 mM NaH2PO4, 150 mM NaCl, 1 mM EDTA, 
pH 7.2. 
IP wash buffer 250 mM NaCl, 0.5% (v/v) Triton X-100, 5 mM NaF, 1 mM Na3VO4, 
1mM Na4P2O7. 
Elution buffer 1.5X NuPAGE LDS sample buffer, 1.5X NuPAGE sample reducing 
agent. 
Confluent HUVECs cultured on 10 cm dishes were lysed with 600 µL of IP lysis buffer 
and cleared as per the immunoblotting procedure. The concentrations of the samples were 
determined and equalized to a concentration between 0.8-1.0 mg/mL. The proteins (400-
500 µg) were precleared with 50 µL of 50% protein G sepharose beads (Life 
Technologies) on a MACSmix rotator (Miltenyi Biotec) at 4°C for 1 h. The beads were 
collected at 10,000 x g for 30 s and the supernatant transferred to another tube. Ten µg of 
ARHGAP18 (2A3) or MsIgG1 isotype control antibodies were then added and incubated 
overnight on the rotator at 4°C. The protein G sepharose beads were blocked with 2% 
(w/v) BSA/PBS for 2 h at 4°C, restored to a 50% slurry and 20 µL added to each sample 
for 2 h at 4°C. The samples were collected at 10,000 x g for 30 s, the unbound fractions 
were collected and the beads were washed with IP wash buffer 5 times. On the final wash, 
the samples were resuspended in 1 mL PBS, transferred to a new tube and collected by 
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centrifugation. The samples were eluted with 20 µL of elution buffer, heated at 70°C for 
10 min, centrifuged and the supernatant collected for SDS-PAGE and immunoblotting.  
2.3.4.  IMMUNOFLUORESCENCE STAINING 
2.3.4.1. Immunostaining of monolayer cells 
Transfected, transduced or normal HUVECs were seeded overnight at 6 x 104 cells on 8-
well Lab-Tek chamber slides (Thermo Scientific) pre-coated with 50 µg/ml fibronectin 
(BD Biosciences). Basal or stimulated HUVECs were washed once with serum-free 
HUVEC media, prior to fixation with 4% methanol-free formaldehyde in PBS for 10 min 
at RT or with 50% (v/v) methanol, 50% (v/v) acetone at -20°C for 20 min, depending on 
the antigen. The cells were washed with PBS then permeabilised with 0.1% (v/v) Triton 
X-100 for 10 min at RT. The cells were then blocked with 2% (w/v) BSA (Sigma 
Aldrich) in PBS for 30 min at RT, then incubated in diluted primary antibody, prepared in 
2% (w/v) BSA in PBS, for 1 h at RT. The unbound antibodies were washed 5 times for 2 
min each with PBS, then incubated in Alexa Fluor-conjugated secondary antibodies 
(Molecular Probes, Life Technologies), prepared in 2% (w/v) BSA in PBS for 30 min at 
RT. A list of primary and secondary antibodies and the dilutions used are in Table 2.8. 
The secondary antibodies were washed off as per the primary antibodies. Where 
applicable, formaldehyde-fixed cells were stained with 0.2 U rhodamine phalloidin for 20 
min at RT. The nuclei were counterstained with 200 ng/mL 4',6-diamidino-2-
phenylindole (DAPI) (Sigma Aldrich) for 10 min. The chamber slides were disassembled, 
and mounted with ProLong Gold antifade reagent (Life Technologies) using Nr 1 glass 
coverslips (Menzel-Glaser, Braunschweig, Germany) Immunostained slides were imaged 
by confocal microscopy. 
Table 2.8. Antibodies used for immunofluorescence staining 
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Antigen Species and Clonality Manufacturer 
Concentration/ 
Dilution 
ARHGAP18 Mouse mAb (2A3) In house 5 µg/mL 
ARHGAP18 Rabbit pAb In house 1:200 
Pan-Ras Rabbit pAb Cell Signaling 1:200 
Vimentin Rabbit mAb (D21H3) Abcam 1:200 
α-Tubulin Rabbit mAb Sigma Aldrich 1:2000 
PECAM-1 Rabbit pAb Abcam 1:200 
VE-Cadherin Rabbit mAb (D87F2) Cell Signaling 1:400 
β-Catenin Rabbit mAb (D10A8) Cell Signaling 1:100 
Ezrin/Radixin/Moesin Rabbit pAb Cell Signaling 1:100 
Moesin Rabbit pAb Cell Signaling 1:100 
Cortactin Rabbit pAb Cell Signaling 1:100 
IgG1 Control Mouse mAb (G3A1) Cell Signaling 5 µg/mL 
Normal Ig Rabbit pAb Cell Signaling 1:10000 
Mouse IgG-AlexaFluor 
488 conjugated Goat pAb Life Technologies 1:500 
Rabbit IgG-AlexaFluor 
488 conjugated Goat pAb Life Technologies 1:500 
Mouse IgG-AlexaFluor 
594 conjugated Goat pAb Life Technologies 1:500 
Rabbit IgG-AlexaFluor 
594 conjugated Goat pAb Life Technologies 1:500 
Mouse IgG-AlexaFluor 
647 conjugated Goat pAb Life Technologies 1:500 
Rabbit IgG-AlexaFluor 
647 conjugated Goat pAb Life Technologies 1:500 
2.3.4.2. Immunostaining of spheroid sprouts 
Following sprouting induced by VEGFA or FGF-2, spheroid sprouts washed twice with 
PBS. The gels were fixed with 4% formaldehyde in PBS at RT for 2 h then overnight at 
4°C. The gels were washed with PBS to remove the formaldehyde, then extracted with 
100% methanol overnight at -20°C. The methanol was washed out with PBS and blocked 
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with 1% (v/v) Triton X-100, 3% (w/v) BSA, 3% (v/v) NGS for 2 d at 4°C. The gels were 
then incubated in primary antibody diluted in the blocking buffer for 2 d at 4°C. The 
antibodies are listed in Table 2.9. The unbound antibodies were washed 8 times with 1% 
Triton-X in PBS for 1 h each. The gels were then incubated in Alexa Fluor-conjugated 
secondary antibodies, diluted in blocking buffer, for 2 d at 4°C, then washed as per the 
primary antibody. The nuclei were counterstained with 500 ng/mL DAPI for 30 min, then 
washed in PBS for 4 times 30 min each, dH2O for 4 times 30 min each and air-dried 
overnight on a StarFrost microscope slide (Waldemar Knittel, Germany) in a fume hood. 
The dried gels were mounted with glass coverslips with ProLong Gold Antifade reagent. 
Immunostained spheroid sprouts were imaged by confocal microscopy. 
Table 2.9. Antibodies used for immunofluorescence staining of spheroid 
sprouts 
Antigen Species and Clonality Manufacturer 
Concentration/ 
Dilution 
ARHGAP18 Mouse mAb (2A3) In house 10 µg/mL 
PECAM-1 Rabbit pAb Abcam 1:100 
VE-Cadherin Rabbit mAb (D87F2) Cell Signaling 1:200 
Rabbit IgG-AlexaFluor 
488 conjugated Goat pAb Life Technologies 1:500 
Mouse IgG-AlexaFluor 
594 conjugated Goat pAb Life Technologies 1:500 
Mouse IgG-AlexaFluor 
647 conjugated Goat pAb Life Technologies 1:500 
2.3.5.  RHOGTPASE ACTIVITY ASSAY 
The measurement of active RhoGTPase activity was performed using the GLISA kits 
(Cytoskeleton) according to manufacturers instructions. Transfected or transduced ECs 
were cultured to confluence in 10 cm dishes. The starved and stimulated or non-
stimulated cells were quickly washed twice with cold PBS and lysed with 600 µL GLISA 
lysis buffer containing protease inhibitors for 1 min. The cells were scraped, collected and 
centrifuged at 10,000 x g at 4°C for 1 min. The cleared cell lysate was transferred and 
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distributed into aliquots, which were then snap-frozen in liquid nitrogen. Each aliquot was 
used to measure a single RhoGTPase and was not reused. The protein concentration was 
determined using the Dc Protein Assay kit and equalized between samples. The protein 
samples (25-50 µg) were added to the immobolised RhoGTPase protein binding wells and 
incubated on ice with shaking at 320 rpm for 30 min. The wells were washed to remove 
unbound samples, the antigens were retrieved and then incubated with primary antibodies 
against the RhoGTPases at RT with shaking at 320 rpm for 45 min. The primary 
antibodies for RhoA, Rac1 and Cdc42 were supplied with the GLISA kits. A RhoC 
antibody (Cell Signaling) was used with the RhoA GLISA kit to measure active RhoC 
and was used at a 1:100 dilution. A RhoJ antibody (Abnova) was used with the Cdc42 
GLISA kit to measure active RhoJ and was used at a 1:100 dilution. The unbound primary 
antibodies were washed and the HRP-conjugated secondary antibodies were added and 
incubated at RT with shaking for 45 min. The secondary antibodies were washed and the 
HRP detection substrate was added for 10-15 min at 37°C after which the reaction was 
stopped. The absorbance at 490 nm was read in a POLARstar OMEGA plate reader. The 
signals were corrected against a blank sample and the readings were normalized against 
the total RhoGTPase levels as determined by immunoblotting. 
2.4. MOUSE STUDIES 
2.4.1.  MOUSE LINES 
C57BL/6J mice were purchased from the Animal resources centre (WA, Australia). The 
ARHGAP18-/- mouse was generated through the Knockout mouse project (KOMP) 
repository (CA, USA). The generation and features of the mouse is described in section 
4.2.5. All mouse experiments were performed in accordance to animal ethics guidelines 
from the University of Sydney and Sydney local health district.  
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2.4.2.  AORTIC RING SPROUTING ASSAY 
The ex vivo aortic ring sprouting assay was performed on 6-week old mice as described 
(Baker et al., 2012). The aortas were isolated from the mice and washed with PBS. The 
aortas were cut into 1 mm rings, placed in 96-well plates containing 100 µL Matrigel (BD 
Biosciences) and covered with an additional 100 µL Matrigel. The aortas were cultured 
for up to 7 d and imaged by brightfield microscopy. 
2.4.3.  POST-NATAL RETINA VASCULARISATION MODEL 
The analysis of post-natal retina vascularisation was performed according to (Pitulescu et 
al., 2010). 
2.4.3.1. Solutions for retina staining 
BSA blocking buffer 1% (w/v) BSA, 0.3% (v/v) Triton-X in PBS 
Serum blocking buffer 3% (v/v) NGS, 1% (w/v) BSA, 0.3% (v/v) Triton-X 
in PBS 
Mouse on mouse blocking buffer 2X Mouse Ig blocking reagent (Vector Laboratories), 
3% (v/v) NGS, 1% (w/v) BSA, 0.3% (v/v) Triton-X 
in PBS 
PBLEC 1 mM MgCl2, 1 mM CaCl2, 0.1 mM MnCl2, 1% 
Triton-X in PBS 
Wash buffer 0.3% Triton-X in PBS 
2.4.3.2. Eye and retina dissection 
WT and ARHGAP18-/- pups were euthanased on P6 by decapitation. The eyes were 
collected by surgical incision around the eye and severing the optic nerve. The eyes were 
transferred to cold PBS then fixed in 4% (w/v) formaldehyde for 2 h on ice. The fixative 
was washed out and replaced with PBS then dissected to remove the retina. Firstly, the 
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extra fat was removed from the exterior of the eye, and a small incision was made on the 
cornea-sclera junction of the eye. The cornea was subsequently removed by extending the 
incision across the junction. Next, the sclera and choroid layers were removed using fine 
forceps. The lens was extracted out and the iris and the hyaloid vessels were removed, 
leaving the retina. Each retina was cut into quadrants approximately two-thirds of the 
length of the retina and kept in PBS until staining. 
2.4.3.3. Isolectin B4 staining of retinal vessels 
Retinas for isolectin B4 (IB4) staining were first re-fixed with 4% (w/v) formaldehyde for 
1 h at RT. The extra post-dissection fixation preserves the filipodia staining of retinal 
sprouts while preventing overfixation of hyaloid vessels onto the retina (Pitulescu et al., 
2010). The retinas were washed with PBS then blocked overnight at 4°C BSA blocking 
buffer. The blocked retinas were equilibrated in PBLEC for 1 h then incubated with 10 
µg/ml biotinylated Griffonia (Bandeiraea) Simplicifolia lectin I isolectin B4 (Vector 
Labs) in PBLEC overnight at 4°C. The retinas were washed 6 times for 10 min each with 
wash buffer then incubated in 10 µg/ml streptavidin-Alexa Fluor 594 or Alexa Fluor 405 
(Molecular Probes, Invitrogen) for 2 h at RT. The stained retinas were washed 6 times for 
10 min each with wash buffer, then 2 times for 5 min with PBS prior to mounting.  
2.4.3.4. Antibody staining of retinas 
Dissected retinas for antibody staining were blocked overnight with serum blocking 
buffer overnight at 4°C with rocking. The blocked retinas were incubated with primary 
antibodies prepared in serum blocking buffer overnight at 4°C. A list of antibodies and 
dilutions used is listed in Table 2.10. The retinas were washed as for IB4 staining of 
retinas, then incubated in Alexa Fluor dye-conjugated goat anti-mouse or -rabbit 
secondary antibodies (1:500) prepared in serum blocking buffer for 2 h at RT. The retinas 
were washed as per IB4 staining following secondary antibody incubation.  
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2.4.3.5. ARHGAP18 staining of retinas 
ARHGAP18 staining of mouse retinas was performed with the mouse monoclonal 
antibodies against ARHGAP18. The dissected retinas were blocked with mouse on mouse 
blocking reagent overnight at 4°C with rocking. The retinas were washed twice with 
serum blocking buffer then incubated with anti-ARHGAP18 and co-staining antibodies 
prepared in serum blocking buffer overnight at 4°C (Table 2.10). The retinas were washed 
as for IB4 staining of retinas and incubated with the goat anti-mouse Alexa Fluor 647-
conjugated F(ab’)2 antibodies (at 1:500 dilution) (Molecular Probes, Invitrogen) and goat 
anti-rabbit Alexa-Fluor 488-conjugated secondary antibodies prepared in serum blocking 
buffer for 2 h at RT. The retinas were washed as per IB4 staining following secondary 
antibody incubation. 
Table 2.10. Antibodies used for immunofluorescence staining of retinas 
Antigen Species and Clonality Manufacturer 
Concentration/ 
Dilution 
ARHGAP18 Mouse mAb (2A3) In house 20 µg/mL 
VE-Cadherin Rat mAb (11D4.1) BD Biosciences 1:400 
VE-Cadherin Rabbit pAb Abcam 1:200 
NG2 Rabbit Millipore 1:200 
Collagen IV Rabbit Abd Serotec 1:200 
 
2.4.3.6. Mounting of stained retinas 
The stained retinas were transferred using 2 ml transfer pipettes to StarFrost glass slides 
and orientated with the inner retina facing the coverslip. The excess PBS was removed 
and the retinas were flat-mounted using Nr. 1 glass coverslips (Menzel-Glaser) and 
ProLong Gold anti-fade mounting media. The stained retinas were imaged by stereo and 
confocal microscopy. 
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2.4.4.  CROTON OIL-INDUCED EAR INFLAMMATION AND NEUTROPHIL 
INFILTRATION 
Ear inflammation was induced in WT and ARHGAP18-/- mice using the irritant, croton 
oil. Croton oil was dissolved in acetone at concentration of 2.5% (v/v) and 20 µL of 
croton oil applied topically on the left and right ear. The acetone vehicle control was 
applied to separate control animals. The ear thickness was measured using a micrometer. 
At 24 h, the cells were isolated for characterization by flow cytometry. The ears were 
dissected and split into the dorsal and ventral halves using forceps. The tissues were 
digested using 2 mg/mL collagenase type IV (Sigma Aldrich) in PBS for 1 h at 37°C. The 
digestion was stopped by the addition of FACS buffer (5% FCS, 2 mM EDTA, 0.02% 
sodium azide in PBS). Single cell suspensions were obtained by filtering through a 80 µm 
stainless steel mesh and the cell numbers determined by haemocytometer counting. For 
flow cytometric analysis of neutrophils, the cells were incubated with fluorochrome-
conjugated antibodies (BD Biosciences) against CD45 (30-F11), Ly6G (1A8), and CD11b 
(M1/70) for 30 min on ice. The cells were washed three times with FACS buffer and 
resuspended in 300 µL of FACS buffer. Immediately prior to flow cytometric acquisition, 
DAPI was added as a viability marker. The samples were acquired on the LSR Fortessa 
(BD) and the data analysed using FlowJo. 
2.5.  IMAGING AND IMAGE ANALYSIS 
2.5.1.  MICROSCOPES AND OBJECTIVES 
Table 2.11. List of microscopes and objectives used. 
Imaging Microscope Objective Immersion 
Brightfield & 
Widefield 
Fluorescence 
Nikon Eclipse Ti 
Nikon PL FL 4x/0.13 NA Air 
Nikon PL FL 10x/0.30 NA Air 
Nikon PL FL 20x/0.45 NA Air 
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Imaging Microscope Objective Immersion 
Stereo Leica M205 FA Leica PL APO 1.6x/0.175 NA Air 
Confocal Leica TCS SP5 
HC PL FL 10x/0.3 NA Air 
HCX PL FL 20x/0.50 NA Air 
HCX PL APO Lbd Bl 63x/1.40-0.60 NA Oil 
2.5.2.  IMAGE ANALYSIS 
2.5.2.1. Cell circularity and cell size 
Analysis of cell circularity and size as parameters of cell morphology were performed on 
brightfield images using Fiji. Outlines of cells were traced manually and the area and 
perimeter determined. The size of the cell corresponds to the measured area and was 
converted to µm2 units. The circularity of the cell, a measure of the elongation/roundness 
of the cell, is determined by the formula: 4 x π x area / perimeter2. A circularity value of 
1.0 indicates a perfect circle while values approaching 0.0 indicates an increasingly 
elongated polygon. For measurement of these parameters, the results of a minimum of 
three independent experiments consisting of at least 20 individual cells were pooled. 
2.5.2.2. Cell density measurement by counting of cell nuclei 
Analysis of cell density was performed on DAPI-stained cells cultured on coverslips for 
immunostaining. Using Fiji, a macro was programmed to count the number of nuclei in a 
field of view. The macro was designed to convert the image to black and white, 
distinguished the nuclei from the background, blurred the image, set a threshold intensity 
and counted the particles above a certain size. The macro is detailed in Appendix A.1.1. 
2.5.2.3. Aortic ring sprouting 
The magnitude of aortic ring sprouting was defined as the sprouted area (SA). This was 
determined using Fiji by manually tracing the total area (TA) of the sprouted aortic ring 
and subtracting the ring area (RA). The SA was then corrected for the size of the aortic 
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ring by measuring the surface area (perimeter) of the ring (RP). This is also given by the 
formula: Corrected sprouted area = (TA - RA) / RP. Since each experiment had different 
rates of sprouting, the measurements were corrected to each experimental WT control.    
2.5.2.4. Analysis of retina vascularization 
The radial extension, the longitudinal distance to which the vessels had migrated to, was 
determined using whole retina images acquired on the stereo microscope by measuring 
the distance from the optic nerve to the angiogenic front.  
For the other parameters of retinal vascularization, confocal images of whole retina 
quadrants were analysed by Wimasis GmbH (www.wimasis.com/, Germany) using a 
skeleton analysis program. As described in section 4.2.7, the analysis of the whole retina 
did not show noticeable differences in the vascular phenotype, which may be due to the 
complex architecture of the retina or the different sizes of the retina quadrants. In order to 
eliminate these irregularities, the analysis was redefined to a smaller area located in 
between the two large vessels (veins and arteries). A macro was programmed to execute 
the analysis in an automated and unbiased manner. This analysis is described in Fig 4.14 
and the macro is listed in Appendix A.1.2. The macro utilised the original analysed 
image, and selected a 250 pixel (380 µm) x 250 pixel square, which was re-analysed for 
the individual parameters by colour thresholding. The area of the vessel outline (black) 
was determined as a percentage of the whole area and defined as the vessel density. The 
branch points were isolated into single (red dots), double (green dots) and triple (blue 
dots) branches which were individually counted and totaled.   
2.5.2.5. Pericyte coverage 
Analysis of pericyte coverage was determined post-acquisition on VE-cadherin and NG2 
stained retinas and is described in Fig 4.17. A macro was programmed for the automated 
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analysis of pericyte coverage, as defined as the percentage of vessels that are covered by 
pericytes and is listed in Appendix A.1.3. VE-cadherin stains the junctions of ECs so the 
vessel outline was determined by filling the VE-cadherin outlines to define the vessels. A 
binary pericyte mask was created by thresholding the pericyte signal and an overlay of the 
pericyte mask (green) and the vessel mask (red) was created. The non-pericyte covered 
area was indicated by the red areas, while the pericyte covered vessels were the yellow 
areas, and the pericyte areas not associated with vessels as the green areas. 
2.6.  STATISTICAL ANALYSIS 
Statistical significance was analysed using Prism (v6.0d, Graphpad Software. For 
comparison of two groups, t-test were used. For multiple comparisons, analysis of 
variance (ANOVA) was used. A P-value less than 0.05 was considered significant.  
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3.1.  INTRODUCTION 
One of the major regulators of cell signaling and function are the Ras GTPases. Aberrant 
signaling of the Ras pathway is one of the most common causes of cancer (Bos, 1989; 
Downward, 2003; Pylayeva-Gupta et al., 2011). Physiologically, the Ras proteins act in 
response to receptor tyrosine kinase (RTK) stimulation by GF to control fundamental 
cellular processes such as proliferation and migration (Pylayeva-Gupta et al., 2011; 
Rajalingam et al., 2007). Ras, like the Rho GTPases, cycle between active GTP-bound 
and inactive GDP-bound forms through interaction with GEFs and GAPs, respectively 
(Pylayeva-Gupta et al., 2011). Following GF binding, the RTK activate and recruit GEFs, 
which subsequently interact with Ras proteins and facilitate the exchange of GDP for 
GTP (Chardin et al., 1993; Karnoub and Weinberg, 2008). The active form of Ras then 
binds to effectors including Raf kinase and phosphatidylinositol 3-kinase (PI3K), which 
signal to downstream pathways such as the MAPK-ERK and Akt pathways, respectively 
(Rajalingam et al., 2007). Interaction with GAP proteins then facilitates the hydrolysis of 
GTP and a return to the inactive GDP-bound state.  
The Ras family consists of 39 Ras proteins, of which the functions of three proteins, 
HRas, KRas and NRas have been the most well studied (Karnoub and Weinberg, 2008). 
Of the three major Ras proteins, only KRas is essential, as knockout of KRas, but not 
HRas or NRas, results in embryonic lethality (Esteban et al., 2001; Johnson et al., 1997; 
Koera et al., 1997; Umanoff et al., 1995). However HRas-/- NRas-/- double knockout 
animals have reduced Mendelian ratios while KRas+/- NRas-/- animals are embryonic 
lethal, which suggests that there is partial overlap in function between proteins (Esteban et 
al., 2001; Johnson et al., 1997). Furthermore, mice that have had the KRas gene replaced 
with HRas display normal embryonic development indicating that the KRas promoter-
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driven expression of the Ras protein, rather than the actual specific Ras isoform, is 
essential during development (Potenza et al., 2005). 
Aberrant signaling of the Ras pathway is common in many disorders and involves several 
different aspects of the pathway. These include mutations of the Ras proteins, deletion of 
the GAP proteins, sustained GFR activation, and amplification or mutation of the 
downstream effectors (Downward, 2003). Mutations of the Ras proto-oncogenes are very 
common in cancers, comprising approximately 30% of all tumours (Bos, 1989). Notably, 
certain tumours are associated with mutations in specific Ras proteins, as for instance, 
KRas is mutated in 60% of pancreatic cancers compared to HRas and NRas which are 
mutated in 0% and 2% of cases respectively (Karnoub and Weinberg, 2008). This 
association has been largely attributed to the preferential expression of the specific Ras 
isoforms in the different organs (Leon et al., 1987). Most oncogenic mutations of Ras 
target its inactivation by GAPs (Pylayeva-Gupta et al., 2011). In particular, the 
substitutions of the Gly residues at positions 12 or 13 (most frequently with Val or Asp) 
prevent the formation of van der Waals bonds between Ras and the GAP through steric 
hindrance (Scheffzek et al., 1997), while mutations of Gln61 prevent GTP hydrolysis 
(Buhrman et al., 2010). These mutations result in persistence of the GTP-bound form and 
hyper-activation of the downstream effector pathways leading to increased cell 
proliferation, transformation, survival, migration and metastasis, metabolism and 
induction of angiogenesis, all of which are hallmarks of cancer (Hanahan and Weinberg, 
2000; Pylayeva-Gupta et al., 2011). Therapeutically, this has resulted in the development 
of molecules to target aberrant Ras signaling in the treatment of cancers (Downward, 
2003). 
Aberrant Ras signaling is also common in vascular diseases. Mutations in Ras have been 
identified in angiosarcomas, an uncommon malignant neoplasm arising from endothelial 
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cells (Boivin-Angele et al., 2000; Przygodzki et al., 1997; Weihrauch et al., 2002; Wen 
and MacKenzie, 2013). Additionally, mice lacking the Ras GAP, RASA1, develop 
defects in the vascular system (Henkemeyer et al., 1995). In humans, mutations in 
RASA1 are associated with arteriovenous malformations with complications including 
bleeding and heart failure (Boon et al., 2005; Eerola et al., 2003; Revencu et al., 2008). 
Furthermore, deficiency of another Ras GAP, NF1, results in cardiovascular defects in 
mice and humans (Brannan et al., 1994; Friedman et al., 2002; Gitler et al., 2003).  
In ECs, Ras functions as an essential signaling molecule downstream of growth factor 
pathways including VEGFA and FGF-2 (Meadows et al., 2001; Rennel et al., 2003). In 
particular, HRas, which is the highest expressing isoform in ECs (Bajaj et al., 2010; 
Haeussler et al., 2013), is required for proliferation, migration and tube formation 
following VEGFA activation, as introduction of a dominant negative HRas (HRasN17) 
inhibits such phenotypes (Meadows et al., 2001). During sprouting angiogenesis, ERK, a 
downstream molecule of Ras-MAPK signaling, is highly activated at the angiogenic front 
while absent from the mature quiescent vessels (Westenskow et al., 2013). Conversely, 
the negatively regulator of Ras signaling, RASA1 is absent at the angiogenic front while 
highly expressed in the mature vessels, suggesting that the regulation of RASA1 
expression is the critical factor in controlling Ras signaling during angiogenesis 
(Westenskow et al., 2013). Overexpression of constitutively active HRas (HRasV12) in 
ECs has been shown to promote tube formation, migration and proliferation (Meadows et 
al., 2004) and induce angiosarcoma formation when introduced into mice (Arbiser et al., 
1997; Rennel et al., 2003). However, other groups have conflicting studies that show that 
overexpression of active HRas results in an inhibition of invasion (Rennel et al., 2003), 
induction of cellular senescence (Spyridopoulos et al., 2002) and abnormal vascular 
morphogenesis (Bajaj et al., 2010).  
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Given this controversy, the project was initially aimed at investigating whether active 
HRas overexpression invoked an oncogene-induced senescence response in ECs. Further, 
given the established role of ARHGAP18 in oxidative-stress induced senescence, the 
project was focused at determining whether there was a role of ARHGAP18 in the 
regulation of HRas-induced senescence. However, the early results indicated that HRas 
induced a dualistic phenotype of OIS in addition to pro-angiogenic EC phenotype. 
Furthermore, this coincided with a dramatic downregulation of ARHGAP18. Hence the 
aim of this chapter was to characterize the phenotype induced by active HRas 
overexpression and to determine whether there was a role of ARHGAP18 in the 
regulation of this phenotype. 
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3.2.  RESULTS AND DISCUSSION 
3.2.1.  OVEREXPRESSION OF ACTIVE HRAS IN ECS INDUCES A DOSE-
DEPENDENT TRANSFORMED-LIKE AND SENESCENT-LIKE CELL 
APPEARANCE 
In order to determine the phenotype induced by Ras activation, a retroviral vector 
overexpressing constitutively active HRas (G12V mutation, subsequently denoted as 
HRasV12) was used to transduce HUVECs. HRas was the chosen isoform as it is the 
most abundant isoform in ECs (Bajaj et al., 2010; Haeussler et al., 2013). To produce the 
retroviruses GP2-293 cells, which stably express the Murine Moloney Leukemia Virus 
(MMLV) gag and pol genes, were transfected with the pMIG or pMIG-HRasV12 
retrovirus expression vectors in combination with the VSV-G envelope plasmid. These 
retroviruses, which encode for HRasV12 and GFP from a bicistronic mRNA or GFP 
alone, were titred by transducing NIH3T3 cells, and determining the number of GFP 
positive cells by flow cytometry (See section. 2.2.4.2) (Dolnikov et al., 2003).  
To determine the effect of HRasV12 overexpression on ECs, HUVECs were transduced at 
two different doses of HRasV12 retrovirus, which represented a multiplicity of infection 
(MOI) of 10 and 1, while control cells were transduced with the pMIG retrovirus at an 
MOI of 3. At these doses the ECs were efficiently transduced with over 80% of control 
and 90% of HRasV12 cells expressing GFP (Fig 3.1 A and B). The GFP intensity levels 
indicated that the cells were indeed expressing at different levels and this is likely to be 
due to additional copies of the transgene integrating into the genome (Fig 3.1 B and C). 
This was confirmed by the expression of the HRas transgene, and was accompanied with 
hyper-activation of the Ras signaling pathway, as evident by the increased 
phosphorylation of ERK1/2 and Akt (Fig 3.1 D, see also Fig 3.11 A). Notably however, 
there was no further activation of Akt at the higher dose. Surprisingly, ARHGAP18 was 
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markedly downregulated following HRasV12 overexpression regardless of the dose of 
virus used (Fig 3.1 D, see also Fig 3.11 A). This is unexpected as it was hypothesized that 
since ARHGAP18 is upregulated and crucial during oxidataive stress-induced senescence, 
there would be a similar function of ARHGAP18 in OIS. Therefore, in order to establish 
the function of ARHGAP18 in the context of chronic Ras activation, it was first 
imperative to first ascertain the HRas phenotype. 
Transduction of the ECs with the HRasV12 retroviruses resulted in two very distinct and 
different phenotypes: a senescent-like (SL) phenotype at the higher dose, and a 
transformed-like (TL) cell appearance at the lower (Fig 3.1 A). These SL cells had a large 
flattened morphology, increased vacuolation and polyploidy, which are all characteristics 
of senescent cells (Campisi and d'Adda di Fagagna, 2007). On the other hand, at the lower 
dose, the TL cells did not have the typical cobblestone phenotype of confluent HUVECs 
but had increased cell density, irregular cell shapes, and extensive cell protrusions that 
resemble the phenotype of fibroblasts.  
3.2.2.  ECS OVEREXPRESSING HRASV12 AT HIGH LEVELS ARE SENESCENT 
To confirm that the SL phenotype was indeed cellular senescence and not another cell 
phenotype such as cell spreading, the cells were stained for the senescence marker, 
senescence-associated β-galactosidase (SA-β-gal). In this assay, the activity of β-
galactosidase is measured at pH 6.0, a suboptimal pH for β-galactosidase staining, with 
positive SA-β-gal staining resulting from an increase in lysosomal-mass and -β-
galactosidase in senescent cells (Kurz et al., 2000; Lee et al., 2006). HRasV12SL cells 
exhibited strong SA-β-gal staining, while control and HRasV12TL cells had little to no 
staining. Quantification of the number of senescent cells based on SA-β-gal staining and 
cell morphology showed a significant difference between the HRasV12SL dose and the 
control and HRasV12TL dose, confirming that the level of HRasV12 overexpression 
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induces a dose-dependent senescence response (Fig 3.2 B). However, although senescent 
cells were present, most cells (90%) transduced at the SL dose were not senescent, but 
had the typical TL phenotype. 
 This is likely due to two reasons. Firstly, although the cells were transduced at a high 
dose, most cells were likely to integrate only a single copy of the transgene, rather than 
the multiple copies needed for senescence. Secondly, the senescence response induces 
cell-cycle arrest, while the non-senescent cells continue to proliferate and gradually 
overtake the population. Such a dose-dependent response to oncogene activation in 
mediating cell transformation and senescence has been described previously (Sarkisian et 
al., 2007). While oncogene activation promotes proliferation and tumourigenesis, further 
oncogene hyper-activation results in hyper-proliferation and DNA hyper-replication 
resulting in accumulation of DNA damage and a p53 driven senescence response (Di 
Micco et al., 2006; Sarkisian et al., 2007; Serrano et al., 1997). This dose-dependent 
response to HRas activation is likely to be the cause of the conflicting phenotypes seen by 
other groups (Meadows et al., 2004; Spyridopoulos et al., 2002). Notably, the 
(Spyridopoulos et al., 2002) study utilized an adenoviral vector, which routinely 
overexpress proteins to extremely high levels (100-1000 fold) and thus is likely to account 
for the HRas-mediated cellular senescence observed.  
Although the senescence phenotype was interesting, the remainder of the chapter is 
devoted to TL phenotype and the role of ARHGAP18 in this phenotype as: 1. 
Transduction with the TL dose reproducibly resulted in a near pure population of 
HRasV12TL cells, whereas isolating the HRasV12SL cells from the HRasV12TL cells for 
experiments was difficult, and 2. There was no difference in the regulation of 
ARHGAP18 between the HRasV12TL and the HRasV12SL ECs (also see section 3.2.9).  
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3.2.3.  THE HRASV12TL CELLS ARE SMALLER, MORE ELONGATED, 
EXHIBIT LONG FILOPODIAL EXTENSIONS AND HAVE PROFOUND 
CHANGES IN THE CYTOSKELETON 
The HRasV12TL cells had increased elongation of cells coupled with long filopodial 
extensions (Fig 3.3 A top panels). Additionally, the cells were substantially smaller and 
had a higher cell density. In order to quantify the changes in cell morphology, the cell size 
and circularity, a measure of the elongation/roundness (0.0 being a straight line, 1.0 a 
perfect circle), was assessed (Fig 3.3 A, bottom panels and 3.3 B). The HRasV12TL cells 
were ~35% smaller in size, and significantly more elongated.  
Given the gross changes in the cell morphology, the organization of the cytoskeleton was 
next assessed. The cytoskeleton is composed of three main kinds of cytoskeletal 
filaments: actin filaments, intermediate filaments and microtubules, which collectively 
regulate cell shape, structure and function, such as in migration and division (Fletcher and 
Mullins, 2010; Rodriguez et al., 2003). To visualize the cytoskeleton, the cells were 
stained for F-actin (actin filaments), vimentin (intermediate filaments) and tubulin 
(microtubules) (Fig 3.4 A). The arrangements of all of the filaments in the HRasV12TL 
cells were distinctly different from normal cells with the evident localization of 
microtubules and intermediate filaments in the long protrusive extensions of HRasV12TL 
cells. Furthermore, the arrangement of the actin microfilaments were profoundly 
different; in control cells, the actin cytoskeleton was organized into predominantly 
cortical actin fibres surrounding cell junctions and the occasional actin stress fibres 
running across the cells. On the other hand, the HRasV12TL had a disorganized actin 
structure with large actin clusters, a distinct lack of cortical actin and prominent 
membrane ruffles. 
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3.2.4.   THE HRASV12TL PHENOTYPE IS PRO-MIGRATORY AND PRO-
SPROUTING 
Since the long filipodial extensions and membrane ruffles are a characteristic of motile 
cells (Le Clainche and Carlier, 2008), the migratory ability of the HRasV12TL cells was 
next assessed (Fig 3.5 A and B). Using a 2D wound healing assay, the HRasV12TL had a 
~50% increase in cell migration. This was accompanied with increased spreading of the 
leading migratory cell, consistent with the prominent membrane ruffles.   
To further confirm this phenotype, the ability of HRasV12TL to form 3D endothelial 
spheroid sprouts was investigated. The 3D model represents a more physiological model 
of angiogenesis in which cells are maintained in a tight quiescent cell mass and only 
sprout in response to the presence of GF (Korff and Augustin, 1998). In this model, 
HUVECs were transduced with control or HRasV12 then the monolayer of cells 
harvested and resuspended in the viscous methylcellulose media to form a 600-cell 
spheroid (Fig 3.6 A). These spheroids were collected and embedded in a collagen I gel, 
where the cells remain quiescent until stimulated with GF to induce endothelial sprouting 
(Fig 3.6 C vs E). Even prior to collagen I embedding, overexpression of HRasV12 
resulted in striking difference in the spheroid morphology with an overall increased 
looseness with the cells in the spheroid, and the formation of cell blebs (Fig 3.6 B). The 
HRasV12TL cells had extensive sprouting in the absence of stimulation, while control 
cells did not sprout at all (Fig 3.6 C and D). The morphology of EC sprouts vary with the 
different stimuli, with VEGFA induced sprouts more numerous, but less stable sprouts (as 
indicated by the number of detached cells) with many filopodia, while FGF-2 stimulation 
results in less numerous sprouts that have long multi-cellular and stable EC sprouts (Fig 
3.6 E). HRasV12 overexpression resulted in sprouting phenotype that was more 
reminiscent of VEGF-induced spheroids, rather than by FGF-2. The migratory and 
sprouting phenotype is consistent with one other study where HRasV12 overexpression 
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resulted in increased membrane ruffle formation and transwell migration (Meadows et al., 
2004). 
3.2.5.  HRASV12 DOES NOT ALTER CELL PROLIFERATION BUT PROMOTES 
BYPASS OF CONTACT-MEDIATED GROWTH INHIBITION 
One other major function of Ras and its downstream signaling is in cell proliferation 
(Bos, 1989; Rajalingam et al., 2007). To next determine whether HRasV12 
overexpression was affecting EC proliferation, control and HRasV12 transduced ECs 
were cultured for up to 5 days and the cell numbers determined at days 1, 3 and 5 (Fig 3.7 
A). Both cell populations exhibited a growth lag phase initially after 1 d of cell seeding 
and reached close to confluence by the third day, but the cell proliferation was indifferent. 
The rate of cell growth was also measured in other experiments at 2 d, during the 
exponential growth phase, but was found to be unchanged (data not shown). This is in 
contrast to other studies that have shown an increase in EC proliferation in response to 
active HRas (Bajaj et al., 2010; Meadows et al., 2001; Rennel et al., 2003). However, 
these studies were performed in suboptimal growth medium suggesting HRas activation 
permits the bypass of growth factor receptor activation. We did not examine the growth of 
HRasTL cells in these conditions. On the other hand, we observed that HRas activation 
permits the bypass of cell contact inhibition. While the control cells grew minimally after 
reaching confluence, the HRasV12 transduced ECs had an increased ability to further 
increase in cell numbers (Fig 3.7 A). To quantify the changes in cell density, the cells 
were grown for 2 d following confluence, DAPI stained for cell nuclei, and the number of 
cells determined by counting the nuclei (Fig 3.7 B). The HRasV12TL cells had a ~40% 
increase in density compared to control cells. This suggests that rather than undergoing 
quiescence with G0-G1 arrest following cell confluence, the HRasV12TL cells bypass this 
arrest and continue the cell cycle. Further analysis of the cell cycle and the cell cycle 
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proteins is subject to future studies, but has demonstrated by others to be attributed to the 
increase in cyclin D1 (Meadows et al., 2004). 
3.2.6.  THE HRASV12TL CELLS HAVE VASTLY ALTERED CELL-CELL 
JUNCTIONS 
The EC junctions are essential in maintaining cell-cell contacts and regulating cell contact 
inhibition by controlling GF signaling (Grazia Lampugnani et al., 2003). In order to 
determine whether the result of the bypass of contact inhibition was due to altered EC 
junctions, control and HRasV12TL cells were stained for the junctional proteins PECAM-
1, β-catenin and VE-cadherin (Fig 3.8 A). Indeed, while control cells had typical 
junctional localization of these proteins, their localization in the HRasV12TL cells were 
severely disorganized. PECAM-1 was predominantly absent in HRasV12TL cells. The 
adherens junctions proteins, VE-cadherin and β-catenin appeared to be downregulated 
and were largely expressed in the cell protrusions and lacked the distinct junctional 
distribution.  
3.2.7.  OVEREXPRESSION OF HRASV12 INDUCES A PARTIAL ENDMT 
We next hypothesized whether this may be the result of an endothelial-mesenchymal 
transition (EndMT). EndMT is a specialized form of epithelial-mesenchymal transition 
(EMT) that occurs in ECs, whereby EC identity is lost and the cells acquire a 
mesenchymal phenotype (Kovacic et al., 2012). EndMT is crucial in the development of 
the cardiac system in the formation of the heart valve and septum (Kovacic et al., 2012). 
EndMT, however is also a main contributor to many diseases, including cardiac fibrosis 
(Zeisberg et al., 2007b), CCM (Maddaluno et al., 2013), and cancer (Potenta et al., 2008), 
where EndMT accounts for 40% of cancer-associated fibroblasts (Zeisberg et al., 2007a). 
EndMT is characterized by loss of EC-EC junctions, acquisition of an invasive and 
migratory phenotype, the loss of endothelial markers (PECAM-1, VE-cadherin) and gain 
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in mesenchymal markers (α smooth muscle cell actin (α-SMA), fibroblast specific 
protein-1 (FSP1)), and is driven by the increased expression of the Snail family of 
transcription factors (Snail, Slug, Twist) (Potenta et al., 2008).  
In agreement with the immunostaining, the HRasV12TL cells had a marked reduction in 
PECAM-1 at the protein (Fig 3.9 A) and the mRNA level (Fig 3.9 B), although not a 
complete loss of PECAM-1 as seen by others (Medici et al., 2010). However, the total 
expression of VE-cadherin protein and mRNA were unchanged. Furthermore, the 
expression of the mesenchymal marker, α-SMA was absent at the protein level, although 
interestingly upregulated at the mRNA level. HeLa lysates were run as the positive 
control for α-SMA. This lack of the mesenchymal phenotype was confirmed by the 
absence of FSP1 (data not shown). This partial EndMT was confirmed with the 
upregulation of Snail at both the protein and mRNA level. Snail is a key initial regulator 
of EndMT as it drives the loss of cell-cell junctions by mediating VE-cadherin 
downregulation (Potenta et al., 2008). Other family members of the Snail family, 
including Slug and Twist were unchanged (data not shown). Overall, this suggested that 
HRasV12TL cells were undergoing a partial EndMT with incomplete loss of endothelial 
and an absence of mesenchymal identities. EndMT, however, is a progressive process that 
involves the gradual loss and gain of the respective identities (Zeisberg et al., 2007a). One 
potential explanation was that the HRasV12TL cells were undergoing a transition phase at 
the time assessed. To address this, the HRasV12TL cells were cultured for up to 20 d, but 
there was no change in the phenotype compared to 5 d transduced cells (data not shown) 
suggesting that the timing was not the cause of the phenotype. 
Another explanation could be that the intermediate transition phase required another 
signal to trigger complete EndMT. One of the most crucial signaling pathways controlling 
EMT and EndMT is TGF-β signaling (Chen et al., 2012; Cooley et al., 2014; Kalluri and 
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Weinberg, 2009; Kumarswamy et al., 2012). TGF-β is abundantly expressed in the 
microenvironment during injury and in tumours and is thought to be the main signaling 
mechanism to drive EndMT (Potenta et al., 2008). It has been previously reported that 
treatment of ECs including human coronary endothelial cells (Zeisberg et al., 2007b), 
mouse lung endothelial cells (Zeisberg et al., 2007a), and HUVECs (Cooley et al., 2014) 
(Kitao et al., 2009) induces EndMT, with the characteristic loss of endothelial and gain of 
mesenchymal identity. In contrast to the other studies, TGF- β1 or TGF- β2 treatment did 
not induce a morphological change in either control or the HRasV12TL cells nor did the 
stimulation result in any changes in the expression of the EndMT genes (data not shown). 
This was despite multiple time, dose and media optimization experiments. We concluded 
that this is likely to be due to the source of ECs used, where the freshly isolated primary 
HUVECs were responding differently to ECs used in other studies. Indeed in reviewing 
the literature, most if not all EC seemed to be either long term passaged or transformed 
EC lines. Interestingly, it has also been shown that FGF signaling attenuates TGF-β 
signaling to retain endothelial identity (Chen et al., 2012), and a difference in the inherit 
FGF signaling may be another explanation for the differences between the cells. The 
response of HRasV12 and TGF-β signaling in EndMT is subject to further study. Overall, 
however this establishes that HRasV12TL cells are undergoing a partial EndMT, and that 
the expression of the EndMT genes and proteins are suitable markers for examining the 
function of ARHGAP18 in the context of HRas activation. 
3.2.8.  THE HRASV12TL PHENOTYPE IS DEPENDENT ON THE 
RAF/MAPK/ERK PATHWAY AND NOT THE AKT PATHWAY 
We next sought to determine the influence of the downstream Ras signaling pathways on 
the HRasV12TL phenotype. Ras activation has been shown to regulate a multitude of 
downstream signaling pathways including the Raf/MEK/ERK, Akt, JNK and the 
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p38MAPK pathways to control cell phenotypes including proliferation, migration, cell 
survival (Meadows et al., 2004).  
To determine which signaling pathway was important for the HRasV12TL phenotype, 
control and HRasV12 transduced HUVECs were treated with MEK (U0126 and 
PD98059) and PI3K (LY294002) inhibitors. Overexpression of HRasV12 resulted in the 
activation of ERK and Akt, and treatment with the inhibitors restored basal ERK (Fig 
3.10 A) and Akt (Fig 3.10 B) activity. We observed that the inhibition of the MAPK/ERK 
pathway reverted the elongated phenotype to a more cobblestone-like phenotype (Fig 3.10 
C) and is quantified by the restoration of cell circularity (Fig 3.10 D). On the other hand, 
treatment with the PI3K inhibitor did not alter the elongated phenotype and also resulted 
in increased cell death, which is in agreement with the function of the Akt pathway in 
mediating cell survival (Kennedy et al., 1999). Inhibition of the MAPK-ERK pathway 
also resulted in a decrease in spheroid sprouting (Fig 3.10 E and F).  
These results are in agreement and in conflict with several similar studies. By also 
overexpressing HRasV12, (Meadows et al., 2004) demonstrated that Ras activation leads 
to an altered cell morphology, increased tube formation, and migration. The migratory 
ability was dependent on both ERK and Akt activation. Further, (Serban et al., 2008) 
utilized additional mutations of HRas that elicit PI3K (HRasV12C40) or ERK 
(HRasV12S35) only activation and demonstrated that both of these pathways promote 
angiogenesis. In contrast, (Bajaj et al., 2010) found that proliferation was ERK dependent, 
and HRas activation results in abnormal vascular morphogenesis that was dependent on 
Akt and not ERK. While we dismissed the functional effects of Akt based on its lack of 
effect on cell morphology, these other studies indicate that it would be of interest to 
determine its actual effects on EC sprouting. Furthermore, the influences of the other 
downstream pathways such as JNK and p38MAPK remain to be elucidated. 
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3.2.9.  THE RHOGAP, ARHGAP18, IS DOWNREGULATED FOLLOWING 
HRASV12 OVEREXPRESSION 
The major focus of the project and thesis involves the functional characterization of the 
relatively novel protein ARHGAP18. The Vascular Biology laboratory at the Centenary 
Institute previously identified a role of ARHGAP18 in oxidative stress-induced 
senescence (Coleman et al., 2010). ARHGAP18 is upregulated following hydrogen 
peroxide-induced senescence and overexpression of ARHGAP18 induces cellular 
senescence in ECs. Therefore the initial hypothesis was that ARHGAP18 is also 
upregulated and is crucial in HRas-driven OIS. Unexpectedly, and as described above, 
both the HRasV12SL and HRasV12TL cells downregulated the levels of ARHGAP18, 
indicating that overexpression of HRasV12 results in a senescence-independent 
downregulation of ARHGAP18 (Fig 3.11 A). However, transduction at the SL dose of 
virus also results in a high amount of HRasV12TL cells (Fig 3.2 B). To delineate these 
different responses, the HRasV12SL cells were purified by partial trypsin digestion, re-
cultured and assessed for ARHGAP18 expression. The expression of ARHGAP18 was 
found to be indifferent in this population compared to the HRasV12SL and HRasV12TL 
cells (data not shown). To further confirm this, the expression and localization of 
ARHGAP18 was assessed by IF staining. Optimisation and confirmation of this staining 
is described in section 5.2.1. While the localization of ARHGAP18 in the control and 
HRasV12 transduced HUVECs was predominantly in the cytosol, the expression of 
ARHGAP18 was markedly reduced in the HRasV12 transduced ECs, in agreement with 
the immunoblots (Fig 3.11 B). Notably, the expression of ARHGAP18 was further 
reduced in the HRasV12SL cells (white arrows) in comparison to the HRasV12TL cells. As 
for the reasons described earlier, the rest of this chapter focused on determining the role 
of ARHGAP18 in the HRasV12TL phenotype. 
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To first characterize the downregulation of ARHGAP18 following HRasV12 
overexpression, the protein and mRNA levels were assessed at early (2 d), mid (5 d) and 
late (8 d) timepoints, which respectively represent the time points prior to, during and 
following the transition to the TL phenotype (Fig 3.12 A). At the protein level 
ARHGAP18 was significantly downregulated at the mid and late time points (Fig 3.12 B 
and C). Notably at the mRNA level, the expression of ARHGAP18 in control cells was 
significantly upregulated from 2 to 5 and 8 d, which correlates with an increase in cell 
density to confluence (Fig 3.12 C). On the other hand, transduction with HRasV12 
resulted in a time-dependent downregulation of ARHGAP18, and an extensive 
downregulation when compared to the control at the same time point.  
3.2.10.  DOWNREGULATION OF ARHGAP18 BY HRASV12 
OVEREXPRESSION IS DEPENDENT ON MAPK/ERK ACTIVATION 
We next sought to determine which of the Ras activating pathways were regulating the 
downregulation of ARHGAP18. HUVECs were transduced with HRasV12 expressing 
retroviruses for 2 d then treated with U0126 or LY294002 and the expression of 
ARHGAP18 was determined by immunoblotting (Fig 3.13 A). While vehicle and 
LY294002 treated HRasV12 overexpressing HUVECs both resulted in the 
downregulation of ARHGAP18, treatment with U0126 resulted in substantially more 
ARHGAP18 suggesting that activation of the MAPK/ERK, but not the Akt pathway, 
controlled ARHGAP18 downregulation. However, inhibition of the MAPK/ERK pathway 
only partially prevented the downregulation of ARHGAP18. We next sough to determine 
whether prolonged MAPK/ERK inhibition could restore ARHGAP18 to baseline levels. 
To investigate this, HUVECs were transduced with HRasV12 retrovirus for 2 d then 
treated with U0126 every second day and harvested 3, 5 and 7 d post-transduction. While 
vehicle treated HRasV12-transduced HUVECs displayed a continuous downregulation of 
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ARHGAP18, HRasV12 transduced HUVECs treated with U0126 had similar levels of 
ARHGAP18 following 1, 3 and 5 d of U0126 treatment (Fig 3.13 B). This suggested that 
MAPK/ERK inhibition did not restore ARHGAP18 levels to basal control levels, but only 
inhibited the downregulation, hence resulting in a constant level of ARHGAP18. The 
reason for the partial downregulation of ARHGAP18 is postulated to be due to the time of 
U0126 treatment following HRasV12; the initial 2 d MAPK/ERK signaling triggers 
ARHGAP18 downregulation to the intermediate levels, which following U0126 treatment 
remains constant during the whole time course. This may have been circumvented by 
earlier addition of U0126, but it is important to note that successful retrovirus 
transduction and expression requires active proliferating cells, and that treatment with 
U0126 suppresses cell proliferation. Regardless, this suggested that HRasV12 
overexpression triggers the downregulation of ARHGAP18. Furthermore, like the 
HRasV12TL phenotype, this downregulation was dependent on the activation of the 
MAPK/ERK and not the PI3K/Akt pathway. On the contrary however, while 
MAPK/ERK inhibition restored the control cell phenotype, ARHGAP18 expression could 
only be maintained and not restored to basal levels. However, the simultaneous regulation 
of ARHGAP18 and the TL phenotype by MAPK/ERK suggested that ARHGAP18 itself 
might have a role in regulating the HRasV12TL phenotype. In order to address this, we 
sought to determine the effects of rescuing the expression of ARHGAP18, by 
overexpression of ARHGAP18, in HRasV12 transduced ECs. 
3.2.11.  RETROVIRAL OVEREXPRESSION OF ARHGAP18 DOES NOT INDUCE 
EC SENESCENCE 
The overexpression of ARHGAP18 was previously reported to induce EC senescence 
(Coleman et al., 2010). This was mediated using an adenoviral vector overexpressing GFP 
and ARHGAP18 off two separate CMV promoters. HUVECs transduced with control or 
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ARHGAP18 adenoviral vectors indeed induced EC senescence as indicated by the large 
flattened morphology (Fig 3.14 A). The control cells, however, had a spread phenotype 
that is distinctly different to NT control cells. Immunoblots confirmed ARHGAP18 
overexpression and was in the magnitude of 100-1000 fold levels (Fig 3.14 B). There are 
several disadvantages of the adenovirus expression system (Warnock et al., 2006). Firstly, 
cell transduction results in episomal adenoviral DNA viral particles, which dilute 
following cell division and hence results in a transient overexpression. Secondly, 
transduction with adenoviruses results in a varied expression between cells with 
populations of cells not transduced and other cells expressing varying levels of the 
transgenes. Finally, adenoviral transduction results in many copies of the episomal 
particles, which leads to the extremely high levels of overexpression seen (Fig 3.14 B). 
Given that the HRasV12 phenotype develops over several days, this transient and 
inconsistent system was deemed to be inappropriate for rescue studies. It is to be noted 
also that plasmid transfection into HUVECs is very toxic, inefficient and inconsistent. As 
the ECs described above were successfully transduced with HRasV12 and the control 
retroviruses, a retroviral system was designed to overexpress ARHGAP18. 
The pMIG retroviral vector, as used for HRasV12 overexpression, was first utilized to 
overexpress ARHGAP18. Human full-length ARHGAP18 was subcloned from the 
pcDNA3 vector into the pMIG vector to express ARHGAP18 and GFP from a bicistonic 
transcript under the control of an MSCV promoter. Transduction of HUVECs with pMIG-
ARHGAP18 resulted in poor transduction efficiency (~30-50% efficiency), despite 
repeated attempts to concentrate the retroviral particles (Fig 3.14 C). Immunoblotting for 
ARHGAP18 indicated that there was a  ~2 fold overexpression of ARHGAP18 (Fig 3.14 
D). Importantly, the transduced ECs had an indifferent phenotype to control cells, the 
normal cobblestone morphology as opposed to the senescence phenotype induced by 
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adenoviral overexpression. This lack of senescence may be due a few reasons: firstly, the 
low level of overexpression of ARHGAP18 in the retroviral system compared to the 
adenoviral system or secondly, a combination of the non-specific effects of the adenovirus 
itself with the high levels of ARHGAP18 overexpression. The additive effects of 
ARHGAP18 and the adenovirus on EC senescence are not disputed though. 
Overexpression of ARHGAP18 with the pMIG backbone brought upon a few problems: 
1. low level overexpression, 2. low transduction efficiency, and 3. GFP expression, which 
would not distinguish between cells overexpressing HRasV12, ARHGAP18 or both 
transgenes. Therefore, in order to address all of these problems, the pQCXIN backbone 
was utilized to overexpress ARHGAP18. The pQCXIN backbone encompasses a self-
inactivating retroviral vector to express ARHGAP18 and the neomycin resistance gene in 
a bicistonic transcript off a CMV promoter. This theoretically allows for higher 
expression off the stronger CMV promoter, but also allows for the selection of transduced 
cells by G418 (Geneticin). Furthermore to address the GFP issue, a separate vector 
denoted pQCXIN-mCherry-ARHGAP18 was designed to express the red fluorophore, 
mCherry. To do this, mCherry was first cloned into pQCXIN and ARHGAP18 was 
subcloned immediately downstream of the mCherry to produce an N-terminal mCherry-
ARHGAP18 fusion protein vector (details of this are listed in the methods section 2.1.12). 
An N-terminal GFP-ARHGAP18 fusion protein was previously used in the Vascular 
Biology laboratory and shown to be functionally similar to non-tagged ARHGAP18. 
Transduction with pQCXIN-mCherry-ARHGAP18, unlike the control mCherry vector, 
resulted in a predominantly cytosolic expression of mCherry (Fig 3.14 E) that was typical 
of ARHGAP18 localisation in normal cells (see Fig 3.11 B and Fig 5.1), but there was no 
notable alteration in cell phenotype. Confirmation of overexpression by immunblotting, 
however, revealed that while there was ectopic overexpression of fusion ARHGAP18, 
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these were in the form of two distinct protein products ~93 kDa and ~88 kDa in sizes (Fig 
3.14 F). Immunoblotting for mCherry by a DsRed antibody suggested that the smaller of 
the two was in fact the mCherry-fusion protein. However, the presence of the larger 
protein could not be explained and therefore the construct was not used for rescue 
experiments, as any potential effects could not be attributed to one form or the other. This 
vector however was useful for preliminary experiments investigating the changes in 
ARHGAP18 localisation following stimulation with thrombin (section 5.2.4). 
3.2.12.  RESTORATION OF ARHGAP18 DOES NOT ALTER THE HRASV12TL 
PHENOTYPE 
Overexpression of ARHGAP18 was eventually performed using the pQCXIN-
ARHGAP18 retrovirus vector, to express non-tagged ARHGAP18 and the neomycin 
resistance gene. HUVECs were transduced with pQCXIN-ARHGAP18 or empty vector 
control and selected for 1 week with G418. Non-transduced (negative control) and 
pQCXIN-mCherry (positive control) transduced ECs were performed concurrently to 
monitor G418 efficacy and transduction efficiency following selection and was routinely 
>90%. Transduction with pQCXIN-ARHGAP18 resulted in overexpression of 
ARHGAP18 (Fig 3.15 C, lane 1 vs 3) that was more consistent than the pMIG vector. 
However, like the pMIG vector, there was no indication of cellular senescence (Fig 3.15 
A, panel 1 vs 3). This further indicates that the AdvARHGAP18 senescence phenotype is 
likely due to a combined effect of ARHGAP18 overexpression with the non-specific 
adenoviral effects. 
To finally determine whether ARHGAP18 restoration could rescue the effects of 
HRasV12, the control or pQCXIN-ARHGAP18 transduced cells were further transduced 
with pMIG-HRasV12 or a pMIG control vector and assessed for changes in the cell 
phenotype and analysed for the EndMT phenotype. Contrary to the hypothesis, 
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ARHGAP18 overexpression did not alter the phenotype induced by HRasV12 with the 
presence of the typical dense morphology with extensive cell protrusions (Fig 3.15 A). 
These changes were quantified by measurement of the cell circularity and were found to 
be indifferent (Fig 3.14 B). Overexpression of ARHGAP18 and rescue of ARHGAP18 in 
the presence of HRasV12 expression was confirmed by immunoblotting (3.14 C, top 
panel) and qRT-PCR (Fig 3.14 D, top panel). HRas overexpression reduced endogenous 
levels of ARHGAP18 in the pQCXIN-ARHGAP18 transduced ECs resulting in 
ARHGAP18 levels similar to that of the control ECs. 
While there was no change in the gross phenotype, we next sought to assess whether 
ARHGAP18 was regulating the development of the partial EndMT phenotype by 
assessing the markers at the protein (Fig 3.14 C) and mRNA level (3.14 D). In the 
absence of HRasV12, ARHGAP18 overexpression did not alter the expression of any of 
the aforementioned EndMT markers. Furthermore, while HRasV12 overexpression 
induces the downregulation of PECAM-1 (protein and mRNA), alteration of VE-
cadherin, and upregulation of α-SMA (mRNA) and Snail (protein and mRNA), restoration 
of ARHGAP18 did not alter the expression of these markers. This convincingly 
concluded that ARHGAP18 did not have a direct role in regulating the HRasV12 
phenotype. In retrospect, given the role of ARHGAP18 in EC sprouting (chapter 4), an 
ideal functional assay to assess the contribution of ARHGAP18 in the HRas phenotype 
would be the spheroid sprouting assay. This was not performed due to the timing of the 
experiments (the ARHGAP18 rescue experiments were performed much prior to 
establishing the spheroid sprouting assay, which was predominantly used for assessing 
ARHGAP18 knockdown in chapter 4).  
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3.3.  SUMMARY AND CONCLUSIONS 
Ras is one of the major signaling pathways downstream of growth factor receptor 
signaling, including that of VEGF. Here, we describe that in agreement with some other 
studies (Meadows et al., 2001; Meadows et al., 2004; Serban et al., 2008), chronic HRas 
activation induces a pro-angiogenic phenotype in ECs. This is accompanied with a drastic 
alteration in the cell morphology, with profound changes in the cell cytoskeleton and EC 
junctions, and elicits a partial EndMT, with semi-loss of endothelial status and incomplete 
gain of the mesenchymal phenotype. The gross phenotype is dependent on chronic 
activation of the MAPK/ERK and not the PI3K/Akt pathway. Finally, we observe that the 
expression of the novel protein, ARHGAP18, is drastically downregulated also via a 
MAPK/ERK dependent pathway, however, restoration of ARHGAP18 does not influence 
the HRas phenotype directly (Fig 3.16).  
As there was no clear indicator of ARHGAP18 as a crucial regulator of the drastic 
HRasV12TL phenotype, the project was left in this preliminary state. Since we have 
further established roles of ARHGAP18 in regulating EC sprouting (chapter 4) and 
junctional regulation (chapter 5), it would now be of future interest to determine whether 
ARHGAP18 restoration could affect these functional aspects of HRas. In addition, we 
established that ARHGAP18 acts as a RhoC GAP protein in its regulation of EC junctions 
(chapter 5). The RhoGTPases are the major regulators of cell morphology and the 
cytoskeleton and there is substantial cross-talk between the Ras and Rho pathways (Bar-
Sagi and Hall, 2000; Sahai et al., 2001). A major future direction would be investigating 
the roles of the different Rho proteins in regulating the HRasV12TL phenotype. In the 
context of ARHGAP18, it would be very interesting to determine whether there are 
elevated levels of RhoC in the HRasV12TL cells and whether there is a direct role of 
ARHGAP18 in regulating this. We would predict that, regardless of the changes in 
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activity in the Rho proteins, there would be a minimal role of ARHGAP18 in regulating 
this due to the substantial redundancy within the RhoGAP family members. It would be 
interesting to analyse the expression of the other RhoGAPs and RhoGEFs to determine 
whether there is a collective response in the regulation of Rho activity or whether this 
downregulation of ARHGAP18 is a specific phenomenon. 
It would also be of future interest, in the context of ARHGAP18 and Ras, to investigate 
the effects of chronic activation of the downstream pathways, such as using membrane 
tagged-Akt (myr-Akt) and mutated BRAF, or mutated Ras transgenes that only signal 
through one of the pathways (Serban et al., 2008). Further, the JNK and p38MAPK are 
also associated with Ras activation so investigating these would collectively assist in 
delineating the pathways that regulate the HRasV12TL phenotype and ARHGAP18 
expression. Additionally, the results hinted that Ras overexpression directly affects the 
transcription of ARHGAP18, so further investigations into this regulation by ARHGAP18 
promoter analysis and the identification of the associated transcription factors may give 
further insight into the function of ARHGAP18. 
Aberrant signaling of the Ras signaling pathway is common in many vascular diseases, 
including angiosarcomas and vascular malformations. A detailed understanding of the 
regulators and downstream pathways can therefore potentially lead to the development of 
novel targeted therapeutics. Additionally, chronic activating mutations of Ras and its 
downstream signaling proteins, such as BRAF, occurs in a majority of many cancers 
(Brose et al., 2002; Davies et al., 2002). It would therefore be of major significance to 
determine whether there is similar regulation of ARHGAP18 in other epithelial cells and 
whether there is a crucial role of ARHGAP18 in regulating Ras-mediated cancer 
development. 	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Fig 3.1. Overexpression of constitutively active HRas in ECs induces a dose-dependent 
transformed-like and senescent-like cell appearance. 
A.  Bright!eld and GFP wide!eld images of non-transduced (NT), pMIG retrovirus-transduced, and 
HRasV12 retrovirus-transduced HUVECs following 6 d transduction. Cells were transduced with 
two diﬀerent MOI of HRasV12 viruses that induced a senescent-like morphology (HRasV12SL) 
and a transformed-like cell appearance (HRasV12TL). Bar 100 μm. 
B.  Flow cytometric analysis of GFP expression from NT (grey), pMIG (black), HRasV12TL (blue) and 
HRasV12SL transduced HUVECs. Representative of n=3 experiments. 
C.  Quanti!cation of the mean $uorescence intensity (MFI) of the GFP expression of HUVECs 
transduced in B. Data was normalised to the pMIG control and represents the mean ± SEM from 
n=3 experiments. * P<0.05; one-way ANOVA, Tukey’s post-test. 
D.  Immunoblots of Ras, downstream phosphorylated kinases (p-ERK and p-Akt) and ARHGAP18 
from HUVECs transduced with pMIG or RasV12 retroviruses for 5 d. Actin was used as a loading 
control. Representative blots of n=3 experiments. 
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Fig 3.2. HUVECs overexpressing HRasV12 at SL MOI are senescent. 
A.  SA-β-gal staining of NT, pMIG and HRasV12TL and HRasV12SL HUVECs. Senescent cells exhibit 
strong β-galactosidase activity as evidenced by intense blue staining. Bar 100 μm. 
B.  Quanti!cation of senescent cells in NT, pMIG and HRasV12TL and HRasV12SL transduced HUVECs. 
Senescent cells were classi!ed based on the large $attened morphology, polyploidy, increased 
vacuolation and positive staining for SA-β-gal and expressed as a percentage of the total 
population. Data represents the mean ± SEM from n=4 experiments. * P<0.05, ** P< 0.01; one-
way ANOVA, Tukey’s post-test. 
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Fig 3.3. The transformed-like cells of HRasV12TL overexpression are smaller, more elongated 
and exhibit long !lipodial extensions. 
A.  Top panels, High magni!cation of control and HRasV12TL ECs showing the altered cell 
morphology. Active HRas overexpression results in a reduced cell size, an increase in cell 
elongation and the appearance of long !lipodial extensions (arrow). Bottom panels, manual 
outlines of the cells (yellow) were performed in Fiji to quantitate the changes in morphology. 
Bar 50 μm. 
B.  Quanti!cation of the cell size and cell circularity from control and HRasV12TL ECs. Data 
represents the mean ± SEM from n=3 experiments. * P<0.05, ** P<0.01; t-test. 
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Fig 3.4. The HRasV12-induced elongated cell phenotype is associated with profound 
alterations in the cell cytoskeleton. 
A.  HUVECS transduced with control (left panels) or HRasV12 (right panels) retroviruses were stained 
for Ras and cytoskeletal proteins, including vimentin, tubulin and F-actin, counterstained with 
DAPI (blue) and imaged by confocal microscopy. HRasV12TL ECs accumulate vimentin and 
tubulin in the long !lipodial !laments and actin forms large clusters as opposed to the 
organised structure in control ECs. Bar 25 μm. 
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Fig 3.5. HRasV12TL ECs have increased cell migration. 
A.  HUVECS transduced with control or HRasV12 retrovirus were subjected to a scratch wound assay 
and imaged at 0 and 5 h post-scratch. The sizes of the wounds were determined using Fiji. Bar 
100 μm. 
B.  Quanti!cation of the wound recovery at 3 and 5 h post-scratch in A. Data represents the mean ± 
SEM from n=4 independent experiments. * P<0.05, *** P<0.001; t-test. 
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Fig 3.6. HRasV12 overexpression promotes EC spheroid sprouting. 
A.  Schematic diagram of the spheroid sprouting assay. Monolayer ECs were resuspended in 
methylcellulose to form suspended spheroids. These spheroids were embedded into collagen I 
gels and stimulated to sprout. 
B.  Morphology of the spheroids formed from control and HRasV12 transduced HUVECs. Control 
cells formed a tight spheroid structure while the spheroids from HRasV12 transduced ECs had a 
relatively looser and irregular structure with apparent cell blebs. Bar 100 μm. 
C.  Non-stimulated spheroids comprised of control or HRasV12 transduced ECs were embedded in 
collagen I gels and imaged after 24 h. EC spheroids overexpressing HRasV12 resulted in proli!c 
cell sprouting. Bar 200 μm. 
D.  Quanti!cation of the sprouted area in C. Data represents the mean ± SEM of 16 control and 13 
HRasV12 sprouted spheroids from n=3 independent experiments. **** P<0.0001; t-test. 
E.  HRasV12 spheroid sprouts have a VEGF-like sprouting appearance. Representative morphology 
of normal HUVEC spheroids stimulated with VEGF (25 ng/mL, 24 h) and FGF-2 (25 ng/mL, 48 h). 
Non-phase contrast in VEGF and FGF-2 stimulated sprout spheroid images. Bar 200 μm 
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Fig 3.7. Overexpression of active HRas does not alter cell proliferation but promotes bypass of 
contact-mediated growth inhibition. 
A.  Control and HRasV12 transduced HUVECs were seeded in 6 well plates and cultured for up to 5 
d. The cells were collected and counted after 1, 3 and 5 d. Data represents the mean ± SD from 
n=3 experiments. . * P<0.05; two way ANOVA, Sidak’s post-test. 
B.  Control and HRasV12 transduced HUVECs were cultured on chamber slides for 1 d following cell 
con$uence and stained for DAPI. Fluorescent images of DAPI alone (top panels) or DAPI and GFP 
(bottom panels) were taken and the number of cells per !eld determined by counting the cell 
nuclei. Bar 50 μm. 
C.  Quanti!cation of cells per !eld in B. Data represents the mean ± SEM from n=4 independent 
experiments from at least 4 !elds each. * P<0.05; t-test. 
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Fig 3.8. Overexpression of constitutively active HRas profoundly alters the expression and 
localisation of cell junction proteins. 
A.  Control (left panels) and HRasV12 (right panels) transduced HUVECs were cultured on chamber 
slides, !xed, stained for the junction proteins: PECAM-1, β-catenin and VE-cadherin; 
counterstained with DAPI and imaged by confocal microscopy. Bar 25 μm.  
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Fig 3.9. Overexpression of constitutively active HRas results in partial EndMT. 
A.  Immunoblots of endothelial (PECAM-1, VE-cadherin), mesenchymal (α-SMA), and EMT (Snail) 
markers from 5 d control and HRasV12 transduced HUVECs. HeLa lysate was used as a positive 
control for α-SMA. Actin was used as a loading control. Representative blots from n=3 
independent experiments. 
B.  The mRNA levels of PECAM-1, VE-cadherin, α-SMA and Snail from 5 d control or HRasV12 
transduced HUVECs were determined by qRT-PCR and normalised to β-actin. Data represents 
the mean ± SEM from n=4-7 independent experiments. ** P<0.01; t-test. Statistical tests were 
performed on log2(fold change) values. 
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Fig 3.10. The HRasV12TL phenotype is dependent on MAPK/ERK and not Akt activation. 
A.  Con!rmation of MAPK inhibition by the MEK inhibitors, U0126 and PD98059. Immunoblots for 
p-ERK1/2 from control or HRasV12 transduced HUVECs treated with DMSO Vehicle , 30 μM 
U0126 (U) or 100 μM PD98059 (PD). Pan-Ras was used to show successful transduction; Actin 
was used as the loading control. 
B.  Con!rmation of Akt inhibtion by the PI3K inhibitor, LY294002. Immunoblots for p-Akt from 
control or HRasV12 transduced HUVECs treated with DMSO vehicle or 30 μM LY294002 (LY). 
Actin was used as the loading control. 
C.  Inhibition of MAPK/ERK but not PI3K/Akt partially reverts the HRasV12TL elongated phenotype. 
Bright!eld images of HUVECs transduced with control or HRasV12 retroviruses for 2 d were 
treated with vehicle, 30 μM U0126, 100 μM PD98059 or 30 μM LY294002 for 2 d. Bar 50 μm. 
D.  Quanti!cation of cell elongation in C. Cell circularity of control or HRasV12TL HUVECs treated 
with MEK or PI3K inhibitors were assessed using Fiji. Data represents the mean ± SEM of n=3 
independent experiments. ** P<0.01; one way ANOVA, Tukey’s post-test. 
E.  MAPK inhibition suppresses the sprouting phenotype of HRasV12 overexpression. HRasV12 EC 
spheroids were embedded in collagen I gels and treated with vehicle or 30 μM U0126. Bar 200 
μm.  
F.  Quanti!cation of the sprouted area of HRasV12 EC spheroids treated with vehicle or U0126 in E. 
Data represents the mean + SEM from 11 vehicle and 14 U0126 spheroids from n=2 
independent experiments. **** P<0.0001; t-test. 
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Fig 3.11. ARHGAP18 is downregulated in ECs overexpresing HRasV12. 
A.  Immunoblots of ARHGAP18 from 5 d control and HRasV12 (TL and SL doses) transduced ECs. 
Overexpression of HRasV12 at diﬀerent levels was con!rmed by immunoblotting for pan-Ras. 
Actin was used as a loading control. 
B.  Confocal images of control and HRasV12 transduced ECs immunostained for ARHGAP18 (red). 
Cell nuclei were counterstained with DAPI (blue). White arrows represent the senescent HRasV12 
cells. ARHGAP18 is localised predominantly in the cytosol of ECs and is expressed at a lower 
level in HRasV12 overexpressing cells relative to control ECs. Bar 50 μm. 
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Fig 3.12. ARHGAP18 is downregulated following HRasV12 overexpression in a time-
dependent manner. 
A.  Bright!eld images of HRasV12 overexpressing HUVECs following 2, 5 and 8 d transduction. Bar 
100 μm. 
B.  Immunoblots of ARHGAP18 from 2, 5 and 8 d control and HRasV12 transduced ECs. 
Representative blots from n=3 independent experiments. p-ERK1/2 was used as an activation 
control for HRasV12 transduction. Actin was used as a loading control. 
C.  The mRNA level of ARHGAP18 from 2, 5 and 8 d control and HRasV12 transduced ECs was 
determined by qRT-PCR and normalised to β-actin. Data represents the mean + SEM from n=3 
independent experiments. **** P<0.0001, *** P<0.001, ** P<0.01; two-way ANOVA, Sidak’s post-
test. Blue and red stars represent the signi!cance of 5 and 8 d relative to 2 d from control and 
HRasV12, respectively. Black stars represent the signi!cance of the diﬀerences between control 
and HRasV12 at the same time points. Statistical tests were performed on log2(fold change) 
values. 
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Fig 3.13. ARHGAP18 downregulation is dependent on MAPK/ERK activation and is not 
restored to basal levels following MAPK inhibition 
A.  ARHGAP18 downregulation by HRasV12 overexpression is inhibited by MAPK/ERK inhibition but 
not PI3K/Akt inhibition. Three day control and HRasV12 transduced HUVECs were treated with 
vehicle, 30 μM U0126 or 30 μM LY294002 for 2 d, lysed and immunoblotted for ARHGAP18. p-
ERK1/2 and p-Akt were used to con!rm activation and inhibition of the MAPK/ERK and Akt 
pathways respectively. Actin was used as the loading control. Representative blots from n=3 
independent experiments. 
B.  Long-term inhibition of MAPK/ERK signaling does not restore ARHGAP18 levels. Two day control 
and HRasV12 transduced HUVECs were treated with vehicle or 30 μM U0126 for 1, 3 and 5 d, 
lysed and immunoblotted for ARHGAP18. p-ERK1/2 was used to con!rm activation and 
inhibition of the MAPK/ERK pathway. Actin was used as the loading control. Representative blots 
from n=2 independent experiments. 
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Fig 3.14. Retroviral overexpression of ARHGAP18 does not induce EC senescence. 
A.  Bright!eld and GFP images of HUVECs transduced with control or ARHGAP18 adenoviruses. 
Adv-ARHGAP18 cells are senescent with the typical enlarged and $attened cell appearance. Bar 
100 μm. 
B.  Immunoblots of ARHGAP18 from non-transduced, control and ARHGAP18-adenovirus 
transduced HUVECs. Actin was used as the loading control. 
C.  Bright!eld and GFP images of HUVECs transduced with control or ARHGAP18 pMIG retroviruses. 
pMIG-ARHGAP18 cells are phenotypically indiﬀerent from control cells. Bar 100 μm. 
D.  Immunoblots of ARHGAP18 from non-transduced, control and ARHGAP18-pMIG-retrovirus 
transduced HUVECs. Actin was used as the loading control. 
E.  Bright!eld and mCherry images of HUVECs transduced with control or mCherry-ARHGAP18 
pQCXIN retroviruses. pQCXIN-mCherry-ARHGAP18 cells are phenotypically indiﬀerent from 
control cells. mCherry expression is throughout the cell in control-transduced cells, but 
predominantly cytosolic in cells expressing the mCherry-ARHGAP18 fusion protein. Bar 100 μm. 
F.  Immunoblots of ARHGAP18 and DsRed from control and mCherry-ARHGAP18 pQCXIN-
retrovirus transduced HUVECs. Actin was used as the loading control. Expression of the fusion 
protein resulted in two distinct bands of which the lower stronger band was immunoreactive to 
the DsRed antibody. 
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Fig 3.15. ARGHGAP18 restoration does not revert the Ras phenotype 
A.  Bright!eld images of HUVECs overexpressing ARHGAP18, HRasV12 or both ARHGAP18 and 
HRasV12. ARHGAP18 expression did not aﬀect the typical TL phenotype of HRasV12. Bar 100 
μm. 
B.  Quanti!cation of cell circularity in A. Data represents the mean ± SEM of 40 cells from n=2 
independent experiments.  
C.  Immunoblots of ARHGAP18 and the EndMT proteins (PECAM-1, VE-cadherin, Snail) from 
HUVECs overexpressing ARHGAP18, HRasV12 or both ARHGAP18 and HRasV12. Actin was used 
as the loading control. Representative blots from n=2 independent experiments. 
D.  Quantitative RT-PCR of ARHGAP18 and EndMT genes (PECAM-1, α-SMA and Snail) from HUVECs 
overexpressing ARHGAP18, HRasV12 or both ARHGAP18 and HRasV12. β-actin was used as the 
normalising gene. Data represents the mean ± SEM from n=2 independent experiments. 
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Fig 3.16. Proposed pathway for the HRas mediated TL phenotype and the role of ARHGAP18 
A.  Constitutive activation of HRas results in a partial EndMT phenotype with altered cell 
morphology, disrupted cell-cell junctions and increased cell sprouting and migration that is 
dependent on MAPK/ERK, but not Akt activation. Constitutive HRas activation also results in 
MAPK/ERK-dependent downregulation of ARHGAP18, however the HRas phenotype is not 
dependent the loss of ARHGAP18. The functional consequence of ARHGAP18 downregulation in 
the context of constitutive HRas activation remains to be elucidated. 
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4.1.  INTRODUCTION 
ARHGAP18 was identified from an array of genes regulated during in vitro tube 
formation (Coleman et al., 2013; Hahn et al., 2005). It was investigated further because it 
showed an unusual pattern of regulation, being downregulated during the migratory 
phase, followed by a later upregulation during tube stabilization (Coleman et al., 2010). 
This suggested that ARHGAP18 may have roles in regulating EC migration or vessel 
stabilization. Furthermore, in the previous chapter, we established that chronic HRas 
activation induces a pro-angiogenic phenotype with cytoskeletal and junctional defects 
and is associated with near complete loss of ARHGAP18 expression. However, since Ras 
regulates a multitude of signaling pathways and elicits an extreme gross change in 
phenotype, we were unable to identify a role of ARHGAP18 in this instance. On the other 
hand, this result indicated that there was an environment where there was a loss of 
ARHGAP18 expression, and thus makes the investigation of ARHGAP18 knockdown 
physiologically relevant. The aim of this chapter was to investigate whether there was a 
role of ARHGAP18 in the regulation of sprouting angiogenesis.  
By in vitro and in vivo models of angiogenesis, we describe here that loss of ARHGAP18 
results in EC hypersprouting. This is an EC-centric phenotype and is mediated by changes 
in VEGFA responsiveness, and the development of a tip cell (TC) profile and phenotype.  
4.2.  RESULTS AND DISCUSSION 
4.2.1.  OPTIMISATION OF ARHGAP18 KNOCKDOWN IN ECS 
In the previous studies, ARHGAP18 knockdown was performed using the HiPerFect 
transfection reagent (Coleman et al., 2010). However, using the same conditions (50 nM 
siRNA), a consistent level of gene silencing was unable to be reproduced (data not 
shown). Therefore, the conditions for gene knockdown were re-established. The 
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Lipofectamine RNAiMax reagent was used, as this had been reported to be efficient and 
low in toxicity to ECs (Life Technologies manufacturer’s documentation). The 
concentrations of siRNA and lipofectamine reagent were first optimized using a pool of 
the three siRNAs used in the previous study (Fig 4.1 A and B). Even at low doses of 
siRNA/lipofectamine (5 nM siRNA, 2.5 µL lipofectamine), ARHGAP18 expression was 
significantly reduced, with over 90% decrease in protein expression (Fig 4.1 B). 
Transfection at the higher dose of siRNA/lipofectamine (10 nM siRNA, 5 µL 
lipofectamine) resulted in noticeable toxicity, as indicated by the prominent change in cell 
morphology in the control siRNA transduced cells (Fig 4.1 A). The lower dose of 
siRNA/lipofectamine was therefore chosen and the efficiency of transfection was 
confirmed to be over 90% by monitoring the uptake of a fluorescent oligo (Fig 4.1 C). 
The siRNA gene silencing ability is known to be transient and time-dependent. A time 
course of cells transfected with siRNAs was performed to establish the time conditions for 
future experiments. As expected, the siRNAs were marginally effective 1 d following 
transfection, but highest at 3 to 5 d. By day 7 the level of ARHGAP18 expression had 
returned to near endogenous levels (Fig 4.1 D). Therefore, all subsequent experiments 
were performed on cells following 3-4 d transfection.  
Finally, the effects of the individual siRNAs targeting ARHGAP18 were examined (Fig 
4.2 A-C). All the siRNAs targeted the coding sequence of ARHGAP18 and not the 5’ or 
3’ untranslated regions (Fig 4.2 A) Individual transfection of the original siRNAs 
(siGAP18-1, siGAP18-2, siGAP18-3) all resulted in efficient gene knockdown. However, 
out of these three, one of the siRNAs (siGAP18-2) resulted in an elongated phenotype 
(Fig 4.2 C, white arrows). Therefore, to determine whether this was due to a non-specific 
effect, four other siRNAs (siGAP18-4, siGAP18-5, siGAP18-6, siGAP18-7) were tested 
for their ability to knockdown ARHGAP18 and induce an elongated phenotype. 
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Transfection with these siRNAs resulted in relatively poor gene knockdown in 
comparison to the original siRNAs, with only siGAP18-6 resulting in acceptable 
knockdown. This is likely due to the different targeting sequences or chemistries used by 
each manufacturer. However, importantly none of these siRNAs resulted in any alteration 
of the cell phenotype. Overall, it is likely that siGAP18-2 induced non-specific effects in 
ECs, and was therefore omitted from further experiments. From these optimization 
experiments, it was decided that a pool of siGAP18-1 and siGAP18-3 were to be used as 
the transfection conditions for subsequent knockdown experiments.  
4.2.2.  ARHGAP18 KNOCKDOWN DOES NOT ALTER THE GROSS EC 
PHENOTYPE OR AFFECT EC PROLIFERATION 
Using the aforementioned conditions from the optimization experiments, we first assessed 
whether knockdown of ARHGAP18 altered the gross EC phenotype (Fig 4.3 A-C). As 
previously described for the HRasV12TL cells, the gross phenotype was assessed by 
analyzing cell size and circularity. Knockdown was confirmed at the protein (Fig 4.3 D) 
and mRNA (Fig 4.3 E) levels and was routinely over 90% and 80% respectively. 
Knockdown of ARHGAP18 resulted in a typical cobblestone EC morphology (Fig 4.3 A) 
and had no changes in cell size (Fig 4.3 B) or circularity (Fig 4.3 C).  
The effect of ARHGAP18 on cell proliferation was next assessed. HUVECs transfected 
with siRNAs were cultured for 3 d and counted using a hemocytometer. Knockdown of 
ARHGAP18 did not have an effect on cell proliferation (Fig 4.4 A). While other 
proliferation assays (e.g MTT assays, CFSE) could have been performed to more 
accurately assess proliferation, there was no indication that ARHGAP18 was affecting 
cell proliferation and so these were not performed. Next, the effects of ARHGAP18 
knockdown on the cell density was assessed by determining the number of cells per field 
after culturing the chamber slides. Intriguingly, knockdown of ARHGAP18 resulted in a 
Chapter 4. ARHGAP18 in Angiogenic Sprouting 
	   155 
slight ~10% decrease in cell density (Fig 4.4 B and C), which given that there was no 
effect on cell proliferation, may indicate a more spread out phenotype, and one possibly 
involved in migration.      
4.2.3.  ARHGAP18 KNOCKDOWN RESULTS IN A PRO-MIGRATORY AND 
PRO-SPROUTING PHENOTYPE 
We next assessed the effects of ARHGAP18 knockdown on cell migration using a 2D 
wound healing assay. Control knockdown ECs had migrated predominantly as a uniform 
front within the first 5 h (Fig. 4.5 A). In contrast, ARHGAP18 knockdown resulted in an 
irregular and protruded migratory front and an overall 16% increase in wound closure at 
this early time point (Fig. 4.5 A and B). Notably, while the protrusive lamellipodium were 
unchanged, the proximal edge of the leading cell at the migratory front had disrupted cell-
cell junctions (Fig. 4.5 C). The increased migratory phenotype was also observed in the 
3D spheroid sprouting assay although with a more pronounced effect. Following VEGFA 
stimulation for 20 h, knockdown of ARHGAP18 resulted in a significant increase in both 
the number of sprouts and the cumulative sprout length of the spheroids (Fig. 4.6 A-C). 
Unlike HRasV12TL cells, neither knockdown nor control spheroids sprouted in the 
absence of stimulus (data not shown). We confirmed that ARHGAP18 was silenced in the 
spheroid assay by assessing the ARHGAP18 mRNA levels (Fig 4.6 D). One of the 
reviewers of the publication indicated that the ARHGAP18 knockdown 
migratory/sprouting phenotype should be reproduced using individual siRNAs. Therefore, 
using the spheroid sprouting assay (as the effects of ARHGAP18 depletion were more 
pronounced and consistent), we confirmed the sprouting phenotype of spheroids 
generated from ECs transfected with the individual siRNAs. Each of these siRNAs 
resulted in a significant increase in spheroid sprouting, and was no different to the other 
ARHGAP18 siRNAs nor the combined siRNA approach (Fig 4.6 E). Notably, these 
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results are in contrast to those seen by (Maeda et al., 2011) in epithelial cells. This may be 
due to intrinsic differences between epithelial and endothelial cells or a result of different 
targets in these cells. This is discussed further in section 5.2.5. 
4.2.4.  KNOCKDOWN OF ARHGAP18 PROMOTES ZEBRAFISH ISV 
SPROUTING 
We next sought to confirm the sprouting phenotype using in vivo models of angiogenesis, 
firstly with the zebrafish model performed by Dr. Ka Ka Ting, from the same laboratory. 
The zebrafish embryo model has emerged as an excellent model to study in vivo 
angiogenesis for several reasons: the ability to be genetically manipulated, small size, 
rapid and external development, and optical transparency that allows it to be visualized 
microscopically (Gore et al., 2012). Initial blood vessel morphogenesis occurs by 
vasculogenesis to form the dorsal aorta (DA) and the posterior cardinal vein (PCV) 
(Ellertsdottir et al., 2010). Following the primary axial vessels, the elaborate vascular 
structure predominantly forms via sprouting angiogenesis, with the initial development of 
the intersegmental vessels occurring ~22 hours post fertilization (hpf)  (Ellertsdottir et al., 
2010).  
A morpholino based approach was used to silence the expression of ARHGAP18 using 
two different morpholino approaches: a splice morpholino to inhibit splicing of 
ARHGAP18, and a translational morpholino to inhibit the initiation of translation of 
ARHGAP18 (Fig 4.7 A). The morpholinos were injected in the 2-4 cell stage of the 
zebrafish embryos and monitored for up to 48 h. Injection of the SpMO resulted in 
retention of ARHGAP18 intron 3 in the mRNA, and decreased expression of ARHGAP18 
exon 5, thus confirming efficacy of the injection and the morpolino (Fig 4.7 B). 
Assessment of the gross morphology at 48 h indicated the presence of hindbrain, 
pericardial and yolk odema in both the TrMO and SpMO (Fig 4.7 C) and this was coupled 
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with reduced zebrafish viability (data not shown). This was not due to non-specific 
apoptotic effects, as reported by others (Gerety and Wilkinson, 2011), since there was an 
absence of TUNEL staining in the MO injected embryos (Fig 4.7 D). 
To assess the effects of ARHGAP18 silencing on angiogenesis, the fli1-GFP transgenic 
zebrafish embryos, which have the ECs expressing GFP, were injected with the 
morpholinos and imaged by confocal microscopy. At 24 hpf, both the TrMO and the 
SpMO resulted in a significant increase in ISV lengths compared to the control MO (Fig 
4.8 A and B). This was coupled with an increase in filopodial extensions further 
confirming the hypersprouting phenotype. It was also observed that the lumen diameter of 
the dorsal aorta (DA) was notably reduced in the SpMO, and trending in the TrMO, 
whereas the lumen diameter of the posterior cardinal vein (PCV) in both ARHGAP18 
morphants were similar (Fig 4.8 C and D). This may be an indicator of the increased 
migration of the cells from the DA into the ISV, which occurs first at ~22 hpf, whereas 
the cells migrate from the PCV at ~32 hpf (Ellertsdottir et al., 2010). Further, in 
collaboration with Dr. Neil Bower and Dr. Ben Hogan, at the Institute for Molecular 
Biosciences, University Queensalnd, they observed similar effects with the MOs on 
vascular hypersprouting, but also showed that the development of the lymphatics was 
unchanged (Chang et al., 2014), indicating that the effects of ARHGAP18 knockdown is 
vascular specific. 
4.2.5.  GENOMIC CHARACTERISATION OF THE ARHGAP18 KNOCKOUT 
MOUSE 
To next investigate the effects of ARHGAP18 loss in mammalian vascular development, 
a global ARHGAP18 KO mouse was generated through the KOMP repository. This 
mouse utilizes a splice cassette which is inserted downstream of the mouse ARHGAP18 
exon 1 and just upstream of exon 2 (Fig 4.9 A). The splice cassette encodes for a splice 
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acceptor that continues to the expression of lacZ driven by an IRES element. In addition, 
a neomycin resistance gene is expressed from a separate constitutive promoter, which 
allows for neomycin/G418 selection of the murine ES cells for the generation of the KO 
mouse. Expression of the lacZ gene would have occurred in the KO cells under the 
control of the murine ARHGAP18 promoter and would have been be detected by β-
galatosidase staining (Fig 4.9 B). However, following genotyping and sequencing of the 
mRNA (performed by Dr. Angelina Lay), it was concluded that, in the actual 
ARHGAP18 KO mouse, there was a cryptic splice donor site present in the cassette (Fig 
4.9 B). This results in re-splicing of the cassette element and joining of the rest of the 
ARHGAP18 exons. As a result, this forbids the use of lacZ, (since it is spliced out) to be 
used as a marker of ARHGAP18 expression. Fortunately, despite the presence of the 
cryptic splice donor, there was still a stop codon present in the splice cassette, which 
prematurely terminates expression of the ARHGAP18 protein product. Analysis of mouse 
lung lysates confirmed the absence of ARHGAP18 in the ARHGAP18-/- mouse (Fig 4.9 
C). The endothelial protein, VE-cadherin, was used as a loading control for the lung 
endothelium, thus confirming the absence of ARHGAP18 also in the endothelial 
population. The mice are phenotypically normal and display no changes in the rate of 
pregnancy or litter size.  
4.2.6.  ARHGAP18 LOSS PROMOTES EX VIVO AORTIC RING SPROUTING 
ANGIOGENESIS 
To determine the effects of ARHGAP18 loss on angiogenesis, the aortic ring assay was 
used. The aortas from WT and ARHGAP18-/- mice were isolated, dissected into small 
sections and embedded and cultured in Matrigel. This matrix contains growth factors that 
allows the ECs to invade into the 3D environment and generate EC sprouts. The loss of 
ARHGAP18 resulted in significantly increased sprouting of the aortas, with earlier onset 
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and increased expansion of the sprouts (Fig 4.10 A and B). Strikingly, while the WT cells 
formed mainly linear sprouts, the EC from the ARHGAP18-/- mice had an increased 
propensity to form branches (Fig 4.10 B iii and iv). 
4.2.7.  LOSS OF ARHGAP18 RESULTS IN HYPERSPROUTING OF THE 
DEVELOPING RETINA VASCULATURE 
We next utilized the retina model to investigate the effects of ARHGAP18 on 
angiogenesis in vivo. This is a widely used and well-characterised model of 
developmental angiogenesis in vivo (Gariano and Gardner, 2005; Pitulescu et al., 2010; 
Stahl et al., 2010). Retinal vascularization occurs post-natally and begins with sprouting 
angigogenesis and radial expansion of the superifical layer (Fig 4.11 A). The vasculature 
undergoes constant remodeling and expands until it reaches the peripheral edges of the 
retina at P8. This is then followed by invasion of the vasculature into the deeper retinal 
layers, which is accompanied by pruning and further remodeling until the complete 
development of the adult retinal vessels at P21 (Stahl et al., 2010). Preliminary analysis of 
the adult retinal vasculature of the ARHGAP18-/- mice appeared to indicate more 
vascularization but did not reveal any major defects (Fig 4.11 B). 
4.2.7.1. ARHGAP18-/- mice have delayed expansion of the retinal vasculature 
We investigated the effects of ARHGAP18 loss in P6 mice, as this represents a time point 
where angiogenesis is occurring at a linear rate (Stahl et al., 2010). The retinas from WT 
and ARHGAP18-/- mice were dissected and stained for the vessels using isolectin B4. We 
observed a significant (~10%) decrease in radial extension in the vessels of the 
ARHGAP18-/- mice (Fig 4.12 A-C). This was regardless of whether it was determined in 
the actual distance radiating from the optic nerve (Fig 4.12 B) or as a percentage of the 
total retina diameter (Fig 4.12 C). 
4.2.7.2. ARHGAP18-/- mice have increased vascularization of the central plexus 
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The vascular network was next assessed using whole quadrants of the retinas. Images of 
the quadrants were analysed using Wimasis GmbH (www.wimasis.com, Germany) (Fig 
4.13 A and B). Here using a skeleton algorithm, a number of parameters, including the 
vessel density, the number of branch points and the loops can be analysed. There was 
slight but not significant increase in each of these parameters (Fig 4.13 C-E). From 
discussion with Prof Ralf Adams, an expert with multiple publications in the field of the 
retina vasculature (Benedito et al., 2012; Ehling et al., 2013; Gaengel et al., 2012; 
Nakayama et al., 2013), he advised us that analysis of the whole retina can be inconsistent 
due to differences in vessel numbers in different areas, for example next to the larger 
arterial and venous vessels. Therefore, we reanalyzed the plexus to focus on a smaller 
area in the central vascular plexus that was between two large vessels (usually arteries and 
veins) and approximately ~5 branches away from the sprouting front. To do this, a macro 
was created in which the whole quadrant image was re-analysed to the smaller area while 
keeping the results from the original algorithm (Fig 4.14, Appendix A.1.2). Firstly, the 
image was isolated in the individual parameters, each of which was re-coloured and 
merged for downstream re-analysis. A suitable area of 380 x 380 µm region was selected 
and the parameters were re-analysed. Analysis of the central plexus revealed significant 
increases in vessel density (6%), the number of branch points (13%) and in the number of 
loops (13%) (Fig 4.15 A-D).  
4.2.7.3. ARHGAP18-/- mice have increased sprouting at the angiogenic front 
The vessels at the angiogenic front were next assessed. Loss of ARHGAP18 resulted in a 
23% increase in sprout formation (Fig 4.16 A and B). Furthermore, examination of the 
sprouts revealed that the ARHGAP18-/- sprouts had extensive filopodia formation (Fig 
4.16 C), which is consistent with the zebrafish ISV phenotype and the overall 
hypersprouting phenotype. 
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4.2.7.4. The hypersprouting phenotype is not assicated with changes in pericyte 
coverage 
Mural cells, such as pericytes, facilitate the stabilization of angiogenic vessels, and 
reduced pericyte coverage is associated with increased hypersprouting (Feng et al., 2007). 
To determine whether loss of ARHGAP18 results in changes with pericyte coverage, the 
retinas were stained with NG2 to label the pericytes and VE-cadherin to label the vessels 
(Fig 4.17 A). In retrospect, the vessels would ideally be stained with isolectin B4, as VE-
cadherin stains the junctions of ECs resulting in an outline of the ECs. However, in order 
to assess the pericyte coverage in these VE-cadherin stained vessels, the images were 
post-processed and analysed using a Fiji macro (Appendix A.1.3). This macro was 
designed to fill in the VE-cadherin junctions to fill in the cell outlines to create an EC 
mask. Next, the pericyte image was also converted into a mask and the overlaying of the 
two images resulted in three regions: the green pericyte only area, the red EC only area, 
and the yellow pericyte and EC area (Fig 4.17 B). Therefore, the overall pericyte coverage 
is defined as the percentage of the yellow area of the total red and yellow area. We 
observed that there was a subtle but non-significant decrease in pericyte coverage in the 
ARHGAP18-/- retinas (Fig 4.17 C).  
Overall, these results confirm the hypersprouting phenotype as observed in vitro, ex vivo 
and in vivo in the zebrafish embryos. While the decrease in radial extension appears 
contradictory, this highlights that there are major changes in vascular patterning with 
favouring of TCs over SCs that results in the excessive branching rather than extension of 
the vascular plexus. Furthermore, these in vivo results further indicate that the effects of 
ARHGAP18 loss are likely to be EC specific and not due on the effects of other cells such 
as lymphatic ECs or pericytes. 
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4.2.8.  ARHGAP18 LOSS PROMOTES VEGF HYPERRESPONSIVENESS AND 
A TIP CELL PHENOTYPE 
4.2.8.1. ARHGAP18 knockdown promotes Akt but not ERK hyperactivation 
following VEGF stimulation. 
The in vitro and in vivo observations indicated that the loss of ARHGAP18 promotes 
hypersprouting, with earlier and more prominent development of angiogenic vessels. One 
of the main regulators that controls sprouting angiogenesis is VEGFA and its downstream 
signaling pathways. We next sought to determine whether the hypersprouting phenotype 
was due to a hyper-responsiveness to VEGFA by examining the activation of the 
downstream MAPK/ERK and Akt pathways. Control or ARHGAP18 depleted HUVECs 
were starved and stimulated with VEGFA for different times, then the activation of ERK 
and Akt assessed by immunoblotting. Both the ERK and Akt are activated at early time 
points and restored to basal levels at the later time points. While ARHGAP18 knockdown 
EC displayed a similar level of ERK activation, there was a higher maximal, albeit subtle, 
and prolonged activation of Akt (Fig 4.18 A). 
4.2.8.2. ARHGAP18 loss have increased expression of TC genes 
VEGF-Notch signaling is the major regulator of TC-SC differentiation and a coordinated 
regulation of VEGF-Notch driven TCs and SCs is required for effective vascular 
patterning (Herbert and Stainier, 2011; Potente et al., 2011). Based on the in vitro and in 
vivo results, loss of ARHGAP18 resulted in a typical TC-like phenotype, with increased 
sprouting and migratory capacity and extensive filopodial extensions. These TCs initiate 
sprouting angiogenesis by extending filopodial extensions and migrating towards the 
guidance cues and are characterized by increased expression of genes including the VEGF 
receptors Flk1 (VEGFR2), Flt4 (VEGFR3), the Notch ligand Dll4, and guidance 
receptors including Pdgfb and Unc5b (Gerhardt et al., 2003; Phng and Gerhardt, 2009). 
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To assess whether ARHGAP18 promotes a TC phenotype, the expression of Dll4, Flk1, 
Flt4 and Flt1 (VEGFR1) were assessed by qRT-PCR (Fig 4.19). Knockdown of 
ARHGAP18 was confirmed and was unchanged following 6 h VEGFA stimulation (Fig 
4.19 A). We observe that the expression of Dll4 was significantly upregulated in both 
basal and VEGFA stimulated ARHGAP18 knockdown ECs (Fig 4.19 B). VEGF signaling 
upregulates the expression of Dll4, which in a physiological environment acts on the 
neighbouring EC Notch receptor to suppress the TC phenotype to promote the stabilizing 
SC phenotype. Consistent with the VEGF hyper-responsiveness, we observe that 
ARHGAP18 loss further drives Dll4 expression following VEGFA stimulation. This 
hyper-responsiveness is likely due to the increased signaling of the main VEGF receptor, 
Flk1/VEGFR2, which we found was upregulated ~1.7 fold (Fig 4.19 C). Furthermore, we 
observed that Flt4/VEGFR3 is also significantly upregulated in ARHGAP18 knockdown 
EC (Fig 4.19 D). VEGFR3 is also crucial in angiogenesis and is highly expressed in TC, 
where it forms VEGFR2/VEGFR3 heterodimers that are enriched in TCs and promote 
angiogenic sprouting (Tammela et al., 2011). On the other hand, we observe that the 
expression of the inhibitory VEGF receptor, Flt1/VEGFR1, was unchanged in 
ARHGAP18 knockdown EC. Overall, these results indicate that the loss of ARHGAP18 
promotes the expression of the TC genes. It would be interesting to determine the changes 
in the expression of the other TC genes, Pdgfb and Unc5b, that are involved in guidance 
and also to assess whether ARHGAP18 loss affects the SC phenotype and downstream 
Notch signaling, but this would be for future study. One of the major difficulties for 
assessing SC phenotypes is in the use of monolayer cells, as it is ineffective in replicating 
the intricacies of TC-SC signaling and interactions. 
4.2.8.3. ARHGAP18 knockdown EC have increased preference for the TC 
position 
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One of the main characteristics of TC is in the preference for the leading position, hence 
known as the TC position. We next sought to determine whether the TC phenotype 
translated to a preference for the TC position. This was performed using the 3D spheroid 
assay to replicate sprouting in vitro by creating chimeric spheroid sprouts comprised of 
control and ARHGAP18-knockdown cells. These cells were labeled with the different cell 
tracker dyes, mixed at 1:1 ratios and used to establish EC spheroid sprouts (Fig 4.20 A). 
The ARHGPA18 knockdown EC displayed a significantly increased number of cells in 
the sprouts, consistent with the increased sprouting ability of these cells (Fig 4.20 B). 
More importantly, these cells also had double the chance of occupying the TC position 
(Fig 4.20 C), thus confirming that ARHGAP18 loss promotes both the expression of TC 
genes and a TC phenotype.   
4.3.  SUMMARY AND CONCLUSIONS 
In this chapter, by using a variety of in vitro and in vivo models of angiogenesis, we have 
established that the knockdown of ARHGAP18 promotes EC hypersprouting. This is 
further associated with changes in VEGF signaling and a TC phenotype, with increased 
preference of the TC position and expression of the TC genes. It remains to be determined 
as to whether the ARHGAP18 pro-sprouting effects are dependent on the slight activation 
of Akt, although interestingly, it has been demonstrated that VEGFR2 signaling via Akt 
and not MAPK/ERK drives DLL4 signaling (Liu et al., 2003). VEGF-Notch signaling is 
the major regulator of TC selection and vascular patterning. The increased expression of 
the VEGF receptors 2 and 3, and most importantly the Notch ligand, DLL4, are 
responsible for the TC favoured imbalance. This ultimately results in abnormal vascular 
patterning with increased hypersprouting and branching and delayed peripheral expansion 
of the vascular network.  
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Fig 4.1. Optimisation of ARHGAP18 siRNA transfection in HUVECs. 
A.  Bright!eld images of HUVECs 3 d following transfection with Lo dose (5 nM siRNA, 2.5 μL 
Lipofectamine RNAiMax) or Hi dose (10 nM siRNA, 5 μL Lipofectamine RNAiMax) control siRNA. 
Transfection at the Hi dose results toxicity as evident by signi!cant alteration in cell shape. Bar 
50 μm. 
B.  Immunoblots for ARHGAP18 of lysates from HUVECs transfected for 3 d with Lo dose or Hi dose 
control or ARHGAP18 (pool of siRNA 1, 2 & 3) siRNAs. Actin was used as the loading control. 
C.  Bright!eld and #uorescent images of HUVECs 2 d following transfection with BLOCK-iT Alexa 
Fluor Red Fluorescent Control. Uptake of the oligo is indicated by the  #uorescent signals in the 
nucleus and as punctate dots in the cytosol. Bar 50 μm. 
D.  Time course of ARHGAP18 knockdown in HUVECs. HUVECs were transfected with control or 
ARHGAP18 siRNAs (pool of siRNA 1, 2 & 3) or non-transfected, lysed following 1, 3, 5 and 7 d 
following transfection and immunoblotted for ARHGAP18. Actin was used as the loading 
control.  
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Fig 4.2. Optimisation of ARHGAP18 siRNAs. 
A.  Location of ARHGAP18 siRNA targeting sequences. All seven siRNAs target the coding sequence 
(CDS) of ARHGAP18. 
B.  HUVECs were transfected for 3 d with the individual ARHGAP18 siRNAs (1-7) and two diﬀerent 
siRNA controls, lysed and immunoblotted for ARHAGP18. Actin was used as the loading control. 
C.  Bright!eld images of HUVECs transfected for 3 d with the individual ARHGAP18 siRNAs (1-7) and 
two diﬀerent siRNA controls or non-transfected. Transfection with siARHGAP18-2 results in 
signi!cant elongation of ECs (arrow). Bar 50 μm. 
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Fig 4.3. Knockdown of ARHGAP18 does not aﬀect the gross phenotype in HUVECs. 
A.  Bright!eld images of HUVECs transfected for 3 d with control or ARHGAP18 (pool of siRNA 1 & 3) 
siRNAs. Bar 50 μm. 
B.  Quanti!cation of cell size of control and ARHGAP18 siRNA transfected ECs. Data represents 
mean ± SEM from n=2 independent experiments comprised of 15 cells each. ns, non-signi!cant; 
t-test. 
C.  Quanti!cation of cell circularity control and ARHGAP18 siRNA transfected ECs. Data represents 
mean ± SEM from n=2 independent experiments comprised of 15 cells each. ns, non-signi!cant; 
t-test. 
D.  Immunoblots for ARHGAP18 of lysates from HUVECs transfected for 3 d with control or 
ARHGAP18 (pool of siRNA 1 & 3) siRNAs. Actin was used as the loading control. 
E.  The mRNA level of ARHGAP18 from HUVECs transfected for 3 d with control or ARHGAP18 (pool 
of siRNA 1 & 3) siRNAs were determined by qRT-PCR and normalised to ACTB. Data represents 
the mean ± SEM from n=4 independent experiments. ** P<0.01; t-test. Statistical tests were 
performed on log2(fold change) values.  
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Fig 4.4. Knockdown of ARHGAP18 does not aﬀect cell proliferation, but reduces cell density. 
A.  HUVECs transfected with control or ARHGAP18 siRNAs for 3 d were collected and counted a 
represented as a percentage of the control cells. . Data represents the mean ± SEM from n=3 
independent experiments, P>0.05, non-signi!cant; t-test. 
B.  HUVECs transfected with control or ARHGAP18 siRNAs were cultured in chamber slides at 
con#uent densities (6 x 104 cells) overnight, !xed and stained for F-actin (red), nuclei 
counterstained with DAPI (blue), and imaged by confocal microscopy. Bar 50 μm. 
C.  Quanti!cation of cell density in B. The number of cells per !eld were determined by counting 
the nuclei in B. Data represents the mean ± SEM  from n=6 independent experiments. * P<0.05; 
t-test.  
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Fig 4.5. Knockdown of ARHGAP18 promotes 2D wound healing and disruption of the proximal 
junctions of the leading cells. 
A.  Bright!eld images of HUVECs transfected for 3 d with control (i & iii) or ARHGAP18 (ii & iv) siRNAs 
at 0 (i & ii) and 5 (iii & iv) h following scratch wound. Bar 250 μm. 
B.  Quanti!cation of wound recovery in A. Data represents the mean ± SEM from n=5 independent 
experiments. * P<0.05; t-test.  
C.  High magni!cation bright!eld images of the migratory front of siCtrl and siARHGAP18 HUVECs 
following 5 h scratch wound. The leading migratory cells in ARHGAP18 knockdown ECs, but not 
control ECs, displayed disrupted proximal junctions (arrows). Bar 25 μm. 
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Fig 4.6. Knockdown of ARHGAP18 promotes 3D spheroid sprouting. 
A.  Bright!eld images of siCtrl and siARHGAP18 HUVEC spheroid sprouts stimulated with 50 ng/
ml VEGF for 20 h. Bar 100 μm. 
B-C. Quanti!cation of the number of sprouts (B) and the cumulative sprout length (C) per spheroid. 
Data represents the mean ± SEM from n=4 independent experiments, consisting of a 
minimum of 20 spheroids per group.  ** P<0.01; t-test.  
D.  Con!rmation of ARHGAP18 knockdown in the spheroid assay. Spheroid sprouts generated 
from siCtrl, siARHGAP18 and a 50:50 chimera of siCtrll:siARHGAP18 ECs or a collagen only 
negative control were lysed and the mRNA level of ARHGAP18 relative to ACTB determined by 
qR-TPCR. Data represents the mean ± SEM from 3 technical replicates from n=1 experiment. 
E.  Con!rmation of ARHGAP18 knockdown eﬀects using individual ARHGAP18 siRNAs. Spheroids 
sprouts were established using HUVECs transfected with the indicated siRNAs and the 
cumulative sprout length quanti!ed. Data represents the mean ± SEM from 15 individual 
spheroids. Representative data of n=2 individual experiments. *** P<0.001; * P<0.05; ns non-
signi!cant; one-way ANOVA, Tukey’s post-test.  
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Fig 4.7. Morpholino-mediated knockdown of ARHGAP18 induces oedema in zebra!sh 
embryos 
A.  Design of morpholinos. A tranalational morpholino (TrMO) (i) and a splice (SpMO) (ii) were used 
to silence ARHGAP18 expression in zebra!sh embryos. The TrMO blocks translation from the 
start codon on the ARHGAP18 mRNA whereas the SpMO blocks splicing resulting in retention of 
intron 3. 
B.  Con!rmation of ARHGAP18 morpholino eﬃciency. Zebra!sh embryos were injected with 
control MO or ARHGAP18 SpMO or uninjected, total RNA collected and indicated amplicons 
ampli!ed by RT-PCR. The absence of exon 5 and presence of intron 3 indicates successful 
injection and eﬃcacy of the morpholino. 
C.  Representative images of zebra!sh embryos injected with control MO, ARHGAP18 SpMO or 
TrMO or uninjected at 48 hpf. Arrows indicate the observable hindbrain, yolk and heart oedema. 
Bar 500 μm. 
D.  ARHGAP18 TrMO eﬀects are not due to non-speci!c apoptotic eﬀects. Zebra!sh embryos 
injected with control or ARHGAP18 SpMO were TUNEL-stained (red). A DNase I treated zebra!sh 
embryo was used as a positive control. The absence of the stain in the ARHGAP18 injected 
embryos suggests an absence of apoptosis. Bar 250 μm. 
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Fig 4.8. Knockdown of ARHGAP18 promotes zebra!sh ISV sprouting. 
A.  Representative GFP confocal images of intersegmental vessels (ISV) in !i1-GFP zebra!sh 
embryos injected with control MO, ARHGAP18 SpMO or TrMO at 24 hpf. ISV from ARHGAP18 
MO injected zebra!sh have increased length and !lopodial extensions. Red = dorsal aorta 
(DA), blue = posterior cardinal vein (PCV). Bar 100 μm. 
B.  Quanti!cation of ISV lengths. Data represents the mean ± SEM  from n=134 control MO, 306 
SpMO, 105 TrMO ISV. * P<0.05, *** P<0.001; t-test.  
C-D. Quanti!cation of (C) dorsoal aorta (DA) and (D) posterior cardinal vein (PCV) lumen diameter. 
Data represents mean ± SEM from n=21 control, 10 SpMO, 10 TrMO ISV. **, P<0.01; t-test.  
 
Experiments performed by Dr. Ka Ka Ting 
174 
Chapter 4. ARHGAP18 in Angiogenic Sprouting   
Fig 4.9. Genomic map of the ARHGAP18-/- mouse. 
A.  Genomic map of the ARHGAP18-/- mouse generated by the KOMP repository. E1-E15 denote the 
ARHGAP18 exons. The splicing cassette was inserted upstream of exon 2. 
B.  Schematic of the mRNAs expected from WT and ARHGAP18-/- mice, and the actual ARHGAP18-/- 
mRNA. The WT mRNA consists of all 15 exons. The ARHGAP18-/- mouse was expected to encode 
for exon 1 and the lacZ gene from the IRES, however the presence of a cryptic splice site in the 
cassette results in the altered transcript with an absence of the lacZ gene, but retention of the 
stop codon that results in the knockout of the ARHGAP18 protein. 
C.  Con!rmation of ARHGAP18 absence in ARHGAP18-/- mice. Western blot of mouse lung lysates 
from WT and ARHGAP18-/- mice blotted for ARHGAP18, and the loading controls VE-cadherin and 
actin. 
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Fig 4.10. ARHGAP18 loss promotes ex vivo aortic ring sprouting. 
A.  Bright!eld images of sprouted aortic explants from WT and ARHGAP18-/- mice. The aortas of WT 
and ARHGAP18-/- mice were harvested, embedded in Matrigel and cultured for up to 5 d. Low 
magni!cation of the sprouted area (i & ii). The sprouted area is outlined in red, the aorta is 
outlined in yellow. High magni!cation of sprouted area (iii & iv) shows extensive branching in 
explants from the ARHGAP18-/- mice. Bar 500 μm (top panels), 100 μm (bottom panels).  
B.  Quanti!cation of the sprouted area as depicted by the red-yellow area in A. Data represents 
mean ± SEM from n=7 experiments. * P<0.05; t-test. 
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Fig 4.11. Adult ARHGAP18-/- mice have no major retina vascularisation defects. 
A.  Schematic of the post-natal retinal angiogenesis model. Retinal vascularisation occurs post-
natally with expansion to the vascular periphery at P8. The vessels constantly remodel and 
invade into the deeper layers until complete development at P21. Top images, #atmount; bottom 
images, cross sections of retinas. Adapted from Gerhardt et al. (2003). 
B.  Confocal images of the retinas of adult WT and ARHGAP18-/- mice stained using antibodies 
against PECAM for the vasculature. The image slices were stacked and merged post-acquisition 
to distinguish between the super!cial (red) and the deeper layers (green). Bar 100 μm.  
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Fig 4.12. ARHGAP18-/- mice have delayed radial expansion of the retinal vasculature. 
A.  Retinas from P6 WT and ARHGAP18-/- mice were stained with isolectin B4 to visualise the 
developing vasculature and the whole retina was imaged by stereo microscopy. The yellow 
ring indicates the radial extension in the WT and is superimposed onto ARHGAP18-/- image. Bar 
1 mm. 
B-C. Quanti!cation of the radial extension in B. The radial extension length was de!ned as the 
distance from the optic nerve to the angiogenic front and expressed in mm (C) or as a 
percentage of the total retinal length (D). Data represents mean ± SEM from n=32 WT and 24 
ARHGAP18-/- mice. **** P<0.0001; t-test. 
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Fig 4.13. Assessment of the quadrant plexus shows indiﬀerent changes. 
A.  Confocal images of the quadrant plexus of isolectin-B4 stained P6 retinas from WT and 
ARHGAP18-/- mice. Bar 250 μm.  
B.  Analysis of the respective quadrant plexi in A. Green outline = analysed area; blue = vessel 
area; red = vessel skeleton; white dots = branch points; yellow crosses = loops. 
C-E. Quanti!cation of the vessel density (C), branch points (D), and loops (E) in whole quadrants of 
retinas. The measurements were averaged from at least 2 quadrants per retina and were 
normalised to the area of the quadrants. Data represents mean ± SEM from n=32 WT and 24 
ARHGAP18-/- mice. ns, non-signi!cant; t-test. 
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Fig 4.14. Schematic for re-analysis of the central plexus. 
A.  A macro was designed for the automated re-analysis of the central plexus (Appendix A.1.2). The 
whole analysed retina was split into the individual parameters and re-merged with an altered 
colour scheme. A 380 x 380 μm region between two large vessels (arteries and veins) was 
selected and the individual parameters were re-analysed. 
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Fig 4.15. ARHGAP18-/- mice have increased vascularisation of the central plexus. 
A.  Confocal images of isolectin B4 stained quadrant plexi of P6 WT and ARHGAP18-/- retinas (top 
panels) and the respective re-analysed central plexi (bottom panels). Black = vessel area; yellow 
crosses = loops; red dots = single branch points; green dots = double branch points. Bar 250 
μm (top panels), 100 μm (bottom panels).  
B-D. Quanti!cation of the vessel density (B), branch points (C), and loops (D) in the central plexus. 
The measurements were averaged from at least 2 quadrants per retina. Data represents mean 
± SEM from n=32 WT and 24 ARHGAP18-/- mice. * P<0.05, ** P< 0.01;  t-test. 
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Fig 4.16. ARHGAP18-/- mice have increased numbers of sprouts and !lopodial extensions. 
A.  Confocal images of isolectin B4 stained angiogenic front of of P6 WT and ARHGAP18-/- retinas. 
The sprouts were counted manually and indicated by the red dot. Bar 200 μm. 
B.  Quanti!cation of the number of sprouts per mm of vessel length. The measurements were 
averaged from at least 2 quadrants per retina. Data represents mean ± SEM from n=32 WT and 
24 ARHGAP18-/- mice. **** P<0.0001;  t-test. 
C.  High magni!cation confocal imagex of the angiogenic sprouts. The EC sprouts from ARHGAP18-/- 
mice have more abundant and longer !lopodial extensions. Bar 50 μm. 
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Fig 4.17. Pericyte coverage is unchanged in ARHGAP18-/- retinas. 
A.  Confocal images of VE-cadherin (red) and NG2 (green) (pericytes) stained central plexi of P6 WT 
and ARHGAP18-/- retinas. Scale 100 μm.  
B.  Analysis of pericyte coverage in A. A macro was designed for the automated analysis of pericyte 
coverage (Appendix A.1.3). The VE-cadherin stained EC junctions were !lled to create an outline 
of the vessel area (red). The pericyte stain was thresholded (green) and overlayed onto the 
vessel image. Pericyte coverage represents the area in which the pericyte overlaps with the 
vessel (yellow) and is represented as a percentage of the total vessel area (red). 
C.  Quanti!cation of pericyte coverage in WT and ARHGAP18-/- retinas. Data represents mean ± SEM 
from n=5 WT and 5 ARHGAP18-/- mice. Number represents the P value, non-signi!cant;  t-test. 
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Fig 4.18. ARHGAP18 knockdown promotes Akt activation following VEGF stimulation. 
A.  HUVECs were transfected with control or ARHGAP18 siRNAs, starved, stimulated with 50 ng/mL 
VEGF-A and whole cell lysates collected at the indicated time points. Immunoblots of p-Akt, and 
p-ERK1/2 to examine responsiveness to VEGF. ARHGAP18 immunoblotting con!rmed 
knockdown. Total Akt and tubulin were used as loading controls. Representative of n=3 
independent experiments.  
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Fig 4.19. ARHGAP18 knockdown promotes expression of TC genes. 
A-E. HUVECs were transfected with control (£) or ARHGAP18 (¢) siRNAs, starved, and stimulated 
with or without 50 ng/mL VEGF-A for 6 h. Total RNA was isolated, reverse transcribed and the 
mRNA level of ARHGAP18 (A), Dll4 (B), Flk1 (C), Flt4 (D), and Flt1 (E) relative to the normalising 
gene ACTB determined by qT-PCR. Data represents the mean ± SEM from n=3-4 independent 
experiments. ns, non-signi!cant; * P<0.05; ** P<0.01; t-test. Statistical tests were performed on 
log2(fold change) values.  
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Fig 4.20. ARHGAP18 knockdown ECs have increased preference for the TC position. 
A.  Schematic of the tip cell competition assay. HUVECs were transfected with control or 
ARHGAP18 siRNAs for 1 d, labelled with CellTracker dyes and Hoescht, and mixed at 1:1 ratios. 
The actual distribution following mixing was determined and the cells were used to establish 
spheroid sprouts. The imaged sprouts were then assessed for the distribution of cell 
populations within the sprout and at the TC position.  
B.  Confocal image of mixed spheroid sprouts following 24 h stimulation with 25 ng/mL VEGF-A. 
Control cells (red) were labelled with CellTracker Orange and ARHGAP18 siRNA cells (green) 
labelled with CellTracker Green. Nuclei (blue) were labelled using Hoescht. Inset location 
indicated by dashed line. Bar 100 μm. 
C-D. Quanti!cation of the percentage contribution of sictrl (red) and siARHGAP18 (green) cells in 
sprouts (C) and in the TC position (D). Data represents the mean ± SEM from n=4 independent 
experiments.  **, P<0.01; ****, P<0.001; t-test. 
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5.1.  INTRODUCTION 
In the previous chapter we established that the loss of ARHGAP18 results in a TC and 
hypersprouting phenotype. The main aim of this chapter was to identify the mechanism in 
which ARHGAP18 regulates EC sprouting.  
We describe here that ARHGAP18 localizes to the junctions of angiogenic ECs in vitro 
and in vivo. This is associated with changes in junctional stability as ARHGAP18 
transiently relocalises to the EC membrane periphery following junctional destabilisation. 
We postulate that this relocalisation is due to the GAP function of ARHGAP18, which we 
identify is targeting RhoC. Furthermore, loss of ARHGAP18 results in a contractile 
phenotype with active serrated EC junctions. The EC junctions have an established role 
regulating TC selection and vascular patterning. We establish here that ARHGAP18 
regulates EC sprouting via its associated GAP dependent effects in regulating the EC 
junctions.   
5.2.  RESULTS AND DISCUSSION 
5.2.1.  ARHGAP18 IS PREDOMINANTLY LOCALISED IN THE CYTOSOL OF 
RESTING ECS 
In order to gain insight into the mechanism of ARHGAP18 function, its localization was 
first assessed. We first optimized the IF staining in monolayer HUVECs using two 
different antibodies raised against the ARHGAP18 peptide: rabbit polycloncal antibodies, 
and mouse monoclonal antibodies (clone 2A3). We first tested the efficacy of staining of 
the two antibodies using formaldehyde fixed or methanol-acetone (1:1) fixed cells (Fig 
5.1). Fixation with formaldehyde resulted in generally poor IF staining, with no notable 
difference in the signal between the control and ARHGAP18 cells (Fig 5.1 A). 
Furthermore, staining with the polyclonal antibodies resulted in non-specific staining of 
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the cell nuclei. On the other hand, the methanol-acetone fixed cells stained with the 
monoclonal antibody had clear cytosolic signals, which were absent in the ARHGAP18 
knockdown cells (Fig 5.1 B, top panels). Staining with the polyclonal antibodies did show 
a difference in staining, but were relatively weak. Subsequent ARHGAP18 IF staining on 
monolayer cells were performed using the monoclonal antibodies on methanol-acetone 
fixed cells.  
The cells stained for ARHGAP18 were imaged by confocal microscopy to examine the 
localization of ARHGAP18 in the cell. We observed that ARHGAP18 was predominantly 
in the localized in the cytosol, and was present in the form of small puncta (Fig 5.2 A). 
There was some localization of ARHGAP18 in the cell nuclei, although the significance 
of this is unknown. However, in these resting ECs there was a distinct lack of 
ARHGAP18 in the cell junctions that had been stained with VE-cadherin. The 
ARHGAP18 knockdown ECs had substantially less staining, thus confirming the 
specificity of the antibody staining (Fig 5.2 A and B). Furthermore, staining with an 
isotype control antibody also had a lack of notable staining (Fig 5.2 B). Recent studies in 
the Vascular Biology laboratory have confirmed that ARHGAP18 is localized as small 
puncta throughout the cell cytosol (Lovalace, et al. in review). Using structured 
illumination microscopy, we have also observed that there is an abundance of 
ARHGAP18 puncta that align to the microtubules, and that this localisation may have 
implications in regulating microtubule stability as loss of ARHGAP18 leads to 
destabilized microtubule organization (Lovelace, et al. in review).  
5.2.2.  ARHGAP18 IS LOCALISED TO THE JUNCTIONS OF ANGIOGENIC 
SPROUTS 
It was hypothesized that since the absence of ARHGAP18 promotes a hypersprouting and 
TC phenotype, there would be a differential expression of ARHGAP18 in the TCs and 
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SCs. In order to test this, we examined the localization/expression of ARHGAP18 in in 
vitro sprouts that were stimulated with VEGFA and FGF-2 (Fig 5.3). VEGFA and FGF-2, 
as mentioned earlier, result in two distinct sprouting phenotypes with abundant but weak 
sprouts in the VEGF-induced sprouts, and fewer, longer and more stable sprouts in the 
FGF-2 induced sprouts. Notably, and surprisingly, we observed that ARHGAP18 is 
distinctly localized to the junctions of both the VEGFA (Fig 5.3 A) and FGF-2 (Fig 5.3 B) 
sprouts. While the TCs and SCs still had abundant localization of ARHGAP18 in the 
cytosol, there was enriched localization of ARHGAP18 that co-localised with the EC 
junctions. On the other hand, contrary to the hypothesis, it did not appear that the 
expression of ARHGAP18 was different between the TCs versus the SCs in the spheroid 
sprouts. 
5.2.3.  ARHGAP18 IS LOCALISED TO THE JUNCTIONS OF CAPILLARY AND 
ANGIOGENIC EC IN THE DEVELOPING RETINAL VASCULATURE 
We next aimed to confirm these observations using the in vivo retina model of 
angiogenesis. We first optimized the staining protocol using both the rabbit and mouse 
antibodies. Staining with the rabbit antibody resulted in a generally weak signal, and most 
notably the rabbit Ig control had substantial non-specific staining (Fig 5.4 A). Ideally, a 
rabbit antibody would be preferred as there are significant complications with the use of 
mouse antibodies to detect mouse antigens. However, the rabbit antibody had poor 
staining and therefore the mouse antibody staining protocol was optimized. We used a 
mouse on mouse blocking protocol to prevent detection of the endogenous Ig. In the 
absence of the endogenous Ig block, addition of the secondary antibody alone was able to 
detect substantial non-specific signals, which were further amplified in the presence of the 
ARHGAP18 or control primary antibodies (Fig 5.4 B, left panels). However, using a 
double amount of the mouse on mouse blocking reagent, coupled with an anti-mouse 
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secondary antibodies containing only the Fab fragments (lacking the Fc chains, and hence 
unable to bind the endogeneous Fc receptors), we were able to observe significant 
staining in the ARHGAP18 antibody stained retinas, that was absent in the isotype control 
(Fig 5.4 B, right panels). We confirmed that the staining was specific by using identical 
staining conditions for WT and ARHGAP18-/- retinas and observed that the signal in the 
knockout retinas was substantially reduced (Fig 5.4 C). 
Examination of the staining of the WT retina revealed that there was highest expression of 
ARHGAP18 in the EC (Fig 5.5). However, we could also see expression of ARHGAP18 
in the retinal axons and astrocytes (Fig 5.5 B, yellow and blue arrows) and the 
macrophages at the angiogenic front. Notably, we also observed that there was differential 
expression of ARHGAP18 in the different vessel subtypes, with higher expression of 
ARHGAP18 in the arteries and angiogenic front compared to the veins (Fig 5.5 A and B). 
Most importantly, there was abundant expression of ARHGAP18 in the EC junctions, as 
indicated by VE-cadherin staining (Fig 5.5 C), and this was more pronounced in the ECs 
in the capillary network and at the angiogenic front compared to the larger arterial and 
venous vessels (Fig 5.5 B).  
It was hypothesised that the EC at the angiogenic front would be underexpressing 
ARHGAP18, as its loss promotes the hypersprouting phenotype. In fact, here we observe 
that ARHGAP18 is more highly expressed in the cells at the angiogenic front. This is 
consistent with two studies that examined the global gene expression profile of TCs 
versus SCs, and found that ARHGAP18 was upregulated 4 fold (del Toro et al., 2010) and 
2.1 fold (Strasser et al., 2010) in the TCs. Furthermore in in vitro monolayer ECs 
stimulated with VEGF, we observe a 2 fold upregulation of ARHGAP18 at the 12 h and 
24 h time points (Chang et al., 2014). These suggest that, while underexpression of 
ARHGAP18 promotes hypersprouting, there is an upregulation of ARHGAP18 in the 
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angiogenic ECs. We hypothesise that this expression is likely to occur as a negative 
feedback to control the extent of angiogenic sprouting. Most importantly however is the 
finding that ARHGAP18 relocalises to the EC junctions, and that this occurs more 
prominently in those of the angiogenic vessels compared to the larger more stable vessels. 
5.2.4.  ARHGAP18 TRANSIENTLY LOCALISES TO THE JUNCTIONS OF 
MONOLAYER ECS FOLLOWING THROMBIN DESTABILISATION 
To address the possibility that ARHGAP18 is involved in stabilisation of vessels, we 
assessed the localization of ARHGAP18 in EC monolayers stimulated with thrombin, 
where the junctions are dynamically remodeled (Rabiet et al., 1996). This was first tested 
by expressing mCherry-ARHGAP18, (described above in section 3.2.11), and assessing 
the localisation of the tagged protein. By live-cell microscopy, we noticed that there was a 
rapid and transient relocalisation of the fusion protein at ~10 min following thrombin 
stimulation (data not shown). To confirm this, we stimulated ECs with thrombin and 
assessed the localisation of endogenous ARHGAP18 over 60 min (Fig 5.6 A). In resting 
EC, ARHGAP18 was distinctly absent from the EC junctional periphery, as indicated by 
staining with β-catenin. Within 2 min of thrombin stimulation, ARHGAP18 was localized 
to the fine filopodial extensions. At 5 min and 10 min following thrombin stimulation, a 
time where the junctions are zippered and disrupted (also termed active) and the 
monolayer highly permeable (Gamble et al., 2000), ARHGAP18 was distinctly localized 
to junctional edges of cell contacts, with a maximal relocalisation at 10 min. By 30 min 
and 60 min, where the junctions return to a straight and mature (also termed inactive) 
characteristic, ARHGAP18 was absent from the junctional edges and returned to the 
cytosol.  
5.2.5.  ARHGAP18 IS A RHOC GAP THAT REGULATES EC JUNCTIONAL 
INTEGRITY 
5.2.5.1. ARHGAP18 is a RhoC GAP 
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RhoGAPs are recruited to the cell membrane where they act to catalyse the inactivation of 
RhoGTPases. We hypothesized that this recruitment of ARHGAP18 to the junctions 
serves to inhibit the activity of its target RhoGTPase. ARHGAP18 has been previously 
shown to be a RhoA GAP in epithelial cells (Maeda et al., 2011), and as a Rho1 (RhoA 
homolog in Drosophila) GAP in Drospohila S2 cells (Neisch et al., 2013). In contrast to 
these studies, ARHGAP18 knockdown did not alter RhoA activation in basal or thrombin 
stimulated ECs (Fig 5.7 A). ARHGAP18 silencing also did not alter Rac-1 (lamellipodia), 
Cdc42 (filopodia) or RhoJ, the EC specific RhoGTPase (Fig 5.7 C-E). However, 
ARHGAP18 knockdown did have a small but reproducible and significant effect on 
promoting RhoC activation in both basal and thrombin stimulated EC (Fig 5.7 B). 
Notably, we observe highest activation of RhoC at 2 min following thrombin stimulation 
(Fig 5.7 F), and ARHGAP18 is recruited following this, thus suggesting that ARHGAP18 
recruitment acts to restore basal RhoC activity levels. 
To confirm this effect on RhoC, we examined the levels of active RhoA and RhoC 
following ARHGAP18 overexpression. As described in section 3.2.11, we designed a 
retroviral system for ARHGAP18 overexpression that did not induce EC senescence. 
However, given the time constraints for the resubmission of the manuscript, and that the 
retroviral production, and viral transduction and selection required a lot of time, a 
different approach was used to overexpress ARHGAP18 at low, non-senescence inducing 
levels. Using the adenovirus, we titred the levels of adenovirus to be 1/10th the normal 
levels and increased the efficiency of transduction by the addition of polybrene, a 
polycation that is normally used in retroviral transduction. This resulted in efficient 
transduction of the ECs (~70-80% compared to ~50% without polybrene) (Fig 5.8 A) and 
low level overexpression of ARHGAP18 (Fig 5.8 B) that did not induce EC senescence. 
We chose not to aim for EC senescence as it is associated with profound changes in the 
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cytoskeleton (large flattened morphology) that is known to be associated with changes in 
the activity of the RhoGTPases. With these conditions, we examined the active levels of 
RhoA and RhoC and found that while RhoA was unchanged (Fig 5.8 C), we observed a 
slight but significant suppression of RhoC activity (Fig 5.8 D), hence confirming the 
subtle effects of ARHGAP18 knockdown.    
5.2.5.2. ARHGAP18 regulates EC junctional integrity 
RhoC belongs to the Rho subfamily, that includes RhoA and RhoB and shares 92% 
sequence similarity with RhoA. One of the key roles of Rho is in cell contractility and in 
the regulation of EC junctional integrity (Papatriantafyllou, 2012; Sahai and Marshall, 
2002). To determine whether this hyperactivation of RhoC induced by ARHGAP18 
knockdown replicated the known functions of Rho, we assessed the intergrity of the EC 
junctions and the arrangement of the actin cytoskeleton. While control cells generally had 
a linear arrangement of VE-cadherin, the ARHGAP18 knockdown cells had a relatively 
open zipper-like VE-cadherin distribution at the cell junctions (Fig 5.9 A, red arrows, and 
Fig 5.2 A), which is characteristic of weak remodeling junctions (Huveneers et al., 2012; 
Ngok et al., 2012). Furthermore, the ARHGAP18 knockdown EC displayed an increased 
amount of stress fibres (Fig 5.9 A, yellow arrows), indicating a more contractile 
phenotype. This matches the contractile phenotype observed during cell migration, where 
we observed disrupted proximal junctions (section 4.2.3, Fig 4.5 C), and is also consistent 
with Rho regulating the trailing edge of migrating cells (Ridley, 2001). 
We next assessed the dynamic remodeling of the junctions following thrombin treatment 
(Fig 5.10 A). Prior to thrombin, we already observed that loss of ARHGAP18 results in 
the disrupted phenotype described above. Following thrombin treatment for 2 and 10 min, 
the ARHGAP18 knockdown cells have an exacerbated response to thrombin with further 
contractility and an increased formation of intercellular gaps. Furthermore, while the 
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control cells start to recover by 60 min (intact junctions) and completely return to baseline 
by 120 min (cortical F-actin arrangement), the ARHGAP18 knockdown cells still remain 
notably disrupted at these time points with substantial actin stress fibres and serrated EC 
junctions. To translate this to a functional readout, the integrity of the monolayers were 
assessed using a FITC-dextran permeability assay. Control or ARHGAP18 knockdown 
cells were cultured on transwell inserts and stimulated with or without thrombin in 
addition to FITC-dextran. A low concentration (0.3 U/mL) of thrombin was used to better 
extrapolate the differences between the cell populations, as the normal concentration (1 
U/mL) results in a dramatic loss of barrier integrity in both populations. Consistent with 
the junctional phenotype, ARHGAP18 knockdown EC displayed increased basal and 
thrombin-induced FITC-dextran permeability (Fig 5.10 B). 
5.2.5.3. The ARHGAP18 junctional phenotype is dependent on RhoC 
We next aimed to determine whether the junctional phenotype induced by ARHGAP18 
knockdown was through the hyperactivation of RhoC. In order to do this, we chose a 
rescue approach whereby ARHGAP18 knockdown cells were transfected with siRNAs 
targeting RhoC. As a control, and to confirm our effects are through RhoC and not the 
previously reported RhoA, we also assessed the effects of RhoA knockdown. Firstly, we 
tested the efficacy of a double knockdown protocol, in which cells were first transfected 
with ARHGAP18 siRNAs then followed with the Rho siRNAs the next day. By assessing 
the expression of ARHGAP18, RhoA and RhoC by immunoblotting, it was confirmed 
that the procedure worked with efficient knockdown of each of the Rho proteins in 
combination with ARHGAP18 (Fig 5.11 A). Interestingly, knockdown of either RhoA or 
RhoC results in an upregulation of the other respective Rho protein and likely occurs as a 
compensatory mechanism for the loss of the original Rho.  
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We chose the junctional and cytoskeletal morphology as the readout of the rescue assay, 
as this was a well defined phenotype of ARHGAP18, and is an established function of the 
Rho proteins (Fig 5.11 B). Double control knockdown resulted in a normal cell phenotype 
with mainly straight junctions and limited actin stress fibres. Surprisingly, in the control 
cells, knockdown of RhoA resulted in more serrated VE-cadherin localisation, whereas 
RhoC had more mature junctions compared to control. Strikingly, knockdown of RhoC in 
ARHGAP18 knockdown cells was able to revert the disrupted phenotype of ARHGAP18 
knockdown alone, and rescue the phenotype to that of control cells with predominantly 
cortical actin with relatively straight junctions. In contrast, RhoA knockdown in 
ARHGAP18 silenced cells exacerbated the phenotype with further disruption of the 
junctions and cytoskeleton. 
These results conclusively indicated that ARHGAP18 acts as a RhoC GAP to regulate EC 
junctions and cell contractility. Despite the small magnitude of ARHGAP18’s regulation 
of RhoC activity, this was sufficient to induce a disrupted cell phenotype that could be 
rescued by modulating RhoC levels. One of the possible reasons for the small magnitude 
of regulation is due to the high level of redundancy that occurs within the GAP proteins, 
where there are over 80 GAPs that regulate the 20 RhoGTPases. In this instance, the 
consequences of ARHGAP18 loss can be limited by the compensatory functions of the 
other GAPs. While we have described here that ARHGAP18 regulates RhoC and not 
RhoA, Rac1, Cdc42, or RhoJ, we do not dismiss the possibility that ARHGAP18 may be 
regulating another RhoGTPase that we have not tested. However, our results clearly 
indicate that ARHGAP18 does not target the previously reported RhoA, but acts to inhibit 
RhoC in ECs. Notably, such epithelial-endothelial differences in RhoGAP specificity 
have also been demonstrated in other RhoGAP family members, such as 
ARHGAP24/VasGAP/FliGAP, which targets Rac1 in podocytes (Akilesh et al., 2011), 
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Rac1 and Cdc42 in HeLa cells (Lavelin and Geiger, 2005), and Rho in ECs (Su et al., 
2004). While RhoC belongs to the same family as RhoA, it is functionally distinct. Most 
importantly, it has been shown that RhoC promotes, whereas RhoA inhibits cell invasion 
and migration (Bellovin et al., 2006; Hakem et al., 2005; Heasman and Ridley, 2008; 
Simpson et al., 2004; van Golen et al., 2000b; Wheeler and Ridley, 2004). These 
functional differences have been attributed to the activation of the downstream activators, 
such as ROCK, Dia (Sahai and Marshall, 2002), and formins (Kitzing et al., 2010; Vega 
et al., 2011). In particular, while RhoA and RhoC both activate ROCK, RhoC has higher 
affinity for ROCK (Sahai and Marshall, 2002). Further, overexpression of RhoC, but not 
RhoA, results in ROCK-dependent disruption of the AJs, while RhoA activation of Dia 
results in stabilization of the AJs (Sahai and Marshall, 2002). Consistent with this, we 
observe that RhoA knockdown disrupts the cell junctions, whereas knockdown of RhoC 
stabilizes the AJs and rescues the disrupted phenotype of ARHGAP18 knockdown.  
5.2.6.  IN VIVO STUDIES OF JUNCTIONAL REGULATION 
5.2.6.1. Loss of ARHGAP18 results in disrupted VE-cadherin distribution in the 
retinal capillary ECs 
We next aimed to confirm the in vitro effects of ARHGAP18 on junctional integrity in 
vivo. We first used the retinal angiogenesis model, which we have previously found to 
result in a hypersprouting phenotype, and assessed the EC junctions by VE-cadherin 
staining. While the junctions of the capillary ECs in the WT mice were predominantly 
straight, the junctions in the ARHGAP18-/- mice had a relatively serrated staining of VE-
cadherin (Fig 5.12, red arrows), consistent with the in vitro findings.  
5.2.6.2. ARHGAP18 in vascular integrity 
We next investigated whether the junctional phenotypes and the in vitro permeability 
results translated to vascular leak in vivo. In the zebrafish model, we observed that there 
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was significant hindbrain, yolk sac and cardiac oedema (Fig 4.7 C), and this was unlikely 
due to changes in the lymphatics. To test this in a mouse model, we first used the Miles 
assay, whereby Evan’s blue was injected intravenously, VEGF-A injected into the skin of 
mice, and quantifying the amount of dye leakage. Confoundingly, we observed that the 
ARHGAP18-/- mice had a significantly reduced amount of vascular leak (Fig 5.13 A). 
However, there are some caveats with the use of the Miles assay, in particular, the assay 
requires hemodynamics for the distribution of the dye (Nagy et al., 2008). In addition to 
hyperpermeability, VEGF-A also causes vasodilation, which increases the blood flow in 
the microvascular beds and in turn can increase solute flux across the vessel wall (Nagy et 
al., 2008). Furthermore, the assay can be affected by changes in the density of the 
capillary beds. As we have not investigated the changes in hemodynamics associated with 
ARHGAP18 loss, these potential effects may be the cause of the conflicting results. 
In collaboration with Dr. Arby Abtin, Immune Imaging Laboratory, Centenary Institute, 
we next investigated the junctional integrity using a mouse model of acute ear 
inflammation. The ears of WT or ARHGAP18-/- mice were treated topically with the 
irritant, croton oil (Shwaireb, 1995) and then assessed for changes in oedema and 
neutrophil infiltration. After 24 h treatment, the ARHGAP18-/- mice had significantly 
increased oedema, as measured by the ear thickness (Fig 5.14 A). These ears were then 
harvested for flow cytometric quantification of neutrophils based on a CD45+ Ly6G+ 
CD11b+ profile (Abtin et al., 2014). The gating strategy is depicted in Fig 5.14 B. Briefly, 
single live cells were gated on CD45+, then the double Ly6G+ CD11b+ cell population 
selected. Despite the single cell gate, this still results in cell doublets, and these 
populations were taken into account when quantifying the absolute numbers of infiltrated 
neutrophils. In the absence of croton oil, there was minimal infiltration of neutrophils in 
WT mice, but there were significantly more neutrophils in the ARHGAP18-/- mice (Fig 
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5.14 C and D). Following croton oil treatment, there was a ~2.4 fold increase in the 
number of infiltrated neutrophils. These results indicate that there was increased vascular 
leak into the ear following inflammatory stimulus, and increased neutrophil infiltration 
into the inflammatory site. However, one major limitation of this result is that the 
ARHGAP18-/- mouse is a global knockout, and therefore we are unable to determine 
whether the increased neutrophil infiltration is due to the effects of ARHGAP18 on 
neutrophil or endothelial function. This would be resolved following the generation of the 
EC specific KO as described above in chapter 7.  
5.2.7.  LOSS OF ARHGAP18 PROMOTES TUMOUR GROWTH AND 
VASCULARISATION 
The results suggested that ARHGAP18 is important dualistically in limiting the sprouting 
phenotype and maintaining junctional integrity. The tumour vasculature is characterized 
by an abundance of tortuous and leaky vessels. Therefore, the development of the tumours 
and the structure of the tumour vasculature were assessed by Yang Zhao, PhD student in 
the Vascular Biology laboratory. B16F10 melanoma cells were injected subcutaneously 
into the flank of WT and ARHGAP18-/- mice and monitored for the development of the 
tumours. The tumours in the ARHGAP18-/- mice developed significantly more rapidly 
compared to the WT mice (Fig 5.15 A). Furthermore, the tumours were harvested and 
found to be more highly vascularized in the ARHGAP18-/- mice (Fig 5.15 B and C). 
Ideally, it would be of much interest to determine whether these tumour vessels were 
more leaky, as would be expected.  
5.3.  SUMMARY AND CONCLUSIONS 
It has been recently established that the EC junctions play a major role in the dynamic 
selection of TCs and vascular patterning (Bentley et al., 2014). We have identified here 
that the hypersprouting phenotype is closely associated with the role of ARHGAP18 in 
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regulating the EC junctions. During sprouting, we observe that ARHGAP18 is distinctly 
localized to the junctions of angiogenic ECs, and we associate this with its function as a 
GAP protein. Here its effects on RhoC act to maintain junctional integrity to suppress the 
angiogenic response. In the absence of ARHGAP18, the translocation of ARHGAP18 to 
the membrane to regulate RhoC is prevented, resulting in elevated RhoC activity, and 
junctional disruption. Based on other studies, these active junctions are highly associated 
with a TC phenotype, DLL4 expression, high shuffling capacity and an overall 
hypersprouting phenotype (Bentley et al., 2014). A further detailed overview of the 
proposed mechanism and pathway is discussed in chapter 7.  
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Fig 5.1. Optimisation of ARHGAP18 staining in HUVECs. 
A-B. HUVECs transfected with control or ARHAGP18 siRNAs were cultured on chamber slides, !xed 
with formaldehyde (A) or methanol-acetone (B), stained with mouse monoclonal or rabbit 
polyclonal antibodies against ARHGAP18 and imaged by wide!eld "uorescence microscopy. 
NT = non-siRNA transfected cell. Cells !xed with formaldehyde poorly stain for ARHGAP18. The 
monoclonal is more eﬃcient at staining for ARHGAP18, as there is clearer distinction of the 
"uorescence signal in control and knockdown cells. Bar 50 μm. 
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Fig 5.2. ARHGAP18 is localised predominantly in the cytosol of resting ECs. 
A.  Confocal images of monolayer ECs transfected with control or ARHGAP18 siRNAs stained for 
ARHGAP18 (green), VE-cadherin (red) and nuclei counterstained with DAPI (blue). ARHGAP18 is 
predominantly localised in the cytosol with some nuclei staining but is notably absent from the 
periphery of resting ECs. Bar 25 μm. 
B.  Validation of ARHGAP18 staining. Control or ARHGAP18 siRNA transfected ECs were stained with 
antibodies against ARHGAP18 or an isotype control antibody. ARHGAP18 siRNA trasnfected ECs 
show reduced staining and the signal is absent in the isotype control. NT = non-transfected cell. 
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Fig 5.3. ARHGAP18 is localised to junctions of angiogenic sprouts. 
A-B. EC spheroids were stimulated with VEGF (A) or FGF-2 (B), !xed and stained for ARHGAP18 (red) 
and junctional markers (VE-cadherin or PECAM) (green), nuclei counterstained with DAPI 
(blue) and imaged by confocal microscopy. ARHGAP18 localises to the junctions of the 
angiogenic sprouts (arrows). Bar 50 μm. 
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Fig 5.4. Optimisation of ARHGAP18 staining in mouse retina. 
A.  Retinas from P6 WT mice were stained with rabbit polyclonal antibodies raised against 
ARHGAP18, rabbit isotype control or a no primary antibody control and imaged by confocal 
microscopy. 
B.  Retinas from P6 WT mice were pre-incubated with or without an endogenous Ig block, stained 
with mouse monoclonal antibodies raised against ARHGAP18, mouse isotype control or a no 
primary antibody control and imaged by confocal. 
C.  Retinas from P6 WT or ARHGAP18-/- mice were stained with the ARHGAP18 monoclonal antibody 
(red) and VE-cadherin (green) to visualise the vasculature and imaged by confocal. 
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Fig 5.5. ARHGAP18 is localised to the junctions of capillary and angiogenic EC in the 
developing retinal vasculature. 
A.  Low magni!cation image of P6 WT retinas stained for ARHGAP18 (red) and NG2 (green) 
(pericytes). A=artery, V=vein, CP=capillary plexus, AF=angiogenic front. Bar 500 μm. 
B.  Localisation of ARHGAP18 in the diﬀerent vessel subtypes. ARHGAP18 is also expressed in the 
retinal axons (yellow arrows) and astrocytes (blue arrows). ARHGAP18 (red) colocalises with VE-
cadherin (green) in ECs in the capillary plexus and angiogenic front (white arrows) but not in the 
larger arterial or venous vessels. Bar 25 μm. 
C.  High magni!cation of ARHGAP18 staining in the capillary plexus showing colcalisation with VE-
cadherin (arrows). Bar 10 μm. 
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Fig 5.6. ARHGAP18 transiently localises to the junctions of monolayer ECs following thrombin 
stimulation. 
A.  Confocal images of HUVECs stained for ARHGAP18 (green), β-catenin (red) and nuclei 
counterstained with DAPI following stimulation with thrombin (1 U/mL) for the indicated times. 
ARHGAP18 localises to the retracting EC extensions at 2 min, to the EC junctional periphery at 
10 min and returns to the cytosol at 30 and 60 min following thrombin simulation. Bar main, 25 
μm; magni!ed, 10 μm. 
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Fig 5.7. ARHGAP18 knockdown increases basal and thrombin-stimulated RhoC activity, but 
does not alter the activity of other Rho GTPases.  
A-E. HUVECs transfected with control (£) or ARHGAP18 (¢) siRNAs were stimulated with or without 
thrombin (1 U/mL) and lysed. Active RhoA (A), RhoC (B), Rac1 (C), Cdc42 (D), and RhoJ (E) levels 
were determined by GLISA. Data represents the mean ± SEM from n=5 (A and B), 3 (C), 2 (D and 
E) independent experiments. ns, non-signi!cant; *, P<0.05; t-test. 
F.  Time course of RhoC activation following thrombin treatment. HUVECs were stimulated with 
thrombin (1 U/mL) and the levels of active RhoC determined by GLISA at the indicated time 
points. RhoC is maximally activated following 2 min of thrombin stimulation. 
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Fig 5.8. ARHGAP18 overexpression suppresses RhoC but not RhoA activity.  
A.  Eﬃciency of HUVECs transduced with empty vector (AdEV) and AdARHGAP18 adenoviruses 
for 24 h in the presence of polybrene. 
B.  Con!rmation of ARHGAP18 overexpression. Immunoblots of ARHGAP18 and actin as the 
loading control from HUVECs transduced with AdEV and AdARHGAP18.  
C-D. HUVECs transduced with AdEV (£) or AdARHAGP18 (¢) adenoviruses were stimulated with or 
without thrombin (1 U/mL) and lysed. Active RhoA (C)and RhoC (D) levels were determined by 
GLISA. Data represents the mean ± SEM from n=3 independent experiments. ns, non-
signi!cant; *, P<0.05; t-test. 
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Fig 5.9. ARHGAP18 silencing induces stress "bre formation and junctional disruption in vitro. 
A.  Confocal images of HUVECs transfected with ctrl or ARHGAP18 siRNAs and stained for VE-
cadherin (green) and F-actin (red) and nuclei counterstained with DAPI (blue). Relative to ctrl, 
ARHGAP18 knockdown EC display more pronounced stress !bres (yellow aarrows) and zippered 
appearance of VE-cadherin (red arrows). Bar 25 μm. 
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Fig 5.10. ARHGAP18 silencing exacerbates the response and delays the recovery to thrombin 
stimulation and promotes basal and thrombin-induced vascular leak. 
A.  Confocal images of HUVECs transfected with control or ARHGAP18 siRNAs, stimulated with 
thrombin (1U/mL) for the indicated times, !xed and stained for F-actin (red), VE-cadherin (green) 
and nuclei counterstained with DAPI (blue). ARHGAP18 knockdown cells display increased 
junctional disruption and cell retraction following thrombin stimulation and are delayed in the 
return to the resting state. Bar 25 μm. 
B.  HUVECs transfected with control (grey) or ARHGAP18 (black) siRNAs were seeded in transwells, 
stimulated with (dashed line) or without (solid line) thrombin (0.3 U/mL) in the presence of FITC-
dextran. The FITC-dextran in media from the bottom chamber was collected, measured at the 
indicated time points and data normalised relative to 0 min. Data represents the mean ± SEM 
from n=8 experiments. * P<0.05, **** P<0.0001; two-way ANOVA, Sidak’s post-test (at 60 min). 
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Fig 5.11. RhoC, but not RhoA, knockdown rescues the junctional and cytoskeletal phenotype 
induced by ARHGAP18 knockdown 
A.  Con!rmation of double knockdown of ARHGAP18 and RhoA or RhoC. HUVECs were transfected 
with ARHGAP18 or control siRNAs for 1 d, then transfected with RhoA, RhoC or control siRNAs 
for an additional 2 d. The lysates were collected and immunoblotted for ARHGAP18, RhoA, RhoC 
and the loading control actin.  
B.  RhoC, but not RhoA rescues the ARHGAP18 knockdown phenotype. Confocal images of HUVECs 
double transfected with the indicated siRNAs, !xed and stained for VE-cadherin (green), F-actin 
(red) and nuclei counterstained with DAPI (blue). Knockdown of RhoA exacerbates the 
junctional and cytoskeletal phenotype, while knockdown of RhoC reverts the ARHGAP18 
phenotype to that of the control. Bar 25 μm. 
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Fig 5.12. Loss of ARHGAP18 alters VE-cadherin junctional distribution in the retinal capillary 
EC. 
A.  Confocal images of retinal capillary EC from P6 WT and ARHGAP18-/- retinas !xed and stained for 
VE-cadherin. Relative to the tight distribution of VE-cadherin in the WT EC junctions, ARHGAP18 
loss resulted in more diﬀuse distribution of VE-cadherin (red arrows). Bar 10 μm. 
A 
213 
Chapter 5. ARHGAP18 – A RhoC GAP in Junctional Integrity   
Fig 5.13. Loss of ARHGAP18 results in decreased vascular leak in vivo.  
A.  WT and ARHGAP18-/- mice were subjected to a Miles assay. The mice were injected intravenously 
with Evan’s blue for 30 min then injected intradermally with PBS or VEGF-A (10 ng) for 30 min. 
The skin was dissected and the Evan’s blue eluted and measured. Data represents the mean ± 
SEM from n=17 mice per group. **, P<0.01; t-test. 
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Fig 5.14. ARHGAP18-/- mice have increased vascular oedema and neutrophil in"ltration in 
response to croton oil 
A.  Loss of ARHGAP18 results in increased ear oedema following in"ammatory stimulus. WT and 
ARHGAP18-/- mice were treated topically with 2.5% croton oil or vehicle control for 24 h and the 
ear thickness measured using calipers. Data represents the mean ± SEM from n=9 mice per 
group. *, P<0.05; t-test. 
B.  Gating strategy for the identi!cation of neutrophils by "ow cytometry. The cell populations 
were !rst gated to remove doublets and dead cells. The CD45+ population was then gated for 
the double Ly6G+ CD11b+ population, which represent the neutrophils. The neutrophils were re-
gated by size to identify the single and double cell populations. 
C.  Representative "ow cytometric plots of WT and ARHGAP18-/- populations treated with vehicle or 
croton oil. Numbers represent the percentage of the population.  
D.  Quanti!cation of in!ltrated neutrophils in WT and ARHGAP18-/- mice treated with vehicle or 
croton oil for 24 h. Data represents the mean ± SEM from n=9 mice per group. ***, P<0.001; *, 
P<0.05; t-test. 
Performed in collaboration with Dr. Arby Abtin and Dr. Angelina Lay 
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Fig 5.15. ARHGAP18 loss promotes tumour growth and vascularisation. 
A.  Loss of ARHGAP18 promotes tumour growth. Tumour volumes were determined in WT and 
ARHGAP18-/- mice following subcutaneous injection of B16F10 melanoma cells. Data represents 
the mean ± SEM from n=5 mice per group. ****, P<0.0001; *, P<0.05; two-way ANOVA, Sidak’s 
post-test. 
B.  Loss of ARHGAP18 promotes tumour vascularisation. Representative confocal images of tumour 
sections from WT and ARHGAP18-/- mice stained for CD31 (red). Bar 50 μm. 
C.  Quanti!cation of tumour vascularisation in B. Data represents the mean ± SEM from n=8 WT and 
7 ARHGAP18-/- mice. *, P<0.05; t-test. 
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6.1.  INTRODUCTION 
In the previous chapter, we established that one of the crucial mechanisms that regulate 
ARHGAP18 function is in its relocalisation to EC junctions. In vitro this occurs as a very 
rapid response to thrombin stimulation and we postulate that this occurs via post-
translational modifications of ARHGAP18. This final chapter is aimed at elucidating the 
molecular mechanisms that regulate this and focuses on two aspects: novel protein-protein 
interactors and phosphorylation. The data presented in this chapter is relatively 
preliminary and will require a substantial amount of further investigation. 
6.2.  RESULTS AND DISCUSSION 
6.2.1.  ARHGAP18 DOES NOT INTERACT WITH THE ERM PROTEINS 
We first assessed whether there were any potential protein-protein interactions that could 
regulate ARHGAP18 translocation. Using protein interaction databases, we identified a 
single potential partner, MPP6, an RNA binding protein (string-db.org). By yeast two-
hybrid screening, the vascular biology laboratory identified a novel putative target in Bif-
1/Endothelin B1 (Mai Tran, unpublished data), a protein involved in membrane curvature. 
It remains to be determined as to whether ARHGAP18 and Bif1 interact by coIP and the 
overall importance of this protein. Assessment of the protein domains of ARHGAP18 
revealed that there was a single RhoGAP domain, and no notable protein interaction 
domains (e.g. SH2, SH3, proline-rich, PDZ) (see section 1.6.1.1).  
The recent publication by (Neisch et al., 2013) in Drosophila recently provided some 
insight into ARHGAP18 function and translocation. It was found that Conundrum, the 
ARHGAP18 orthologue, localises to the cell cortex, the specialized layer where the 
plasma membrane and the cortical actin cytoskeleton interact (Bretscher et al., 2002), 
where it acts as a Rho1 GAP. This was found to be dependent on the interaction with the 
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ezrin-radixin-moesin (ERM) protein, moesin, which is the sole ERM gene expressed in 
Drosophila. These ERM proteins act as anchors that interact with the plasma membrane 
and the actin cytoskeleton and can control Rho activation (Bretscher et al., 2002; Fehon et 
al., 2010). We therefore hypothesized that a similar situation may occur in mammalian 
cells. In ECs in particular we argued that during thrombin stimulation, ARHGAP18 
translocates to the cell cortex, and that this is dependent on the ERM proteins.    
To determine whether there was an involvement of the ERM proteins, we took two 
approaches: colocalisation by IF, and interaction by coIP. Firstly, we examined whether 
there was colocalisation of the two proteins in the presence and absence of thrombin 
treatment for 10 min, which described above results in the translocation of ARHGAP18 to 
the cell membrane. Notably, staining with the ERM antibody, which detects all three 
family members showed a predominantly cortical actin-like localisation of the proteins, 
with organization into the filament structures (Fig 6.1 A). However, this was not similar 
to ARHGAP18 in the presence nor the absence of thrombin treatment. Staining with the 
moesin antibody revealed a more punctate localisation of moesin, but was absent from the 
membrane following thrombin stimulation (Fig 6.1 A, right panels). 
To confirm this negative result, we examined the potential interaction between the ERM 
proteins and ARHGAP18 by coIP. ARHGAP18 was pulled down from total cell lysates, 
consisting of a pool of non-treated and thrombin treated cells, and immunoblotted for the 
ERM proteins. While there was efficient pulldown, which was also quite specific based 
on the absence of the protein in the isotype control antibody pulldown, there was no 
evidence of any of the ERM proteins (Fig 6.1 B). We confirmed that the ERM proteins 
were able to be detected by the antibody using the WCL. Comparison of the protein 
sequences suggests that the lack of interactions is highly likely to be intrinsic differences 
between the Drosophila and mammalian ARHGAP18 proteins (Fig 6.1 C). While 
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alignment of the whole protein shows a 34% sequence similarity to the human 
ARHGAP18 sequence, there is much higher similarity (55%) in the GAP domain. On the 
other hand, the moesin minimal interaction domain appears to be a Drosophila specific 
domain as the similarity is significantly lower, at 28% which is even lower than the whole 
protein alignment. Furthermore, phylogenetic analysis of RhoGAP proteins has also 
demonstrated that Conu displays higher homology to ARHGAP28 and ARHGAP40 than 
to ARHGAP18 (Porazinski et al., 2015). (Neisch et al., 2013) also describes the presence 
of an N-terminal sterile alpha motif (SAM) domain, which like the GAP domain is more 
highly conserved between the species. SAM domains exhibit diverse protein-protein 
interactions, including self-associations, the binding to SAM and non-SAM domains and 
also in binding RNA (Kim and Bowie, 2003), which gives little insight into the function 
of ARHGAP18. 
6.2.2.  ARHGAP18 COLOCALISES AND CO-IMMUNOPRECIPIATES WITH 
CORTACTIN  
We next examined the potential interaction with the cortical actin binding protein 
cortactin. Cortactin has been shown regulate cell migration via its interaction with the 
actin cytoskeleton (Katsube et al., 2004) and regulators of actin polymerization such as N-
WASP, ARP2/3 and MLC kinase (Desmarais et al., 2009; Dudek et al., 2002; Kowalski et 
al., 2005; Oser et al., 2009; Weaver et al., 2002). Cortactin localizes to the cell periphery 
following stimulation with S1P and thrombin (Vouret-Craviari et al., 2002) and has been 
further shown to interact with RhoGAP proteins, such as BPGAP1 (Lua and Low, 2004). 
We therefore hypothesized that the translocation of ARHGAP18 to the cell periphery is 
mediated via its interaction with cortactin and that this is crucial in regulating the function 
of ARHGAP18 as a RhoGAP and in controlling junctions and sprouting. 
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In resting cells, cortactin was localized predominantly in the cytosol like punctate dots, 
much like ARHGAP18 (Fig 6.2, left panels). Interestingly, following treatment with 
thrombin, we observed that cortactin also translocates to the junctional periphery, and 
shows abundant colocalisation with ARHGAP18 (Fig 6.2 A, white arrows). However, we 
also observe that there were also cells which had cortactin translocating to the junctions 
despite an absence of ARHGAP18 colocalisation (Fig 6.2A, yellow arrows).  
Next, we examined whether there was an interaction by co-IP. Strikingly, pulldown of 
ARHGAP18 revealed an abundance of cortactin that was immunoprecipitated, which was 
absent from the control antibody (Fig 6.2 B). Given that ARHGAP18 transiently localizes 
to the cell junctions following thrombin stimulation, it was next assessed whether the 
interaction between cortactin and ARHGAP18 is dynamically altered during thrombin 
destabilization. Interestingly, the interaction between ARHGAP18 and cortactin was not 
changed (Fig 6.2 C). This potentially indicates that ARHGAP18 exists as a protein 
complex with cortactin that is shuttled to and from the membrane during the thrombin-
induced dynamic remodeling. 
To confirm this interaction, a pulldown of cortactin was next performed to determine 
whether ARHGAP18 could be co-immunoprecipitated. While ARHGAP18 could be 
detected, it was surprisingly being detected at a lower molecular weight, that being ~73 
kDa (Fig 6.2 D). While we and (Maeda et al., 2011) have previously identified a smaller 
isoform of ARHGAP18, this would be the first indication of a potential functional 
significance of this isoform. One potential explanation is that ARHGAP18 undergoes 
post-translation cleavage in order to exist in a complex with cortactin. In fact, this may 
suggest that most of the ARHGAP18 exists in a dormant state, which requires cleavage to 
allow interaction with cortactin and/or expose the active domains of ARHGAP18. In 
support of this, the Vascular Biology laboratory have recently discovered that cells 
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overexpressing different truncations of ARHGAP18 have vastly different cell phenotype 
(Mai Tran and Julie Hunter, unpublished data). While the full-length ARHGAP18 and C-
terminal truncations have minimal effects on the cell phenotype, a N-terminal 
ARHGAP18 truncation (expressing amino acids 296-663) results in a prominent rounded 
cell morphology with extensive cell protrusions. This is also dependent on the RhoGAP 
domain, as introduction of the R365A mutation into the GAP domain prevents this 
phenotype. Thus, this potentially suggests that the N-terminal region of ARHGAP18 acts 
as an inhibitor of its GAP function, possibly by obscuring the active site or interaction of 
the domain with the downsteam GTPase, and that the cleavage of this region is required 
for its function (Dr. Aaron McGrath and Dr. Mika Jormakka, unpublished data). While 
this is interesting, it would require extensive further study to extrapolate the intricacies of 
the system.  
6.2.3.  ARHGAP18 TRANSLOCATION TO THE JUNCTIONAL PERIPHERY IS 
DEPENDENT ON CORTACTIN 
We next aimed to determine whether the translocation of ARHGAP18 or cortactin was 
dependent on the respective protein. Given its interaction, and especially since cortactin 
appeared to bind to the ‘functional’ isoform of ARHGAP18, it was hypothesized that 
cortactin is required for the trafficking of ARHGAP18 to the membrane periphery. In 
order to investigate this, we examined the localisation of ARHGAP18 following thrombin 
stimulation in the presence or absence of cortactin. Firstly, knockdown of cortactin by 
siRNA transfection was optimized in HUVECs. Interestingly, like ARHGAP18, we 
observed that transfection with one of the siRNAs, siCTTN1, resulted in significant cell 
elongation, that was absent with the other two siRNAs tested (Fig 6.3 A). We therefore 
attributed these effects with this siRNA as non-specific effects, and therefore siCTTN1 
was not used for downstream experiments. Transfection with all three siRNAs resulted in 
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efficient knockdown of cortactin, and two of the three siRNAs notably resulted in 
downregulation of ARHGAP18 (Fig 6.3 B), which may or may not be due to off-target 
effects of the siRNAs. 
We next investigated the thrombin-induced localisation of ARHGAP18 and cortactin 
following ARHGAP18 or cortactin knockdown. Cortactin knockdown was achieved 
either individually (siCTTN2 or siCTTN3) or through a pool of the two siRNAs. The 
effects of the individual siRNAs were similar to that of the pooled siRNA, but had more 
inefficient knockdown and hence the pooled siRNA results are the only ones shown. In 
the control knockdown cells, we observed that the cells had a contracted cell phenotype 
with notable localisation of both ARHGAP18 and cortactin in the cell periphery (Fig 6.4 
A, left panels). In the ARHGAP18 knockdown cell, we observed that despite the lack of 
ARHGAP18 expression, there was still an abundance of cells that had relocalised 
cortactin (Fig 6.4, middle panels, white arrows). A single non-transfected cell served as a 
control that clearly shows translocated ARHGAP18 that co-localises with cortactin. On 
the other hand, knockdown of cortactin resulted in an absence of ARHGAP18 
translocating to the cell periphery (Fig 6.4, right panels). Furthermore, consistent with the 
immunoblots, knockdown of cortactin also downregulated expression of ARHGAP18. 
This downregulation of ARHGAP18 by immunofluorescence staining was also observed 
in siCTTN3 transfected cells (data not shown), suggesting that cortactin knockdown may 
indeed be downregulating ARHGAP18 and not be a result of off-target siRNA effects. 
Overall, this indicates that cortactin serves as a critical factor to traffic ARHGAP18, 
whereas ARHGAP18 is not essential for cortactin movement. 
6.2.4.  PHOSPHORYLATION OF ARHGAP18 
6.2.4.1. Identification of putative phosphorylation sites 
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Phosphorylation of proteins is a major mechanism that regulates protein function and 
localisation. We used Phosphosite (phosphosite.org) to identify putative ARHGAP18 
phosphorylation sites (Fig 6.5 A). This gathers phospho-protein data from other 
publications, aligns the protein sequence from the mouse and human and identifies 
conserved serine, threonine and tyrosine residues of known phospho motifs. In the human 
sequence, 8 potential sites were identified that were all notably excluded from the GAP 
domain, but congregated at the N- and C-termini of ARHGAP18. Furthermore, out of 
these 8 putative sites, 3 of them (S66, T154, S610) were of significant interest as they 
contain the RXXS*/T* motif, which is a substrate for several kinases including Akt, 
PKA, PKC and also ROCK (Kang et al., 2007). Furthermore, of these 3 sites, two of them 
also contain the S*/T*Q motif, which is a substrate for ATM/ATR phosphorylation 
(Stokes et al., 2007). ATM/ATR are important in the context of DNA damage and 
oxidative stress, and may be implicated in the regulation of ARHGAP18 in oxidative 
stress-induced senescence (Coleman et al., 2010; Powter et al., 2015). However, this 
would be the subject of further study, but not in the context of this project.. 
6.2.4.2. The ARHGAP18 is phosphorylated following thrombin stimulation 
In order to determine whether the RXXS*/T* sites were phosphorylated, HUVEC lysates 
were immunoprecipitated using the ARHGAP18 or control antibodies and immunoblotted 
using the phosphor-ser/thr Akt substrate antibody. This antibody specifically recognizes 
the RXXS*/T* motif only when phosphorylated at the ser or thr positions with arg at the -
3 position. While there was an abundance of phosphorylated proteins in the WCL 
samples, the ARHGAP18 pulldown samples specifically identified a single ~73 kDa 
protein, that was absent in the isotype control pulldown (Fig 6.5 B). Notably, this is the 
same size as that in the cortactin pulldown (Fig 6.2 A), which we speculate is due to post-
translational cleavage. We next investigated whether the phosphorylation of the 
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ARHGAP18 motif was altered by thrombin stimulation. Remarkably, we observed a 
dynamic hyper-phosphorylation of this motif following thrombin stimulation with a 
maximal phosphorylation at 10 min before returning to baseline at 60 min (Fig 6.5 C). 
This interestingly is the same time point at which there is maximal translocation of 
ARHGAP18 to the cell membrane (Fig 5.6 A). Therefore, we hypothesized that this 
phosphorylation is required for the translocation of ARHGAP18. In order to definitively 
confirm this, we would need to mutate the potential phospho sites, however this is outside 
the scope of this thesis and would be for future investigation. 
6.2.4.3.  The thrombin-induced phosphorylation of ARHGAP18 is not dependent 
on Akt 
 We next sought to identify the kinase that was regulating the phosphorylation of 
ARHGAP18 and to determine whether this was driving ARHGAP18 translocation. Firstly 
the effects of Akt were tested by treatment with or without the PI3K inhibitor, LY294002. 
Notably in basal cells there was reduced phosphorylation of ARHGAP18 following 
LY294002 treatment (Fig 6.6 A). However, in thrombin-stimulated cells, there was 
hyperphosphorylation of ARHGAP18. WCL were run as a control for LY294002 
efficacy, and notably indicated that Akt is in fact hypoactivated following thrombin 
stimulation. To confirm this, the activation of Akt and ERK were assessed in a time 
course following thrombin stimulation (Fig 6.6 B). While ERK displays transient 
activation, Akt is markedly hypoactivated following thrombin stimulation. This therefore 
indicates that it is highly unlikely that Akt is the kinase that phosphorylates ARHGAP18 
following thrombin stimulation. To confirm this effect, we assessed ARHGAP18 
translocation in the presence or absence of the inhibitor, and found no difference in 
ARHGAP18 translocation following Akt inhibition (Fig 6.6 C). 
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6.2.4.4. ROCK inhibition suppresses phosphorylation of ARHGAP18 and 
prevents ARHGAP18 relocalisation 
One other kinase that phosphorylates RXXS*/T* motifs is ROCK (Kang et al., 2007). 
ROCK is activated downstream of the Rho and drives disruption of the AJs through 
phosphorylation of MLC. In order to determine whether ROCK mediates phosphorylation 
of ARHGAP18, we immunoprecipitated cell lysates treated with thrombin in the presence 
or absence of the ROCK inhibitor, Y27632, and assessed the phospho motif (Fig 6.7 A). 
We observed that there was substantially less phosphorylation of the motif in all the time 
points. The phosphorylated MLC2 indicates that ROCK is highly activated at 10 min, and 
is effectively inhibited by Y27632.  However, despite the reduction in the phosphorylated 
ARHGAP18 motif, there was still substantial phosphorylation at 10 min. This likely 
indicates that the motif is still being phosphorylated by another kinase, that is not ROCK 
or Akt, This could potentially be PKA or PKC, which are also regulated following 
thrombin stimulation (Aslam et al., 2010; Rahman et al., 2001) and have been found to 
phosphorylate a majority of ROCK substrates (Kang et al., 2007). However, we have not 
examined the contributions of these kinases to ARHGAP18 phosphorylation. 
We next tested the effects of ROCK inhibition of the actin cytoskeleton and cell junctions. 
As has been previously reported (van Nieuw Amerongen et al., 2000), ROCK inhibition 
completely prevents thrombin mediated disruption of the cell junctions and formation of 
the actin stress fibres (Fig 6.7 B). Furthermore, ROCK inhibition completely prevented 
the translocation of ARHGAP18 to the cell periphery (Fig 6.7 C).     
6.3.  SUMMARY AND CONCLUSIONS 
ARHGAP18 dynamically translocates to unstable EC junctions, such as EC monolayers 
stimulated with thrombin or the remodeling angiogenic vessels, where we postulate it acts 
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as a RhoC GAP to inhibit RhoC activity and thus promote junctional stability. In this 
chapter, we have identified two potential mechanisms that regulate the translocation of 
ARHGAP18: its interaction with cortactin and phosphorylation of ARHGAP18. 
6.3.1.   CORTACTIN IS A NOVEL INTERACTING PARTNER OF ARHGAP18 
The preliminary results suggest that cortactin serves as a critical interactor of ARHGAP18 
to actively translocate ARHGAP18 to the cell periphery. We are able to observe this 
interaction through co-localisation and co-IP experiments and show that knockdown of 
cortactin effectively inhibited ARHGAP18 translocation. Further experiments are 
required to substantiate and confirm this possibility. 
One major caveat of these experiments is that the translocation of ARHGAP18 and 
cortactin is a relatively poor readout.  Not all cells respond in the same manner and at the 
same time following thrombin. It is widely assumed that the translocation of ARHGAP18 
to the membrane serves to inhibit RhoGTPase activation, in this case being RhoC. 
Therefore, a further readout of ARHGAP18 function following cortactin knockdown 
would be to measure RhoC activation, which would provide a quantitative readout. 
Further, the co-IP experiments using these antibodies can potentially have non-specific 
effects. Ideally, the co-IP experiments would be performed in ECs that express tagged 
versions (e.g Flag, His) of ARHGAP18 and cortactin, and pulldowns performed using 
antibodies against these specific tags. Moreover, by expressing truncations and mutations 
of ARHGAP18 and cortactin, the ultimate goal would be to establish the domains that are 
important for their interaction and function.  
It has been demonstrated that Src and Rac1 are critical regulators of cortactin 
translocation (Tehrani et al., 2007; Vouret-Craviari et al., 2002; Weed et al., 1998). Both 
Src and Rac1 are activated following VEGFA stimulation and have important functions in 
regulating angiogenic sprouting and junctional regulation (Gavard and Gutkind, 2006). 
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Therefore, it would be of interest to investigate whether Src and/or Rac1 signaling also 
regulates ARHGAP18 trafficking and to determine the potential implication of Src-Rac1-
cortactin-ARHGAP18 signaling in sprouting angiogenesis.  
6.3.2.  PHOSPHORYLATION  
Here we have identified putative phosphorylation sites that may be critical in the function 
of ARHGAP18. In particular, the RXXS*/T* motif present at three sites of ARHGAP18 
is of significant interest, as we show that this is phosphorylated in a time-dependent 
manner that coincides with the translocation to the membrane. While this motif can be 
phosphorylated by several different kinases, we have elucidated that Akt and ROCK 
inhibition can inhibit basal phosphorylation, while ROCK inhibition can suppress, but not 
completely prevent, thrombin-induced phosphorylation. This is likely due to the 
influences of the other kinases such as PKA or PKC. However, we demonstrate that 
ROCK inhibition prevents ARHGAP18 translocation to the membrane. This may indicate 
that ROCK regulates phosphorylation of one or more of the ARHGAP18 
RXXS*/T*motifs, which act as the critical signal to drive its relocalisation. This likely 
indicates that thrombin induces RhoC-ROCK activation, which leads to AJ disruption. 
ROCK thereby phosphorylates and recruits ARHGAP18 to restore basal RhoC activity to 
prevent excessive junctional disruption. The proposed mechanism is described further in 
chapter 7. 
There are some major limitations of these  preliminary experiments. Firstly, we are unable 
to determine whether the phosphorylation is the active driver of ARHGAP18 recruitment. 
Secondly, while ROCK prevents ARHGAP18 translocation, we are unable to establish 
whether this is due to its kinase effects or as a result of inhibiting junctional disruption. 
There is a possibility that ROCK is not directly involved in the recruitment, but that by 
preventing junctional disruption, it is preventing the recruiting signal for ARHGAP18. To 
Chapter 6. Regulation of ARHGAP18 Translocation 
	   230 
address both of these concerns, it would be for future study to investigate the effects of 
the individual phosho ser/thr sites. This could be achieved by constructing ARHGAP18 
mutations, such as substituting the phosphor ser/thr with alanine to prevent 
phosphorylation and examining the contribution of each to ARHGAP18 translocation. 
Further, it would be of future interest to characterise these mutants in the context of RhoC 
activity and in regulating EC sprouting.  
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Fig 6.1. ARHGAP18 does not colocalise or interact with the ERM proteins. 
A.  ARHGAP18 does not colocalise with the ERM proteins. Confocal images of HUVECs stimulated 
with or without thrombin (1 U/mL) for 10 min, !xed and stained for Ezrin/Radixin/Moesin (ERM) 
or moesin (red) and ARHGAP18 (green) and nuclei counterstained with DAPI (blue). ARHGAP18 
shows the typical relocalisation to the membrane, but is not associated with ERM or moesin. Bar 
25 μm. 
B.  ARHGAP18 does not interact with ERM or moesin. HUVEC lysates were immunoprecipitated with 
ARHGAP18 or control antibodies and immunoblotted for ERM and moesin. Whole cell lysate 
(WCL) run as a positive control for the antibody. 
C.  The human and mouse ARHGAP18 and Drosophila Conu protein sequences were aligned using 
ClustalW and the sequence similarity of the whole protein, the GAP domain, the MID and the 
putative SAM domain are indicated by the values. Relative to the GAP and SAM domains, the 
MID shows little sequence similarity. 
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Fig 6.2. ARHGAP18 colocalises with cortactin at the junctional periphery, and co-
immunoprecipitates with cortactin in a thrombin-independent manner. 
A.  Confocal images of HUVECs stimulated with or without thrombin (1U/mL) for 10 min, !xed and 
stained for cortactin (red) and ARHGAP18 (green) and nuclei counterstained with DAPI (blue). 
ARHGAP18 shows abundant colocalisation with cortactin at the junctional periphery (white 
arrows) but is also absent in some cell junctions (yellow arrow). Bar 25 μm. 
B.  ARHGAP18 co-immunoprecipitates with cortactin. HUVEC lysates were immunoprecipiated 
using ARHGAP18 or isotype control antibodies and immunoblotted for cortactin. WCL were run 
as a positive control for the antibody. 
C.  Thrombin does not alter the ARHGAP18-cortactin interaction. HUVECs were stimulated with 
thrombin (1U/mL) for the indicated times, lysed, immunoprecipiated with ARHGAP18 or control 
antibodies and immunoblotted for cortactin.  
D.  HUVEC lysates were immunoprecipitated using cortactin or control antibodies and 
immunoblotted for ARHGAP18. WCL were run as a positive control for the antibody. Cortactin 
immunoprecipitation resulted in the detection of the smaller (~73 kDa) isoform of ARHGAP18. 
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Fig 6.3. Optimisation of cortactin siRNA knockdown. 
A.  Bright!eld images of HUVECs transfected with control or the individual cortactin siRNAs for 3 d. 
Transfection with siCTTN1 results in an signi!cant alteration in cell phenotype that is absent in 
the other cortactin siRNAs. Bar 50 μm. 
B.  Con!rmation of cortactin knockdown. Lysates from cells transfected with control or cortactin 
siRNAs were immunoblotted for cortactin, ARHGAP18 and actin as the loading control. All 
siRNAs resulted in cortactin knockdown. ARHGAP18 is notably downregulated by two of the 
cortactin siRNAs. 
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Fig 6.4. Cortactin relocalisation is not depdendent on ARHGAP18, but is required for 
ARHGAP18 relocalisation. 
A.  Confocal images of cells transfected with control, ARHGAP18 or cortactin siRNAs, stimulated 
with thrombin (1U/mL) for 10 min, !xed and stained for ARHGAP18 (green), cortactin (red) and 
nuclei counterstained with DAPI (blue). Control cells show abundant colocalisation of 
ARHGAP18 and cortactin at the junctional periphery (arrows). Knockdown of ARHGAP18 still 
results in cortactin relocalisation (arrows) but knockdown of cortactin shows an absence of 
ARHGAP18 relocalisation. Bar 25 μm. 
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Fig 6.5. ARHGAP18 contains putative RXXS*/T* phosphorylation sites that are 
phosphorylated in a thrombin-dependent manner. 
A.  Identi!cation of putative ARHGAP18 phosphorylation sites using Phosphosite. ARHGAP18 
contains three RXXS*/T* motif sites at S66, T154 and S610 and two sites with the S*Q motif at 
S66 and S610. 
B.  Pulldown of putative phospho-ARHGAP18. HUVEC lysates were immunoprecipitated using 
ARHGAP18 or isotype control antibodies and immunoblotted using the pS/T Akt substrate 
antibody which is raised against the RXXS*/T* motif. WCL was run as a positive control for the 
antibody.  
C.  Phosphorylation of the putative phospho-ARHGAP18 is regulated by thrombin in a time-
dependent manner. HUVECs were stimulated with thrombin (1U/mL) for the indicated times and 
cell lysates were immunoprecipitated using ARHGAP18 antibodies and immunoblotted for the 
RXXS*/T* motif. Phosphorylation is increased following thrombin, at a maximal at 10 min and 
restored to basal levels at 60 min. 
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Fig 6.6. The putative phospho-ARHGAP18 is not regulated by Akt activation. 
A.  Inhibition of Akt reduces basal but not thrombin-induced ARHGAP18 phosphorylation. HUVECs 
were pre-treated with or without the LY294002 (30 μM, 30 min) then stimulated with or without 
thrombin (1U/mL) for 10 min. Cell lysates were immunoprecipitated using ARHGAP18 
antibodies and immunoblotted for the RXXS*/T* motif. WCL were immunoblotted for p-Akt to 
con!rm Akt inhibition. Akt inhibition results in reduced basal phospho-RXXS*/T* but is 
increased following thrombin treatment. 
B.  Akt is inhibited following thrombin stimulation. HUVECs were stimulated with thrombin for the 
indicated time points and WCL immunoblotted for p-Akt and p-ERK1/2. While ERK1/2 is 
hyperphosphorylated following thrombin stimulation, Akt is hypophosphorylatd. 
C.  Akt inhibition does not prevent ARHGAP18 relocalisation following thrombin stimulation. 
HUVECs were pre-treated with or without LY294002 (30 μM, 30 min) then stimulated with 
thrombin (1U/mL) for 10 min. Cells were stained for ARHGAP18 (green) and nuclei 
counterstained with DAPI (blue) and imaged by confocal microscopy. ARHGAP18 relocalises 
following thrombin in the presence or absence of the Akt inhibitor. Bar 25 μm 
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Fig 6.7. ROCK inhibition suppresses phosphorylation of ARHGAP18 and prevents ARHGAP18 
relocalisation.  
A.  ROCK inhibition suppresses, but does not completely inhibit, phosphorylation of ARHGAP18. 
HUVECs were pre-treated with or without the Y27632 (2.5 μM, 30 min) then stimulated with or 
without thrombin (1U/mL) for the indicated times. Cell lysates were immunoprecipitated using 
ARHGAP18 antibodies and immunoblotted for the RXXS*/T* motif. WCL were immunoblotted 
for p-MLC2 to con!rm downstream ROCK activation and inhibition. ROCK inhibition results in 
reduced phospho-RXXS*/T* at all time points, but still results in substantial activation at 10 min.  
B.  Con!rmation of ROCK inhibitor eﬃciency on actin and junctional phenotypes. HUVECs were 
pre-treated with or without the Y27632 (2.5 μM, 30 min), stimulated with or without thrombin 
(1U/mL) for 30 min, stained for VE-cadherin (green), F-actin (red) and nuclei counterstained with 
DAPI (blue) and imaged by confocal microscopy. ROCK inhbition prevented the thrombin-
induced stress !bres and junctional disruption. Bar 25 μm. 
C.  ARHGAP18 relocalisation to the junctional periphery is dependent on ROCK activity. HUVECs 
were pre-treated with or without 2.5 μM Y27632 for 30 min, stimulated with or without 
thrombin for 10 min, stained for ARHGAP18 (green), and nuclei counterstained with DAPI (blue) 
and imaged by confocal. ROCK inhibition prevented ARHGAP18 translocation to the EC 
junctions. Bar 25 μm. 
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CHAPTER 7.  FINAL DISCUSSION 
Tight regulation of angiogenesis is important in establishing and maintaining normal 
tissue vascularization. This involves highly regulated changes in EC behavior to 
coordinate the processes of vessel sprouting, fusion, lumen formation, stabilization and 
remodeling. Aberrant regulation can drive over- or under-production of angiogenesis, 
which contributes to pathologies such as cancer and ischemia, respectively. Here we have 
identified ARHGAP18 as a negative regulator of the initial steps of sprouting 
angiogenesis, in regulating junctional homeostasis and suppressing EC sprouting. Loss of 
ARHGAP18 promotes activation of RhoC and active serrated EC junctions, and promotes 
a TC-like hypersprouting and migratory phenotype. In pathogenesis, this results in a 
profound increase in tumour vascularization and growth. 
In the stable vessels, quiescent ECs are interconnected with strong VE-cadherin mediated 
cell-cell adhesions. VE-cadherin functions not only to stabilize the interactions but also 
acts to suppress VEGFA signaling (Fig 7.1 A). Following the sensing of VEGFA in the 
microenvironment, VEGFR2 signaling induces junctional disruption by phosphorylating 
VE-cadherin and promotes pro-angiogenic signaling via downstream activation of a 
multitude of signaling pathways. This initiates TC formation, which acts to direct vessel 
sprouting towards the VEGFA gradient. VEGFA signaling also induces activation of 
Notch signaling in adjacent cells to laterally inhibit the TC phenotype and induce a SC 
phenotype, which support the extension of the elongating sprout. The TC and SC 
phenotypes however are transient and constant re-regulation of VEGFR-Notch signals 
and differential EC junction dynamics drive the competition and shuffling of cells within 
the sprout.  
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ARHGAP18 was initially identified for its role in regulating tube formation, where it was 
downregulated during the migratory and upregulated during the stabilization phases 
(Coleman et al., 2010). Further, knockdown of ARHGAP18 prevented the formation of 
stable EC sprouts. This suggested potential roles of ARHGAP18 in regulating cell 
migration and/or stabilization. Using multiple in vitro and in vivo models, we describe 
that ARHGAP18 is a regulator of both angiogenic sprouting and junctional integrity. Loss 
of ARHGAP18 results in increased spheroid sprouting in vitro, zebrafish ISV sprouting, 
ex vivo aortic ring sprouting and vascularization of the post-natal mouse retina. This 
sprouting phenotype is associated with a TC-like phenotype, with increased formation of 
vascular sprouts, filopodia, vessel branching and expression of the TC-enriched genes 
DLL4, Flk1 and Flt4. The increased signaling through the VEGFRs, but not the inhibitory 
VEGFR1, drives Akt hyperactivation, which has been demonstrated to be responsible for 
driving DLL4 expression (Liu et al., 2003). DLL4 acts to regulate lateral inhibition of TC 
phenotype in adjacent SCs through the activation of Notch signaling. Furthermore, the 
expression of the VEGFRs, DLL4 and Notch signaling all regulate the shuffling capacity 
of ECs within the sprout, such that cells expressing high levels of VEGFR activity and 
DLL4 expression are highly motile and have an increased propensity to occupy the TC 
position (Bentley et al., 2014). Consistent with this, we observe that, using a chimeric 
spheroid sprouting model, ARHGAP18 knockdown cells have a significantly increased 
frequency to occupy the leading position. 
We postulate that ARHGAP18 is a negative regulator of sprouting through its Rho GAP 
function in regulating RhoC and junctional integrity. Rho GTPases are recruited to the 
membrane periphery following stimulation where they activate downstream effectors. We 
observe that ARHGAP18 is dynamically recruited to the junctional periphery following 
10 min of thrombin stimulation, whereas RhoC displays maximal activation at 2 min. 
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This suggests that ARHGAP18 is recruited to the destabilized EC junctions in order to 
suppress excessive RhoC signaling (Fig 7.1 B). Consistent with this notion of 
stabilization, we observe that ARHGAP18 is localized to the EC junctions of the unstable 
angiogenic vessels but not to relatively stable junctions of the arteries and veins in the 
retina or in the junctions of quiescent monolayers of EC in vitro. In these stable settings, 
we postulate that ARHGAP18 may be localized in the cytosol or in association with the 
microtubules (Lovelace et al., in review). One of the major functions of RhoC is in its 
regulation of junctional integrity through its downstream activation of ROCK (Abraham 
et al., 2009; Sahai and Marshall, 2002). We show here that ARHGAP18 loss leads to 
hyperactivation of RhoC and junctional disruption, while overexpression of ARHGAP18 
decreases RhoC activation. We confirmed the action of ARHGPA18 on RhoC by 
demonstrating that knockdown of RhoC is able to revert the junctional phenotype 
mediated via ARHGAP18. A recent study has demonstrated that differential VE-cadherin 
dynamics, in addition to VEGF-Notch-DLL4 regulates angiogenic sprouting by 
controlling cell rearrangement (Bentley et al., 2014). Consistent with this notion, the 
disrupted junction phenotype of ARHGAP18 KD is associated with increased cell 
rearrangement. We postulate that through the hyperactivation of RhoC, ARHGAP18 loss 
drives VE-cadherin disruption, which in turn promotes VEGFR-Akt signaling to regulate 
DLL4 expression and angiogenic sprouting. However, while we have not directly 
demonstrated that the effects of ARHGAP18-RhoC signaling on EC sprouting, it has also 
been shown that RhoC regulates VEGF signaling and Akt activation (Liu et al., 2012; 
Ruth et al., 2006). To date the role of RhoC on cell migration is quite controversial and is 
thought to be due to direct effects through downstream effectors such as ROCK or 
indirect effects through activation of Rac1 (Del Galdo et al., 2013; Kitzing et al., 2010; 
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Vega et al., 2011). This effect of ARHGAP18-RhoC and RhoC itself on angiogenic 
sprouting would be for future investigation. 
During sprouting angiogenesis, we, and others observe that ARHGAP18 is upregulated in 
the TCs. Further, ARHGAP18 is upregulated at the late time points following VEGFA 
stimulation. This suggests that rather than being a direct inducer of sprouting, 
ARHGAP18 acts as a negative feedback regulator to control the extent of sprouting 
angiogenesis. Given the correlation between VEGFR-Notch signaling, differential EC 
junctions and ARHGAP18 expression, it would be interesting to determine whether the 
expression or localization of ARHGAP18 changes in a single cell nature within the cells 
of the sprouting vessel. We would postulate that there would first be VEGFR signaling to 
RhoC that disrupts the EC junctions then relocalisation and upregulation of ARHGAP18 
to restrict excessive RhoC-mediated junctional destabilization (Fig 7.1 B). It would 
therefore be very interesting to determine what controls the expression and localization of 
ARHGAP18 in this environment. One potential factor is the transcription factor YAP. 
YAP activity is regulated in a cell contact dependent manner by VE-cadherin (Choi et al., 
2015). It has recently been demonstrated that YAP knockdown triggers downregulation of 
ARHGAP18 and this plays an important role in regulating Rho during 3D morphogenesis 
(Porazinski et al., 2015). Therefore, we predict that during the cycles of active serrated 
EC junctions, YAP is internalized and acts as a TF to upregulate ARHGAP18 (Fig 7.1 B). 
Another mechanism of regulating ARHGAP18 function is through its localization. Our 
preliminary experiments identified two potential mechanisms to control localisation: 
through its phosphorylation and its interaction with cortactin. We observed 
phosphorylation of putative RXXS*/T* motifs present on ARHGAP18 that correlated 
with its dynamic localisation. We identified that this is potentially mediated by ROCK, a 
kinase that is downstream of Rho, as ROCK inhibition reduced phosphorylation of 
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ARHGAP18 and prevented ARHGAP18 relocalisation. We postulate that RhoC signaling 
to ROCK phosphorylates ARHGAP18 that drives its recruitment to the membrane where 
it serves as a negative feedback regulator to prevent excessive RhoC-ROCK signaling 
(Fig 7.1 B). However, these phosphorylation studies will require substantial further 
studies, such as mutation of the putative phospho motifs, to definitely prove such a 
mechanism. The other mechanism to regulate localisation is through its interaction with 
cortactin, an actin and Rho GAP binding protein that regulates cell migration. We 
demonstrated that cortactin and ARHGAP18 interact via coIP and that cortactin and 
ARHGAP18 appeared to colocalise to similar regions of the junctional periphery 
following junction destabilization. Further, knockdown of cortactin prevented the 
recruitment of ARHGAP18 to the periphery. Interestingly, it appeared that cortactin 
interacted with a smaller isoform of ARHGAP18, which was also the isoform of the 
putative phosphorylated version of ARHGAP18. These suggest that post-translation 
modifiications of ARHGAP18 may be crucial in regulating its function. We have further 
evidence to suggest that N-terminal truncations of ARHGAP18 result in gross 
morphological changes, which suggests that the N-terminal region may be acting as a 
negative regulator of ARHGAP18 function, and that the binding to other proteins or its 
phosphorylation are the key mechanisms to relinquish this inhibition. We have also 
recently observed that ARHGAP18 colocalises with the microtubules and that knockdown 
of ARHGAP18 affects microtubule stability (Lovelace et al., in review). These 
microtubules may act as a mechanism to traffic ARHGAP18 to the cell periphery. 
However, these studies will require a substantial amount of further experiments to 
demonstrate the critical regions and/or domains that regulate its interaction with other 
proteins and localization.  
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Another future direction is to examine the influence of ARHGAP18 overexpression. 
While we have demonstrated an importance of ARHGAP18 in regulating EC senescence, 
it would be also interesting to determine whether ARHGAP18 overexpression results in 
changes that are opposite to that of the knockdown. Using our current retroviral model, 
we are only able to overexpress ARHGAP18 to very small magnitudes and are unable to 
direct this to its RhoGAP function, as most of the overexpressed protein remains non-
functional in the cytosol. In order to address this, we would create a lentiviral vector 
(which we have proved is much more efficient) to express a myristolated-ARHGAP18 
that targets it to the membrane, as has been demonstrated by others (Porazinski et al., 
2015). Using this, we would be able to assess the impact of ARHGAP18’s RhoGAP 
function on sprouting angiogenesis and its potential membrane interactors.  
To investigate the sprouting effects in vivo, we are currently developing an inducible 
ARHGAP18 transgenic mouse line (TRE-ARHGAP18-IRES-GFP). This would allow us 
to generate endothelial-specific ARHGAP18 overexpressing mice (by crossing with VE-
cadherin-tTA mice). Further, while we presume that the effects of ARHGAP18 knockout 
are mediated through the endothelial population (based on the other in vitro, and ex vivo 
results and the lack of phenotypes in other cell populations), we are also addressing this 
through the generation of an EC specific knockout mouse. To do this, we are using the 
current global knockout mouse and crossing the mouse with a global flippase (FLP) 
mouse. This utilizes the FLP recombinase, which recognizes the FLP recombinase target 
(FRT) sequences in the knockout cassette (Fig 4.9 A), to remove the En2 splice acceptor 
and restore the WT status. The second step is to cross this mouse with an endothelial 
specific Cre mouse (e.g. the VE-cadherin-Cre (Alva et al., 2006)) which then floxes out 
the loxP sites that flank exon 2 (Fig 4.9 A). This could be alternatively manipulated by 
crossing with the VE-cadherin-CreERT2 transgenic mouse (Monvoisin et al., 2006), 
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which would allow for tamoxifen-inducible EC specific deletion of ARHGAP18. This 
would further also permit for future studies into the later steps of angiogenesis, such as 
vascular remodeling. 
One major unanswered question is the role of ARHGAP18 during chronic Ras activation. 
We established that chronic Ras-MAPK-ERK signaling elicits a dramatic downregulation 
of ARHGAP18 in addition to its induction of a partial EndMT phenotype. However, 
restoration of ARHGAP18 was unable to affect the Ras phenotype in terms of gross 
morphology and EndMT marker expression. Since we have now defined a role of 
ARHGAP18 in regulating sprouting and EC junctions, it is worth investigating whether 
ARHGAP18 acts as a critical intermediate protein to these Ras phenotypes. However, 
given the extensive changes in morphology and cytoskeletal rearrangement, we would not 
predict that restoration of a single RhoGAP would dramatically affect the phenotype. We 
would postulate that this is regulated by a coordinated regulation of multiple Rho 
signaling pathways, regulators and effectors. ARHGAP18 may just be one of these, and 
easily compensated for by other RhoGAPs. Nevertheless, this would be for future 
investigation. One of the implications of aberrant Ras signaling in the vascular system is 
in vascular malformations and tumours. Mutations of TIE2 also result in venous 
malformations and is also linked with a downregulation of ARHGAP18 (Uebelhoer et al., 
2013). This highlights the difference between the physiological and pathological 
environments where upregulation of ARHGAP18 during physiological angiogenesis acts 
to restrict excessive sprouting by maintaining junctional integrity, while the loss of 
ARHGAP18 may act as a driver of vascular pathology. The direct consequences of 
ARHGAP18 loss in the context of vascular diseases will be of much interest. 
In conclusion, understanding the role of ARHGAP18 in the vasculature and in pathology 
is of major importance, given the possibility that targeting the RhoGTPase cycle is a 
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therapeutic opportunity (van der Meel et al., 2011). We have demonstrated that 
ARHGAP18 is a negative regulator of angiogenesis via its control of EC junctional 
integrity and sprouting. Loss of ARHGAP18 drives excessive vessel hypersprouting and 
tumour development consistent with an important role for this regulatory protein in 
stabilisation of the vasculature. 	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Fig 7.1. Proposed pathway 
A.  Resting ECs have stable EC junctions mediated by VE-cadherin, which further acts to inhibit 
VEGFR2 activation to promote EC quiescence. In stable ECs, ARHGAP18 is localised in the cytosol 
or in association with microtubules. 
B.  In response to angiogenic or destabilising stimuli, RhoC activates ROCK which disrupts the AJs 
and induces actomyosin contractility. AJ disruption breaks down the stable EC-EC interactions 
and facilitates VEGFR signaling to promote a pro-angiogenic phenotype. ROCK additionally 
phosphorylates ARHGAP18, which in combination with cortactin is recruited to the cell 
periphery. This serves to inactivate RhoC to prevent excessive ROCK signaling. ARHGAP18 is also 
upregulated, which is potentially mediated via YAP. VE-cadherin disruption facilitates YAP 
translocation to the nucleus where it acts as a TF for ARHGAP18. 
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APPENDIX 
A.1.  FIJI IMAGING MACROS 
A.1.1.  DAPI COUNTING MACRO 
//Macro for the automated determination of cell nuclei in a whole image field 
//------------------------------------------------------------------- 
//Macro Created by Garry Chang 2010-July-21 
//------------------------------------------------------------------- 
//Input image: DAPI stained cell nuclei, only as a DAPI channel image 
 
run("8-bit"); 
run("Subtract Background...", "rolling=1000"); 
run("Brightness/Contrast..."); 
run("Enhance Contrast", "saturated=0.5"); 
run("Apply LUT"); 
run("Gaussian Blur...", "sigma=5"); 
setAutoThreshold(); 
//run("Threshold..."); 
setAutoThreshold(); 
setThreshold(0, 64); 
run("Convert to Mask"); 
run("Convert to Mask"); 
run("Analyze Particles...", "size=0-Infinity circularity=0.00-1.00 show=Outlines display exclude clear 
record"); 
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A.1.2.  RETINA VASCULARISATION MACRO 
//Macro for the subanalysis of Wimasis analysed whole quadrant Retinas 
//Note that the quality of the data depends on the initial analysis 
//This serves as a macro to pull out existing data in a smaller area 
//------------------------------------------------------------------- 
//Macro Created by Garry Chang 2013-April-14 
//------------------------------------------------------------------- 
 
//Image order: 
//1. Junctions 
//2. Loops 
//3. Vessels 
 
//Rename images for generality 
selectImage(3); 
run("Invert"); 
rename("vessels") 
selectImage(2); 
rename("loop"); 
run("Channels Tool... "); 
run("Yellow");//Makes loops yellow 
run("RGB Color"); 
selectImage(1); 
file=getTitle(); 
rename("junction"); 
//Need to adjust colour balance of colours to increase signal:noise 
setMinAndMax(120,130,4);//Red 
setMinAndMax(40,180,2);//Green 
imageCalculator("Add create", "loop","junction"); 
 
 
//Select ROI 
waitForUser("Select ROI");//Select point-will form a 250x250 pixel rectangle from top left 
getSelectionBounds(x,y,width,height); 
makeRectangle(x, y, 250, 250); 
run("Copy"); 
newImage("crop", "RGB Black", 250, 250, 1); 
run("Paste"); 
selectWindow("crop"); 
run("Duplicate...", "title=crop-blue"); 
run("Duplicate...", "title=crop2-green"); 
run("Duplicate...", "title=crop3-red"); 
run("Duplicate...", "title=crop4-yellow"); 
 
selectWindow("vessels"); 
makeRectangle(x, y, 250, 250); 
run("Copy"); 
newImage("vesselcrop", "8-bit Black", 250, 250, 1); 
run("Paste"); 
selectWindow("vesselcrop"); 
imageCalculator("Average create", "crop","vesselcrop"); 
rename("Merge"); 
saveAs("PNG", "/Users/garryhoi-kaichang/Desktop/Retina Test/"+file); 
rename("Merge"); 
 
//=======================VESSEL DENSITY======================= 
selectWindow("vesselcrop"); 
setAutoThreshold("Default"); 
run("Analyze Particles...", "size=30-Infinity circularity=0.00-1.00 show=Nothing display"); 
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selectWindow("Merge"); 
waitForUser("Vessel Density"); 
//=======================VESSEL DENSITY======================= 
 
run("Clear Results"); 
 
//==================LOOP & Junction COUNTING================== 
 
selectWindow("crop4-yellow"); 
// Color Thresholder 1.46r 
// Color Threshold Yellow 
min=newArray(3); 
max=newArray(3); 
filter=newArray(3); 
a=getTitle(); 
run("HSB Stack"); 
run("Convert Stack to Images"); 
selectWindow("Hue"); 
rename("0"); 
selectWindow("Saturation"); 
rename("1"); 
selectWindow("Brightness"); 
rename("2"); 
min[0]=34; 
max[0]=51; 
filter[0]="pass"; 
min[1]=0; 
max[1]=255; 
filter[1]="pass"; 
min[2]=104; 
max[2]=255; 
filter[2]="pass"; 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  setThreshold(min[i], max[i]); 
  run("Convert to Mask"); 
  if (filter[i]=="stop")  run("Invert"); 
} 
imageCalculator("AND create", "0","1"); 
imageCalculator("AND create", "Result of 0","2"); 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  close(); 
} 
selectWindow("Result of 0"); 
close(); 
selectWindow("Result of Result of 0"); 
rename(a); 
// Colour Thresholding------------- 
//Counts particles 
run("Analyze Particles...", "size=30-Infinity circularity=0.00-1.00 show=Nothing display exclude"); 
//Next Channel 
 
//Pause for data input to excel 
 
selectWindow("Merge"); 
waitForUser("Loops"); 
run("Clear Results"); 
 
//Colour Threshold Red 
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selectWindow("crop3-red"); 
min=newArray(3); 
max=newArray(3); 
filter=newArray(3); 
a=getTitle(); 
run("HSB Stack"); 
run("Convert Stack to Images"); 
selectWindow("Hue"); 
rename("0"); 
selectWindow("Saturation"); 
rename("1"); 
selectWindow("Brightness"); 
rename("2"); 
min[0]=25; 
max[0]=225; 
filter[0]="stop"; 
min[1]=0; 
max[1]=255; 
filter[1]="pass"; 
min[2]=104; 
max[2]=255; 
filter[2]="pass"; 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  setThreshold(min[i], max[i]); 
  run("Convert to Mask"); 
  if (filter[i]=="stop")  run("Invert"); 
} 
imageCalculator("AND create", "0","1"); 
imageCalculator("AND create", "Result of 0","2"); 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  close(); 
} 
selectWindow("Result of 0"); 
close(); 
selectWindow("Result of Result of 0"); 
rename(a); 
// Colour Thresholding------------- 
//Counts particles 
run("Analyze Particles...", "size=10-26 circularity=0.00-1.00 show=Nothing display exclude"); 
 
//Pause for data input to excel 
selectWindow("Merge"); 
waitForUser("Single Branches"); 
run("Clear Results"); 
 
 
//Count merged red branches...are still doubles-sorted on size 
selectWindow("crop3-red"); 
run("Analyze Particles...", "size=27-50 circularity=0.00-1.00 show=Nothing display exclude"); 
 
//Colour Threshold Green 
selectWindow("crop2-green"); 
min=newArray(3); 
max=newArray(3); 
filter=newArray(3); 
a=getTitle(); 
run("HSB Stack"); 
run("Convert Stack to Images"); 
Appendix 
	   256 
selectWindow("Hue"); 
rename("0"); 
selectWindow("Saturation"); 
rename("1"); 
selectWindow("Brightness"); 
rename("2"); 
min[0]=70; 
max[0]=100; 
filter[0]="pass"; 
min[1]=0; 
max[1]=255; 
filter[1]="pass"; 
min[2]=104; 
max[2]=255; 
filter[2]="pass"; 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  setThreshold(min[i], max[i]); 
  run("Convert to Mask"); 
  if (filter[i]=="stop")  run("Invert"); 
} 
imageCalculator("AND create", "0","1"); 
imageCalculator("AND create", "Result of 0","2"); 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  close(); 
} 
selectWindow("Result of 0"); 
close(); 
selectWindow("Result of Result of 0"); 
rename(a); 
// Colour Thresholding------------- 
 
//Data for double red and the greens are pooled together 
run("Analyze Particles...", "size=10-Infinity circularity=0.00-1.00 show=Nothing display exclude"); 
 
//Pause for data input to excel 
selectWindow("Merge"); 
waitForUser("Double Branches"); 
run("Clear Results"); 
 
//Colour Threshold Blue 
selectWindow("crop-blue"); 
min=newArray(3); 
max=newArray(3); 
filter=newArray(3); 
a=getTitle(); 
run("HSB Stack"); 
run("Convert Stack to Images"); 
selectWindow("Hue"); 
rename("0"); 
selectWindow("Saturation"); 
rename("1"); 
selectWindow("Brightness"); 
rename("2"); 
min[0]=160; 
max[0]=190; 
filter[0]="pass"; 
min[1]=0; 
max[1]=255; 
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filter[1]="pass"; 
min[2]=104; 
max[2]=255; 
filter[2]="pass"; 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  setThreshold(min[i], max[i]); 
  run("Convert to Mask"); 
  if (filter[i]=="stop")  run("Invert"); 
} 
imageCalculator("AND create", "0","1"); 
imageCalculator("AND create", "Result of 0","2"); 
for (i=0;i<3;i++){ 
  selectWindow(""+i); 
  close(); 
} 
selectWindow("Result of 0"); 
close(); 
selectWindow("Result of Result of 0"); 
rename(a); 
// Colour Thresholding------------- 
//Counts particles 
run("Analyze Particles...", "size=10-Infinity circularity=0.00-1.00 show=Nothing display exclude"); 
 
//Pause for data input to excel 
selectWindow("Merge"); 
waitForUser("Triple Branches"); 
run("Clear Results"); 
 
 
//==================LOOP & Junction COUNTING================== 
 
 
//Close image 
run("Close All"); 	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A.1.3.  PERICYTE COVERAGE MACRO 
//Macro for the analysis of pericyte coverage in mouse retinas 
//Images of NG2 and VE-cadherin stained retinas as the input, using whole confocal stacks 
//------------------------------------------------------------------- 
//Macro Created by Garry Chang 2014-Janurary-23 
//------------------------------------------------------------------- 
 
file=getTitle(); 
run("Z Project...", "start=1 stop=100 projection=[Max Intensity]"); 
run("Subtract Background...", "rolling=50"); 
run("Duplicate...", "title=Merge duplicate channels=1-2"); 
selectImage(2); 
run("RGB Color"); 
setMinAndMax(5,150,4);//Red 
setMinAndMax(10,180,2);//Green 
saveAs("PNG", "/Users/garryhoi-kaichang/Desktop/Pericyte Test/"+file); 
close(); 
selectWindow("Merge"); 
run("Gaussian Blur...", "sigma=1"); 
run("Split Channels"); 
selectImage(3); 
rename("pericyte"); 
selectImage(4); 
rename("VEC"); 
 
 
//VEC vasculature 
selectWindow("VEC"); 
run("Brightness/Contrast..."); 
waitForUser("Set MinMax");//SET MIN MAX----20,30 
run("Apply LUT"); 
run("Make Binary"); 
run("Dilate"); 
run("Close-"); 
 
//Pericytes 
selectWindow("pericyte"); 
run("Brightness/Contrast..."); 
waitForUser("Set MinMax");//SET MIN MAX----10-80 
run("Apply LUT"); 
setThreshold(30, 255); 
run("Convert to Mask"); 
 
//Merge Images 
run("Merge Channels...", "c1=VEC c2=pericyte create keep"); 
run("RGB Color"); 
a="_analysed" 
saveAs("PNG", "/Users/garryhoi-kaichang/Desktop/Pericyte Test/"+file+a); 
 
run("Color Threshold..."); 
 
//Colour Threshold 
waitForUser("Set Yellow-30/50")//Yellow: 30-50 
run("Measure"); 
 
waitForUser("Set Yellow-60/90-Pass")//Red+Yellow: 60-90 Pass 
 
run("Measure"); 
waitForUser("Get area") 
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run("Close All"); 	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